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ABSTRACT 
Autophagy, a cellular homeostasis process that degrades and recycles cytosolic contents, is 
regulated at various stages by protein interactions. BECN1 regulates autophagy through interactions with 
diverse proteins via binding-induced conformational changes in its intrinsically disordered region (IDR) 
and flexible domains. Understanding the structure-function relationship of conformational transitions 
provides a basis for understanding these interactions and may be useful for targeting therapeutics for 
these proteins. We devised a method to identify IDRs likely to become helical upon binding, even in the 
absence of known binding partners, and analyzed BECN1 interactions to further understand how binding-
induced conformational changes affect BECN1-mediated autophagy regulation. 
We showed that the BECN1 coiled-coil domain (CCD) and β-α repeated, autophagy-specific 
domain (BARAD) share an overlapping helix (OH) region that transiently adopts mutually exclusive 
packing states and transiently packs against the CCD and BARAD, but predominantly packs against the 
BARAD in the homodimer, and demonstrated that mutation of OH residues that pack against both 
domains abrogates starvation-induced up-regulation of autophagy. Our results have important 
implications for the relative stability of autophagy-inactive and autophagy-active BECN1 complexes.  
We also attempted to establish the mechanism by which various virus-encoded proteins regulate 
autophagy. Nef, a critical protein for HIV pathogenesis, interacts with BECN1 BARAD regions that pack 
against the OH. However, we show that Nef does not appear to interact directly with the BECN1 
homodimer, suggesting that packing of the OH against the BARAD may inhibit the Nef interaction. 
Several anti-apoptotic viral BCL2 (vBCL2) proteins down-regulate autophagy by binding the BECN1 BH3 
homology domain (BH3D) and mediating binding-induced helical transitions in the BH3D. Although 
protein purification issues prevented analysis of Kaposi’s sarcoma herpesvirus (KSHV) vBCL2 
interactions, we determined that BHRF1, an Epstein-Barr virus (EBV)-encoded vBCL2, down-regulates 
autophagy by binding a flexible region of BECN1 that includes the BH3D. Further, we solved the 2.6 Å 
crystal structure of BHRF1 bound to the BID BH3D, a pro-apoptotic BCL2, and showed that the BID 
BH3D binds ~400-times tighter than the BECN1 BH3D to BHRF1 and inhibits BHRF1-mediated down-
regulation of autophagy.  
 iv 
Together, our studies highlight the importance of binding-induced conformational changes in 
proteins that regulate autophagy. 
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CHAPTER 1. INTRODUCTION 
1.1. BECN1 in autophagy 
Macroautophagy, hereafter called autophagy, is a conserved cellular homeostasis pathway 
facilitating nutrient recycling via engulfment of long-lived, misfolded, aggregated, damaged, or mutated 
proteins, organelles, and pathogens in multi-layered vesicles called autophagosomes that fuse with 
lysosomes to enable degradation of the sequestered contents1-5 (Figure 1.1). Thus, autophagy is a 
survival mechanism that enables cells to withstand nutrient deprivation, environmental stressors, aging, 
and infection by recycling intracellular debris to generate metabolic precursors, such as amino acids and 
ATP. Proteins that execute autophagy are conserved in all eukaryotes and many of these conserved 
autophagy-related effectors are called ATG proteins5-8. Multi-protein complexes mediate each stage of 
autophagy, which include 1) initiation signaling, 2) autophagosome nucleation; which initiates synthesis of 
the autophagic isolation membrane that eventually encloses the cytoplasmic cargo destined for 
degradation, 3) autophagosome expansion, which involves elongation of the isolation membrane resulting 
in an autophagosome that contains multiple phospholipid bilayer membranes surrounding the cytoplasmic 
cargo destined for degradation, and 4) autophagosome maturation, which involves docking and fusion 
with the lysosome, whose degradative enzymes catalyze the breakdown of the autolysosomal contents5-8.  
 
Figure 1.1. Steps of autophagy.  
Upon autophagy initiation, the isolation membrane begins forming during the vesicle nucleation step. The 
autophagy machinery coordinates vesicle elongation and autophagosome formation to engulf cytoplasmic 
contents. The outer membranes of the autophagosome and lysosome fuse during the docking and fusion 
stage to generate the autolysosome. The lysosomal hydrolases then facilitate the breakdown and 
degradation of the sequestered material within the autolysosome. This figure is adapted from9. 
BECN1/Beclin 1/ATG6/VPS30, first identified as a B cell lymphoma 2 (BCL2)-interacting protein 
in humans10 and amongst the first autophagy proteins to be identified in mammals4, is highly conserved in 
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eukaryotes. As a core component of the class III phosphatidylinositol 3-kinase (PI3KC3) complexes 
essential for autophagosome nucleation and maturation11-15, BECN1 forms a parallel heterodimer with 
either ATG14 or UVRAG/VPS38 via their coiled-coil domains (CCDs)16-18. Defective BECN1 or deficient 
expression levels are linked to various diseases, including neurodegenerative disorders19-21, cancers4, 22-
25, and infectious diseases10, 26-28. 
BECN1 upregulates PI3KC3 activity and autophagy in response to diverse signals, although the 
exact mechanisms by which BECN1 performs this function remain unclear. BECN1 appears to be a major 
interaction hub for autophagy, interacting with at least twenty different cellular proteins as well as proteins 
encoded by at least five viruses (HIV, Influenza virus, α-, β-, and ɣ-herpesviruses) that inhibit autophagy 
to prevent virus degradation28-30. While the mechanisms by which BECN1 binds so many diverse partners 
are unknown, conformational flexibility often facilitates multivalent protein interactions, allowing one 
protein to interact with various binding partners to carry out diverse functions. Thus, understanding 
BECN1 conformational flexibility is key to understanding varied BECN1 interactions, which in turn, will 
improve our understanding of the role of BECN1 in autophagy. Ultimately this is essential to better 
understand how eukaryotic organisms respond to and survive cellular stressors. 
BECN1 is a conformationally-flexible protein that has at least four domains31: an N-terminal 
intrinsically disordered region (IDR, residues 1-140)30, 32, a flexible helical domain (FHD, residues 141-
171)33, a coiled-coil domain (CCD, residues 175-265,)18, 34, and a β-α repeated, autophagy-specific 
domain (BARAD, residues 266-450)35, 36. The IDR and FHD both contain “Anchor regions” (sequences 
flanking or overlapping IDRs that are predicted by the program ANCHOR to nucleate binding-associated 
folding37). Four of the BECN1 Anchor regions have been identified as α-molecular recognition features 
(αMoRFs), i.e. regions that undergo disorder-to-helix transitions upon binding to partners38, 39. The BH3D, 
comprising residues 105-130 of the IDR and encompassing an Anchor region, was the first BECN1 
αMoRF identified30. The BH3D is disordered, but folds into a helix upon binding to various BCL2 
homologs30, 40 or in the presence of 2,2,2-trifluoroethanol (TFE), a chemical that induces helicity in 
αMoRFs even in the absence of their binding partners41. Similar methodology shows that residues 76-
10541, which comprise an IDR Anchor region, and the FHD42, which encompasses two Anchor regions, 
are likely also αMoRFs. Even within the well folded CCD18, 34 and BARAD35, 36, residues 248-265 adopt 
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mutually exclusive helical conformations in different crystal structures and undergo conformational 
changes in response to membrane binding17, 31. Thus, conformational flexibility is an over-riding feature of 
BECN1 and many BECN1 regions are now known to undergo binding-associated conformational 
changes. 
1.1.1. BCL2 binding to BECN1 
BECN1 was initially discovered as a BCL2-interacting protein10 and binding of the anti-apoptotic 
BCL2 proteins to BECN1 are now known to down regulate autophagy26, 43, 44. BECN1 residues 88-150 
were named the BCL2-binding domain (BCL2BD), as this region was sufficient for binding BCL2 and 
BCL2L1 (Bcl-XL), and its deletion weakened BECN1 interaction with BCL2 in mammalian cells
10. 
Sequence analysis and structural studies demonstrated that the BECN1 BCL2BD contains a BH3D, 
comprising residues 105-13043-47. A minimal BH3D consists of a four-turn, amphipathic α-helix bearing the 
sequence motif: ɸ-X-X-X-ɸ-K/R-X-X-Sm-D/E-X-ɸ (where ɸ: hydrophobic residues; Sm: small residues, 
typically glycine)48. In BECN1, the conserved hydrophobic residues of the BH3D are L112, L116, and 
F123. The BH3D is conserved amongst pro-apoptotic proteins and enables binding of anti-apoptotic 
BCL2 proteins48.  
Diverse BCL2 homologs bind the isolated BECN1 BH3D with moderate affinity30, 43, 44, 46. 
Mutagenesis studies in combination with diverse binding assays show that the BH3D is both necessary 
and sufficient for BECN1 interaction with several anti-apoptotic BCL2 proteins. Structures of the BECN1 
BH3D bound to human Bcl-230, human Bcl-XL46, 47, or the ɣ-herpesvirus (HV) 68 BCL2 homolog M1143, 44, 
show that, like BH3Ds from pro-apoptotic proteins, the BECN1 BH3D binds as a helix to a hydrophobic 
surface groove on the BCL2 proteins. In each structure, the interface buries conserved BECN1 BH3D 
hydrophobic residues: L112, L116, and F123. The BECN1 G120-D121 pair, which is highly conserved in 
all BH3Ds, interacts with a G-R pair (G86-R87 of M11 and G138-R139 of Bcl-XL) that is highly conserved 
in anti-apoptotic BCL2 homologs. Thus, anti-apoptotic BCL2 proteins bind the BECN1 BH3D in a manner 
similar to the other BH3Ds.  
Despite the overall similarity in the mode of binding of different BCL2 homologs to BECN1, there 
are significant differences. Variations in residues lining the hydrophobic groove of each BCL2 protein 
dictate a differential binding affinity for BECN1. Thus, the BECN1 BH3D binds to M11 with 1.1 µM affinity, 
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and to human Bcl-2 and Kaposi’s Sarcoma HV (KSHV) Bcl-2 with weaker affinities of 8.0 µM and 13.3 
µM, respectively44. Two mechanisms regulate BCL2-mediated inhibition of BECN1-dependent autophagy: 
competitive binding of other BH3D-containing proteins45 and modulation of BECN1:BCL2 interaction by 
phosphorylation of either partner49-51. 
The mechanism by which BCL2 proteins bind the BECN1 BH3D is well established; however, the 
mechanism by which this interaction down regulates BECN1-mediated autophagy is not. BCL2 
overexpression diminishes BECN1 co-immunoprecipitation with VPS3426. Further, in the presence of Bcl-
XL or KSHV Bcl-2, BECN1 binds UVRAG with 4-fold lower affinity52. Isothermal titration calorimetry (ITC) 
experiments indicate Bcl-XL and KSHV Bcl-2 bind the BECN1 homodimer52. Therefore, BCL2 binding may 
stabilize the BECN1 homodimer and disrupt interactions between BECN1 and other components of the 
autophagy nucleation complex.  
1.1.2. BECN1 in PI3KC3 complexes 
BECN1 is a core component of PI3KC3/VPS34 complexes involved in autophagy and vesicle 
trafficking11, 53. BECN1 associates with either ATG14/BARKOR or UVRAG/VPS38 to form two mutually 
exclusive PI3KC3 complexes: i) complex I comprising BECN1:ATG14:PI3KC3:p150 or ii) complex II 
comprising BECN1:UVRAG:PI3KC3:p15012, 14, 15. While p150/PI3KR4/VPS15 is an obligate partner of 
PIK3C3, association of the other proteins up-regulates PI3KC3 activity to convert phosphatidylinositol (PI) 
to phosphatidylinositol 3-phosphate (PI3P), an essential signal for autophagosome formation54-56. 
Complex I nucleates autophagosomes while complex II mediates autophagosome maturation11, 12, 14, 15, 57. 
PI3KC3/VPS34 contains a N-terminal C2 domain, a central helical domain, and C-terminal lipid 
kinase domain58, 59. VPS34 forms a heterodimer with N-terminally myristoylated VPS1511, 60 (p150 in 
humans), a protein Ser/Thr kinase, which consists of a N-terminal kinase domain, a central HEAT 
(Huntington, elongation factor 3 protein phosphatase 2A, yeast kinase TOR1) domain, and a C-terminal 
WD40 domain58. The VPS34 C-terminal lipid kinase domain interacts with the VPS15 N-terminal kinase 
domain17. Human ATG14 contains a N-terminal cysteine-rich repeat region required for targeting ATG14 
to the endoplasmic reticulum61, a central CCD, and a C-terminal BATS (Barkor/Atg14 autophagosome 
targeting sequence) functional domain responsible for sensing and preferentially binding highly curved, 
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PI3P-rich membranes62. Human UVRAG consists of a proline-rich sequence, a C2 domain, a CCD and a 
C-terminal domain53. 
The 28 Å CryoEM reconstructions of complex I and II reveal nearly identical overall V-shaped 
envelopes16. PI3KC3/VPS34 and p150/VPS15 comprise one arm of each V-envelope, while the other arm 
is comprised of BECN1 and either ATG14 or UVRAG. MBP-tag mapping of the CryoEM reconstructions 
reveals that the BECN1 BARAD is located at the tip of one arm of the V, with BECN1 in a parallel 
arrangement with either ATG14 or UVRAG, extending to the N-termini of each protein located at the base 
of the V. Further, the VPS15 HEAT domain is positioned to interact with N-terminal regions of BECN1 and 
ATG14 or UVRAG, at the base of the V-envelope, while the VPS15 WD40 domain is positioned to 
interact with C-terminal regions of BECN1 and ATG14 or UVRAG. A recent 4.4 Å crystal structure of 
PI3KC3 complex II17 confirms this overall architecture (Figure 1.2). 
 
Figure 1.2. Domain architecture of the yeast PI3KC3 complex II.  
All proteins are shown in ribbon, colored as VPS30, yellow; VPS38, green; VPS15, gray; and VPS34, 
blue. Protein domains are labeled. 
1.2. Viral evasion and subversion of autophagy 
Autophagy not only recycles defective or unnecessary macromolecules generated by the cell, but 
also contributes to innate and adaptive immunity by sequestering and degrading intracellular pathogens 
via a subtype of autophagy also referred to as xenophagy63. Enforced autophagy induction protects 
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against Sindbis virus, tobacco mosaic virus, and vesicular stomatitis virus infections64, 65. However, as 
obligate intracellular parasites, many viruses have evolved mechanisms to inhibit autophagic progression 
to evade degradation and even mechanisms to subvert of the autophagic machinery to facilitate viral 
replication and morphogenesis, thereby manipulating autophagy to serve as a pro-viral pathway64. While 
several viral proteins are implicated in interacting with the autophagy machinery63, 64, 66-68, few interactions 
have been characterized.  
Some viruses target BECN1 or BECN1-containing complexes to evade autophagic degradation, 
including the HIV68, 69, influenza A virus70, African swine fever virus67, foot and mouth disease virus71, αHV 
herpes simplex virus type 1 (HSV-1)27, βHV human cytomegalovirus (HCMV)72, and ɣHVs KSHV and 
ɣHV6826, 43, 44, although the mechanisms of xenophagic evasion and subversion by these viruses are 
poorly understood. Elucidation of the structural features of these interactions will provide basic 
information required for the rational design of therapeutics to selectively inhibit interactions between viral 
proteins and the highly conserved autophagy machinery, allowing xenophagic degradation to proceed 
and clear virus from infected cells. Importantly, targeting these interactions could form the basis of 
therapeutic interventions that defy the development of viral resistance. The highly conserved nature of the 
autophagy machinery exerts evolutionary pressure on viruses to prevent mutations that abrogate 
autophagic down-regulation, since the ability to interact with and manipulate the autophagy machinery 
would be lost as well. However, it will be necessary to characterize the nature of these various 
interactions to design therapeutics that specifically inhibit viral evasion or subversion of xenophagy. 
1.3. Overview of methods used in this research 
1.3.1. Cellular autophagy assays 
Cellular autophagy assays are used to investigate the impact of mutations or protein-protein 
interactions on autophagy induction. Since BECN1 is known to be required for autophagosome 
nucleation, cellular autophagy is evaluated by monitoring and comparing levels of puncta labeled with 
green fluorescent protein (GFP)-tagged light chain 3 (LC3), an autophagosome-specific marker, in cells 
grown in either nutrient-rich or starvation media. GFP-tagged LC3-II is commonly used as a marker of 
autophagosome formation in mammalian cells because the lipidated LC3-II localizes to autophagosome 
membranes, resulting in the formation of discreet green fluorescent puncta, while the non-lipidated 
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precursor (soluble LC3-I) generates a diffuse green fluorescence throughout the cytoplasm73. Therefore, 
GFP-fluorescent puncta can be observed under a fluorescent microscope and quantified. We use human 
breast adenocarcinoma MCF7 cells for all autophagy assays presented in this dissertation as they lack 
detectable endogenous expression of BECN1, resulting in very low basal levels of autophagy, even in 
starvation conditions unless BECN1 is ectopically expressed4, 26, 44. This allows the effect of BECN1 
mutants and proteins that interact with BECN1 to be assayed in the absence of endogenous BECN1. 
1.3.2. Isothermal titration calorimetry (ITC) 
ITC, a useful technique for measuring the thermodynamics of binding reactions, directly monitors 
the heats of binding associated with chemical interactions. Protein-protein binding and dissociation events 
are associated with heat energy exchange with the environment, which makes ITC a convenient method 
for quantifying protein interaction thermodynamics since it does not require labeled protein or protein 
immobilization and requires small quantities of protein74. The ITC experiments described in this 
dissertation were performed on a Low Volume Nano ITC from TA instruments, which can detect heats 
from 0.05-5,000 µJ and determine dissociation constants from 10-9-10-4 M74. The calorimeter contains two 
identical cells, a sample cell and reference cell, which are maintained at a constant temperature (Figure 
1.3A). Titration of a molecule into the sample cell causes heat release or absorption upon binding and 
dissociation. In response, the calorimeter heats or cools the sample cell to maintain the sample and 
reference cells at the same temperature, resulting in a titration curve of the heater power as a function of 
time (Figure 1.3B)75. 
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Figure 1.3. ITC experiments.  
A) Experimental setup75 and B) the raw titration data and data analysis for BID BH3D binding to BHRF1. 
Proper sample preparation is imperative for reliable ITC results. Proteins should be highly pure to 
obtain good data since small impurities can affect the heats detected and protein concentration 
measurements should be highly reliable in order to calculate dependable thermodynamics parameters 
upon fitting the data to the appropriate binding model. All samples should be properly dialyzed against at 
least 2 L of the selected ITC buffer to ensure that they are fully buffer-matched in order to guarantee that 
all detected heats are derived from binding or dissociation events rather than from dilution of mismatched 
buffers. For protein binding interactions, the protein loaded into the syringe is titrated into the protein 
loaded in the cell until the protein in the cell is saturated. For protein dissociation experiments, the dimer 
is loaded into the syringe and titrated into dialysis buffer until the dimer no longer dissociates. In both 
cases, the area of each peak of the titration curve is integrated and plotted versus the molar ratio of the 
molecule in the syringe to the molecule in the cell. The resultant binding curve can then be fitted to a 
binding model through the use of programs such as the NanoAnalyze Software (TA Instruments, New 
Castle, US) to determine the enthalpy of interaction (ΔH), association constant (Ka), and stoichiometry 
(Figure 1.3B). The ΔH corresponds to the intercept of two asymptotic lines corresponding to the minimal 
and maximal heats on the binding curve, the slope at the inflection point indicates the Ka (Ka = 1/Kd), and 
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the molar ratio at the inflection point identifies the stoichiometry of the binding reaction. The change in 
entropy (ΔS) and change in Gibbs free energy (ΔG) can be derived from these data and the reaction 
temperature76. 
1.3.3. Circular dichroism (CD) spectroscopy 
All amino acids, except glycine, are optically active due to their chiral nature and; therefore, rotate 
the polarized light. CD spectroscopy is commonly used to evaluate the secondary structure content, 
folding state, and binding properties of optically active molecules due to the unequal absorption of left-
handed and right-handed circularly polarized light77. CD data for protein are commonly reported as molar 
ellipticity per residue in degrees·cm2·dmol-1 or degrees·M-1·m-1, where degrees ellipticity is defined as the 
angle whose tangent is the ratio of the minor axis to the major axis of the ellipse77. 
CD spectra may be used to estimate the secondary structure of proteins. In the far-UV spectra 
(wavelengths below 250nm) the optical transitions that arise from the amides of the protein backbone 
depending on their geometric arrangement in different secondary structures result in characteristic CD 
spectra for different types of secondary structures (Figure 1.4). Proteins with all α-helical content have 
negative bands at 222 nm and 208 nm and a positive band at 193 nm, while proteins with all β-strand 
content have a negative band at 218 nm and a positive band at 195 nm, and completely disordered 
proteins have minimal ellipticity above 210 nm and a negative band near 195 nm77. The CD spectra of 
proteins containing a mixture of secondary structures reflect a combination of the spectra that arise from 
individual secondary structure components. Therefore, CD spectra can be analyzed with programs such 
as the CDPro software package in order to estimate the secondary structure content of proteins78. 
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Figure 1.4. CD Spectra of polypeptides with representative secondary structures. 
Representative spectra for all α-helical (green), all β-strand (blue), and all coil (red) polypeptides are 
shown. This figure is adapted from the website: https://www.fbs.leeds.ac.uk/facilities/cd/. 
CD spectroscopy is also a useful tool to assess the thermal stability of folded proteins. As folded 
proteins are heated, they begin to lose the characteristic CD spectra that arise from their α-helical or β-
strand content, and begin to generate spectra that resemble disordered proteins79. Since disordered 
protein CD spectra lack ellipticity at 222 nm and 218 nm (Figure 1.4), the significant negative bands for α-
helical and β-strand proteins respectively, thermal unfolding can be observed by monitoring the loss of 
molar ellipticity at these wavelengths as a function of temperature. If unfolding is reversible, the melting 
temperature (Tm) of a protein can be determined by fitting the melting curve with an appropriate 
Boltzmann algorithm to calculate the midpoint of the sigmoid. Even if unfolding is irreversible due to 
protein aggregation, information about relative stability can still be obtained79.  
1.3.4. Small angle X-ray scattering (SAXS) 
SAXS permits low-resolution (50-10 Å) tertiary structure characterizations of macromolecules in 
solution, which are useful for understanding macromolecular folding, unfolding, extended conformations, 
flexibly linked domains, shape, conformation, and oligomerization80. Therefore, SAXS is an especially 
useful method for obtaining solution structure information about flexible proteins, which typically do not 
crystallize, and proteins or protein assemblies whose sizes are unsuitable for nuclear magnetic 
resonance (NMR) or electron microscopy studies. 
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In a SAXS experiment, purified protein in solution is exposed to the X-ray source and the 
scattering signal is derived from the difference in average electron density of protein molecules of interest 
and bulk solvent. Subtraction of the buffer scattering from sample scattering generates an isotropic 
scattering curve due to the random orientation of the sample tumbling in solution. The scattered intensity 
(I(q)) is a function of the magnitude of the scattering vector q. q = (4𝜋sinΘ)λ, where 2Θ is the scattering 
angle and λ is the wavelength of the incident X-ray beam80. The scattering curves are typically plotted as 
log(I) versus q2 (Figure 1.5). Protein homogeneity, radius of gyration (Rg), pairwise-distance distribution 
function (P(r)), maximum particle dimension (Dmax), and folding state can be assessed by analysis of the 
scattering curve. 
The Guinier plot (ln(I) versus q2) is used to assess sample homogeneity and Rg. A linear Guinier 
plot in low q regions, where q x Rg ≤ 1.3 for globular proteins or q x Rg ≤ 0.8 for elongated proteins, is 
indicative of a homogenous, monodispersed sample while curvature of the Guinier plot in the low q 
regions is indicative of aggregation (Figure 1.5)80. The Rg is the average root-mean-square distance to the 
center of density from the surface of the molecule weighted by the scattering length and is calculated 
from the slope of the linear fit of the Guinier plot where slope = -Rg2/3 81. Therefore, between two proteins 
of the same molecular weight, the more compact protein will have a smaller Rg than that of a more 
elongated protein. 
 
Figure 1.5. SAXS scattering data and Guinier plot. 
Log(I) versus q2 plot represents scattering from BSA in solvent, solvent, and the buffer subtracted 
scattering. The ln(I) versus q2 plot represents fresh (homogenous) BSA and incubated (aggregated) BSA. 
This figure is adapted from82. 
The P(r), calculated through a Fourier transform of the scattering curve, provides the distribution 
of distances between electrons in the sample. The P(r) plot provides the Dmax of the molecule, which is 
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the radius of the longest dimension of the protein and is defined by the point where the value of P(r) 
approaches zero. The P(r) plot provides the Dmax of the molecule, which is the radius of the longest 
dimension of the protein and is defined by the point where the value of P(r) approaches zero. (Figure 1.6), 
with globular proteins displaying a bell-curve with a maximum at Dmax/2, elongated proteins displaying an 
asymmetric curve with a maximum at small distances corresponding to the radii in the short dimensions, 
and dumbbell-shaped proteins consisting of two well-separated globular domains displaying two 
maxima82.  
 
Figure 1.6. P(r) curves correlated with protein shape. 
Representative curves for globular (red), elongated (green), disk shaped (yellow), hollow sphere (blue), 
and dumbbell-shaped (magenta) molecules. This figure is adapted from82. 
The Kratky plot (I(q) x q2 versus q) permits a qualitative assessment of protein flexibility (Figure 
1.7). A bell-shaped curve with a maximum at low q and convergence at high q indicates a compact 
molecule, a bell-shaped curve with a clear maximum at low q but incomplete convergence at high q 
indicates a partially folded molecule, and a hyperbolic or plateau shaped curve indicates a disordered 
molecule. Although the Kratky is good at identifying unfolded proteins, it cannot clearly distinguish fully 
folded proteins and partially unfolded proteins with significant structured regions. The dimensionless 
Kratky plot, wherein the intensity I(q) is normalized to the forward scattering intensity I(0) and q is 
normalized to the Rg, plots (q/Rg)2I(q)/I(0) versus q/Rg and permits comparison of globular and extended 
proteins regardless of size to permit semi-quantitative assessments of flexibility83. The normalized Kratky 
maxima for a globular protein is 1.1 at q/Rg = √3 while the maxima for increasingly unfolded proteins 
increases as disorder increases and also shifts towards higher q/Rg values. 
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Figure 1.7. Sample Kratky plot corresponding to different folding states. 
Representative curves for disordered (red), partially folded (gray), and globular (black) molecules. This 
figure is adapted from84. 
The scattering profiles can also be used to reconstruct ab initio molecular envelopes of proteins. 
These low resolution three-dimensional structures are generated via applications of programs such as 
DAMMIF85 with subsequent analysis by DAMSEL, DAMSUP, DAMAVER and DAMFILT86 wherein a bead 
model yielding a scattering pattern that fits the experimental data is generated from an random initial 
model followed by several rounds of simulated annealing. Proteins with known atomic structures can be 
fitted into these molecular envelopes either manually or automatically through programs such as 
SUPCOMB87 to obtain information about the oligomerization state or domain arrangement of multi-
domain proteins. For intrinsically disordered proteins or multi-domain proteins with flexible linker regions, 
the Ensemble Optimization Method (EOM) can be used to determine an ensemble of conformations from 
a random pool of conformations whose averaged theoretical scattering best describes the experimental 
SAXS data in order to generate a model that includes flexible or disordered regions. 
1.3.5. Protein X-ray crystallography 
Protein X-ray crystallography permits atomic resolution structural characterizations of 
macromolecules. The function of a protein and the mechanism of protein-protein or and protein-small 
molecule interactions can often be deduced from the atomic resolution three dimensional structures 
determined by X-ray crystallography. Therefore, this technique is a very useful tool for probing the 
structure-function relationship of proteins. However, X-ray crystallography only provides structural 
information about the low-energy conformation trapped during crystallization; therefore, this technique is 
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limited to well-ordered proteins as flexibility typically prevents acquisition of crystals that diffract to atomic 
resolution. 
Protein crystallization requires a highly pure and homogenous protein sample. Crystallization is 
induced by bringing the protein solution to supersaturation, a thermodynamically unstable state that 
induces a portion of the protein to come out of solution either in the form of crystal nuclei that grow into 
larger crystals or precipitate. Protein concentration, precipitant type, precipitant concentration, buffer type, 
buffer pH, temperature, crystallization technique, ionic strength, and additives that promote crystallization 
can all affect the crystallization process88. Therefore, determining the appropriate conditions to promote 
growth of high quality protein crystals may require several rounds of optimization. Vapor diffusion is the 
most widely used crystallization technique, wherein a drop composed of a mixture of protein sample and 
reagent (mixture of precipitant, buffer, salt, crystallization additive, etc.) are placed in vapor equilibrium 
with a reservoir of reagent. Typically, the drop contains a lower reagent concentration than the reservoir 
so that, in order to attain equilibrium, water vapor evaporates from the drop, thereby causing the drop to 
become more concentrated in protein and reagent88. The increased concentrations in the drop may 
induce the state of supersaturation that promotes crystal nucleation and growth.  
X-ray diffraction data is recorded by exposing the protein crystal to a monochromatic X-ray beam 
generated from accelerating electrons in a synchrotron storage ring or from electrons striking a copper 
anode. Synchrotron sources typically facilitate the attainment of a higher signal-to-noise ratio of the 
diffraction image and shorter exposure times due to their more intense and better focused X-ray beams 
and are therefore preferred for obtaining high-resolution diffraction data89. Diffraction data is usually 
collected from frozen crystals at 100 K to facilitate the collection of a complete data set from a single 
crystal by mitigating radiation damage90. X-ray waves are scattered by the electrons within the crystal 
resulting in a diffraction pattern that register as spots of different intensities, called reflections, on the 
detector88.  
Diffraction data processing permits determination of the space group, unit cell parameters, and 
crystal orientation in the beam88. Once the cell and orientation information is known, the reflections can 
be indexed and assigned their Miller indices, which consist of three integers: h, k, and l, to determine if a 
complete data set can be obtained91. The next stage of data processing involves measurement of the 
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intensity of the reflections. A full diffraction data set typically consists of many diffraction images, therefore 
equivalent reflections from each image must be merged and scaled so that the intensities of all of the 
images can be related, permitting all symmetry-related reflections to be merged into a unique set of 
reflections88. The Pearson correlation coefficient between random half-data sets (CC1/2) is used to assess 
data quality and determine the high-resolution cutoff for data processing92. CC1/2 is related to the signal-
to-noise ratio of the data and values of 0.5 and above are considered acceptable. 
The intensity of each reflection is a result of both the amplitude of the diffracted waves and the 
phase difference, expressed as an angle, between the diffracted waves. Both the amplitudes and phases 
of the diffracted X-rays are required for calculation of the electron density map. The electron density 𝜌(x,y,z) is calculated using a Fourier transformation93: 𝜌(x,y,z) =(1/Vz)∑h∑k∑lF(h,k,l)exp[-2𝜋i(hx + ky + lz)], 
where V is the volume of the unit cell; F(h,k,l) is the structure factor for the Bragg reflection with Miller 
indices h, k, and l; x,y, and z are the fractional coordinates of the unit cell, and the triple summation is 
over all values of the Miller indices. F(h,k,l), the structure factor, is defined by the amplitude and phase of 
the reflection. While the amplitude can be calculated from the measured intensity, the phases cannot be 
determined directly. 
Several methods exist for phase determination, including multiple isomorphous replacement, 
multi-wavelength anomalous dispersion, single-wavelength anomalous dispersion, and molecular 
replacement (MR)94. All structures presented in this dissertation were solved by MR. MR utilizes the 
phases of the structure factors from a known structure of a homologous protein to estimate the phases of 
the unknown structure95.   
Once the amplitudes and phases of the reflections are identified, new structure factors can be 
calculated and used to calculate the electron density map into which the new protein structure can be 
built. The newly built structure model must then be refined in order to improve its agreement with the 
electron density map. The PHENIX96 software suite can be used to complete the MR, model building, and 
refinement steps of protein crystal structure solution. The R factor is a useful quality indicator to evaluate 
the agreement between an electron density map and a model97. R factor = ∑hkl||Fobs| - |Fcalc||/∑hkl|Fobs|, 
where |Fobs(hkl)| are the measured amplitudes and |Fcalc(hkl)| are the amplitudes measured from the 
model. In order to permit validation of the final structure, a percentage of reflections are omitted during 
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the modeling and refinement process98. The Rfree refers to how well the observed structure factors from 
the set of reflections omitted during the modeling and refinement process agree with the structure factors 
calculated from the model. The Rwork (calculated from the reflections used during modeling and 
refinement) should be within about 5% of the Rfree.  
1.4. Specific aims of this research 
Given that a growing number of autophagy proteins are recognized to bear IDRs and flexible 
ordered regions, it is important to understand how conformational flexibility affects protein function. 
Therefore, the goal of this dissertation is to identify and understand conformational and binding-induced 
disorder-to-order transitions in proteins that regulate autophagy. The specific aims of this research are:  
1. To devise a diagnostic method to identify IDRs likely to become helical upon binding, 
even in the absence of known binding partners. 
2. To investigate conformational flexibility within BECN1, which contains two structured 
domains sharing an overlapping region that has been crystallized in two mutually 
exclusive states. 
3. To investigate the interaction between BECN1 and Nef, a protein that is critical for HIV 
pathogenesis and modulation of autophagy.  
4. To investigate the binding of the anti-apoptotic KSHV vBcl-2 to the BH3Ds of the NOXA, 
a pro-apoptotic BCL2, and BECN1. 
5. To determine the role in autophagy regulation by BHRF1, a vBCL2 encoded by EBV, and 
characterize its binding to BH3Ds. 
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CHAPTER 2. IDENTIFYING INTRINSICALLY DISORDERED PROTEIN REGIONS LIKELY TO 
UNDERGO BINDING-INDUCED HELICAL TRANSITIONS 
2.1. Introduction 
The canonical view that protein structure dictates function requires a more nuanced 
understanding in light of the growing number of proteins recognized to bear IDRs. IDRs lack the ability to 
form stable secondary structures such as α-helices and β-strands, and well-packed tertiary structures99, 
100. IDRs tend to have sequences of lower complexity and an increased number of polar or charged 
residues rather than hydrophobic residues likely to pack in the interior of a protein99, 101. IDRs also tend to 
have low sequence conservation30, 102. They appear to be especially prevalent in eukaryotes, where at 
least 35-50% of proteins are predicted to bear IDRs103, 104. This prevalence implies that IDRs must confer 
some important evolutionary advantage in advanced organisms. 
IDRs are increasingly recognized to mediate many functions essential for life. They appear to 
regulate protein lifetime by providing targets for proteolysis105, 106. Perhaps their most common function is 
to mediate macromolecular interactions, including protein-protein, protein-DNA, and protein-RNA 
interactions100. The low sequence conservation and conformational flexibility inherent in IDRs may 
provide IDRs with the evolutionary flexibility required to facilitate multiple protein-protein interactions100, 
104.  Consequently, IDRs are common among interaction hub proteins (regulatory and signaling proteins 
that bind a variety of diverse partners)107. IDRs often also serve as sites of phosphorylation, and in turn, 
phosphorylation appears to modulate interactions with other macromolecules108-110. Therefore, it is 
important to understand the structure-function relationship of IDRs and IDR-mediated binding. 
Often, binding to appropriate partners appears to stabilize secondary structure elements within 
IDRs99, 111, although it has recently been shown that up to one third of all residues are disordered in 
protein complexes112. Regions that have experimentally been shown to undergo disorder-to-order 
transitions have been called Molecular Recognition Features (MoRFs)38, 39. MoRFs have been further 
classified as α-MoRFs, β-MoRFs or σ-MoRFs, depending on whether they fold into α-helices, β-strands or 
stable coils, respectively. Understanding the structures of these regions in both unbound and bound 
states is important for understanding the mechanism of biological function of these regions, and ultimately 
for rational design of therapeutics targeting these interactions111. However, binding partners remain 
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unknown for most IDRs, complicating experimental elucidation of structural transitions within IDRs. We 
hypothesized that it would be possible to identify α-MoRFs by bioinformatics analyses using programs 
such as ANCHOR113 and DisoRDPbind114 combined with experimental evaluation of chemically-induced 
disorder-to-helix transitions. 
Therefore, in this study our goal was to develop a method to identify α-MoRFs in the absence of 
known binding partners. We first performed a bioinformatics analysis using the programs IsUnstruct115, 
PONDR-FIT116 and IUPred117 to predict IDRs, then used the programs ANCHOR113 and DisoRDPbind114 
to identify IDRs that are likely to be stabilized in ordered structures upon binding. JPred4118 was used to 
predict potential secondary structure. We used CD spectroscopy to monitor change in secondary 
structure content of diverse IDRs induced by 2,2,2-trifluoroethanol (TFE), which is known to stabilize α-
helical structure in disordered amino acid sequences that have some native tendency to form helices119-
123. Our results demonstrate that IDRs that are not predicted by ANCHOR to fold upon binding do not 
become helical in the presence of TFE. IDRs that are predicted to fold fall into two groups. One group 
becomes more helical upon addition of TFE and includes all the known α-MoRFs that were included in 
our study. The other group does not become helical and includes examples of β-MoRFs. Therefore, we 
propose that predictions using programs such as ANCHOR combined with experimental evaluation using 
TFE may provide a general method to identify IDRs that undergo a binding-induced disorder-to-helix 
transition.  
2.2. Materials and methods  
2.2.1. Production of IDRs  
Peptides corresponding to the selected IDRs (Table 2.1) were chemically synthesized, HPLC 
purified to >90% purity, and purity confirmed by electrospray mass spectrometry (RS Synthesis or 
EZBioLabs). For each peptide, a 1 mM stock solution in 10 mM phosphate pH 7.4, 100 mM ammonium 
sulfate was prepared. 
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Table 2.1. IDR sequences used in TFE study. 
Protein Accession # Peptide Sequence 
TRAP220 Q925J9 637GNTKNHPMLMNLLKDNPA654 
BECN1 Q14457 105DGGTMENLSRRLKVTGDLFDIMSGQT130 
GRIM Q24570 1MAIAYFIPDQAQLLA15 
p53 P04637 367SHLKSKKGQSTSRHKKLMFKTE388 
GOPC Q9HD26 248RHKTVIRACRGRNDLKRPMQAPPGHDQDSL277 
ATG3 Q9NT62 129ENKDNIRLQDCSALCEEEEDEDEGEAADME158 
ATG9A Q7Z3C6 810 AEDGQSASRHPEPVPEEGSEDELPPQVHKV 839 
BECN1 Q14457 76DGVSRRFIPPARMMSTESANSFTLIGEASD105 
AMBRA1 Q9C0C7 527TQQAQEMLNNNIESE541 
GOPC Q9HD26 255ACRGRNDLKRPMQAPPGHDQDSLKK279 
BECN1 Q14457 50AQAKPGETQEEETNSGEEPFIETPRQDGV78 
ATG16L1 Q676U5 59EKHDVPNRHEISPGHDGTWNDNQLQE84 
ATG2A Q7Z3C6 1244HPPPRPPSPTEIAGQKLSESPASLPSCPPV1273 
Table note. Accession # corresponds to the full-length amino acid sequence downloaded from NCBI 
RefSeq protein database (http://www.ncbi.nlm.nih.gov/refseq).   
2.2.2. Prediction of disorder and likelihood of folding upon binding 
The amino acid sequences of the full-length proteins containing the thirteen selected IDRs were 
downloaded from the NCBI RefSeq protein database (http://www.ncbi.nlm.nih.gov/refseq) (Table 2.1). 
These sequences were analyzed with IsUnstruct (http://bioinfo.protres.ru/IsUnstruct/)115, PONDR-FIT 
(http://www.disprot.org/metapredictor.php)116, and IUPred (http://iupred.enzim.hu)117 to predict whether 
the selected peptide sequences were intrinsically disordered (Table 2.2). The sequences were also 
analyzed with ANCHOR (http://anchor.enzim.hu)113 and DisoRDPbind (http://biomine-
ws.ece.ualberta.ca/DisoRDPbind/index.php)114 to predict whether the selected IDRs were likely to 
undergo binding-associated structure stabilization (Table 2.2). Finally, these sequences were analyzed 
with Jpred4 (http://www.compbio.dundee.ac.uk/jpred/)118 to predict secondary structure. 
2.2.3. CD spectroscopy  
Peptides were diluted to 25-100 µM in 10 mM phosphate pH 7.4, 100 mM ammonium sulfate and 
either 0%, 25%, or 40% v/v TFE. After a 1 hour incubation on ice, continuous scanning CD spectra were 
recorded from 190 to 240 nm at 4 °C in a 300 µL quartz cell (0.1 cm path length) on a Jasco J-815 
spectropolarimeter equipped with a Peltier thermoelectric temperature control. Secondary structure 
content was estimated by analyzing the CD data using three analysis programs, SELCON3, CDSSTR, 
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and CONTIN, from the CDpro suite within the Jasco software124-126. For each single peptide set (i.e. 0%, 
25% and 40% TFE), a consistent reference protein database was used for SELCON3, CDSSTR, and 
CONTIN estimations. For each spectrum, the average secondary structure was calculated by averaging 
estimated secondary structure content obtained from the three CD data analysis programs (Tables 2.3-
2.5). 
2.3. Results  
2.3.1. Selection of IDRs for analysis  
We selected thirteen diverse IDRs for examination (Table 2.1), focusing on IDRs or fragments of 
IDRs that were no longer than 30 residues, to ensure that we did not include more than one Anchor 
region within the IDR being examined. IDRs that have experimentally been shown to be either α-MoRFs 
or β-MoRFs with known binding partners were identified by a literature search and served as our control 
set (Table 2.2). The known α-MoRFs selected included TRAP220 residues 637-654 (PDB 1XDK) and 
BECN1 residues 105-130 (PDB 3DVU)30, 44, 127. A β-MoRF comprising GRIM residues 1-15 (PDB 1SE0, 
1JD5) was used as a negative control for the analysis128, 129. We also included p53 residues 367-388, 
which can form either a α-helix (PDB 1DT7) or a β-strand (PDB 1MA3) depending on the binding 
partner130, 131.  
IDRs that have not been experimentally examined were selected from our prior bioinformatics 
analyses wherein we identified consensus IDRs, defined as regions of at least 25 consecutive residues 
predicted to be disordered by at least three of four disorder prediction programs104. The experimentally 
unverified IDRs selected included GOPC residues 248-277, ATG3 residues 129-158, ATG9A residues 
810-839, BECN1 residues 76-105, AMBRA1 residues 527-541, GOPC residues 255-279, BECN1 
residues 50-78, ATG16L1 residues 59-84, and ATG2A residues 1244-1273 (Table 2.1).  
We assessed disorder in all selected sequences by analyzing the full-length protein sequences 
using the programs IsUnstruct115, PONDR-FIT116 and IUPred117. IsUnstruct estimates the energy of each 
residue in either the ordered or disordered state to predict whether each residue will be ordered or 
disordered based upon amino acid sequence115. Our IsUnstruct analyses (Table 2.2) indicate that all 
selected peptides are completely disordered except short stretches comprising GRIM residues 4-8, 
BECN1 residues 115-130, ATG3 residues 129-136, and GOPC residues 255-258. 
 21 
Table 2.2. Predictions of disorder and binding regions. 
Protein 
name 
(residues) 
Residues predicted to be 
intrinsically disordered 
 
Predicted binding region of 
IDR 
 
Predicted 
secondary 
structure 
(Jpred4) 
IsUnstruct PONDR-
FIT 
IUPRED Anchor DisoRDPbind 
(predicted binding 
partner) 
Known MoRFs; contain Anchor regions 
TRAP220  
(637-654) 
637-654 637-654 637-654 637-654 None α: 643-648 
BECN1  
(105-130) 
105-114 105-109 105, 108-
112, 124, 
128 
117-127 None α: 111-124 
GRIM  
(1-15) 
1-3, 9-15 1-15 None 1-15 1-15 (RNA) 
4-15 (protein) 
α: 10-15 
p53  
(367-388) 
367-388 None 367-388 367-388 360-383 (DNA) None 
IDRs with unidentified binding partners; contain Anchor regions 
GOPC  
(248-277) 
258-277 248-277 255-277 248-257 269, 272-277 
(DNA) 
β: 251-254 
ATG3  
(129-158) 
137-158 129-158 139-158 136-143 139-158 (protein) None 
ATG9A  
(810-839) 
810-839 810-839 810-839 831-839 819, 821, 833-839 
(protein) 
None 
BECN1 
(76-105) 
76-105 76-105 76-105 79-103 60-84 (protein) None 
AMBRA1 
(527-541) 
527-541 527-541 527-541 530-538 527-541 (protein) α: 527-535 
IDRs with unidentified binding partners; lack Anchor regions 
GOPC  
(255-279) 
258-279 255-279 255-279 None 269, 272-279 
(DNA) 
None 
BECN1  
(50-78) 
50-78 50-78 50-78 None 59-78 (protein) None 
ATG16L1  
(59-84) 
59-84 None 59-84 None None α: 65-66, 
80-84 
ATG2A  
(1244-1273) 
1244-1273 1244-
1273 
1244-
1273 
None 1257-1260 (protein) None 
 
PONDR-FIT predicts per-residue disorder based on a combination of multiple features such as 
the ratio of net charge and hydrophobicity, amino acid frequency in disordered regions, and sequence 
complexity; with accuracy of prediction increasing with the length of the predicted disordered region116.  
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Our PONDR-FIT analyses (Table 2.2) indicate that all peptides we selected are completely disordered 
except for p53 residues 367-388, ATG16L1 residues 59-84, and a stretch comprising BECN1 residues 
110-130. 
IUPred, a program which is also incorporated into the PONDR-FIT suite, calculates a disorder 
probability for each residue by using the amino acid composition to estimate formation of energetically 
favorable interactions, thereby identifying residues that lack such interactions and do not contribute to a 
stable folded structure132. The long-disorder algorithm, a context-independent prediction that takes 100 
flanking residues into consideration117, predicts all selected peptides to be completely disordered, except 
for GRIM residues 1-15 and shorter stretches comprising BECN1 residues 113-123, GOPC residues 248-
254, and ATG3 residues 129-138 (Table 2.2). 
Thus, except for stretches of BECN1 residues 105-130, all of the protein regions included in this 
study are predicted to be disordered by either IsUnstruct, PONDR-FIT, or IUPred; and most of them are 
predicted to be disordered by at least two programs.  However, since BECN1 residues 105-130 have 
previously been experimentally shown to be disordered even within larger protein fragments30, we 
included it in our study.  
2.3.2. Prediction of IDRs likely to fold upon binding  
Next we used the programs ANCHOR113, DisoRDPbind114 and JPred4118 to analyze full-length 
protein sequences to predict the ability of the selected IDRs to form folded structures (Table 2.2). The 
ANCHOR program analyzes amino acid sequence to predict short regions (that we term Anchor regions) 
within or flanking IDRs that likely stabilize the IDR in an ordered state upon binding.  Of the selected 
IDRs, Anchor regions are predicted (Table 2.2) in all the known α-MoRFs and β-MoRFs: TRAP220 
residues 637-654, BECN1 residues 105-130, GRIM residues 1-15 and p53 residues 367-388; as well as 
in five experimentally untested IDRs: GOPC residues 248-277, ATG3 residues 129-158, ATG9A residues 
810-839, BECN1 residues 76-105 and AMBRA1 residues 527-541 (Table 2.2). Lastly, four experimentally 
untested IDRs were predicted to not contain Anchor regions: GOPC residues 255-279, BECN1 residues 
50-78, ATG16L1 residues 59-84, and ATG2A residues 1244-1273. Although GOPC residues 255-279 
contain three Anchor residues (255-257) (Table 2.2), this is insufficient to be considered an Anchor 
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region, which must contain at least five residues113. Therefore, the IDR comprising GOPC residues 255-
279 was included in the experimental set lacking Anchor regions. 
DisoRDPbind predicts RNA, DNA, and protein binding regions within IDRs based on amino acid 
content, sequence complexity, predicted structure and disorder, and sequence alignments114. Of the 
known MoRFs that we selected, all are predicted to contain Anchor regions; however, only GRIM is 
predicted by DisoRDPbind to contain a protein-binding site (Table 2.2). Among the five experimentally 
unverified IDRs bearing Anchor regions (GOPC residues 248-277, ATG3 residues 129-158, ATG9A 
residues 810-839, BECN1 residues 76-105, and AMBRA1 residues 527-541), only GOPC residues 248-
277 are not predicted by DisoRDPbind to contain a protein-binding region. Conversely however, two of 
the IDRs lacking Anchor regions, BECN1 residues 50-78 and ATG2A residues 1244-1273, are predicted 
by DisoRDPbind to contain protein-binding sites. Thus, the binding regions predicted by ANCHOR and 
DisoRDPbind are not consistent. 
Full-length protein sequences were also analyzed by JPred4118 to predict secondary structure 
(Table 2.2). JPred4 analysis (Table 2.2) indicates some secondary structure in seven of the IDRs, 
however; only five of these predicted secondary structures were of sufficient length for the formation of 
stable α-helices or β-strands.  
Three of these IDRs, BECN1 residues 105-130, TRAP220 residues 637-654 and GRIM residues 
1-15 are known MoRFs, with known binding partners, and were predicted by JPred4 to contain at least 
six contiguous α-helical residues (Table 2.2).  While TRAP220 residues 637-654 and BECN1 residues 
105-130 are α-MoRFs, GRIM residues 1-15 form a β-MoRF, with residues 3-6 forming a β-strand that is 
hydrogen-bonded to one end of a β-sheet from its binding partner DIAP1 (Drosophila melanogaster 
inhibitor of apoptosis protein)128, 129. Only the prediction for TRAP220 (Table 2.2) is entirely consistent with 
available experimental data, as TRAP220 residues 643-648 have been shown to be become helical upon 
binding127. While Jpred4 only predicts that BECN1 residues 111-124 are helical (Table 2.2), BECN1 
residues 108-126 have been shown to become helical upon binding30, 44, 46, thus; JPred4 does not predict 
the complete extent of the helical structure adopted by this IDR upon binding. Finally, for p53, residues 
383-384 have been shown to form a β-strand with two residues of the Sir2 enzyme130, and residues 378-
384 have been shown to become helical upon binding Ca2+-bound S100B (ββ)131, but neither region is 
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predicted by JPred4 to be structured (Table 2.2). Thus the JPred predictions do not appear to completely 
accurately predict the secondary structure induced upon binding to known partners.  
2.3.3. All the selected IDRs lack α-helical structure in solution  
CD spectra reflect the average signal from the entire molecular population over the time course of 
the measurement. Therefore, it is impossible to distinguish between the average secondary structures 
maintained in the entire population of the sample, versus more extensive secondary structure maintained 
in a smaller sub-population of the sample with a corresponding decrease of that secondary structure in 
the remainder of the population. Although the flexible structure of IDRs enables rapid (<millisecond) 
conformational exchange amongst multiple conformations including fully disordered and transient, 
partially-folded conformers in solution133, 134, there is no reason to expect that a sub-population within a 
chemically identical set of molecules in a chemically homogeneous environment would be more ordered 
on average than the rest of the population. Therefore, since the molecules in solution are identical in 
terms of conformational behavior, we can apply the first interpretation, which requires a definition of 
minimal length to define a stable secondary structure, rather than the second interpretation, which 
requires a definition of minimal percentage of the population that should adopt a given secondary 
structure to be considered a physiologically relevant structural state. The first interpretation has been 
commonly used in classical literature, and definitions of minimal length to define secondary structure are 
well established135. A minimal helix is defined by the formation of two consecutive hydrogen bonds, 
therefore; a minimal α-helix requires at least six residues in a helical conformation135, 136. A β-strand 
cannot exist unless stabilized by hydrogen bonds to another strand. Stable β-structure is defined by four 
consecutive hydrogen bonds in either a parallel or anti-parallel bonding pattern, thereby involving at least 
six residues (three residues in each of two strands)135. 
Secondary structure content estimated by analysis of CD spectra for each of the thirteen IDRs 
showed that none contained more than two residues in a helical conformation (Figures 2.1-2.3, Table 2.3-
2.5), which is insufficient for the formation of a stable α-helix requiring a minimum of six residues. 
Formation of a minimal beta-structure requires six residues135, and seven of the thirteen IDRs (Table 2.3-
2.5) appear to have between six to eight residues in extended or β-conformation which may be sufficient 
for forming short stable β-hairpins (Table 2.3-2.5). Thus, while none of the selected IDRs had stable 
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helical structure, several may have short β-strands. However, the marginal secondary structure content 
suggests that all the peptides tested are IDRs. 
 
Figure 2.1. CD spectra of IDRs lacking Anchor regions.  
Different spectra correspond to 0% TFE (blue), 25% TFE (red), or 40% TFE (green). 
 
Figure 2.2. CD spectra of IDRs with Anchor regions that do not undergo a TFE-induced helical transition.  
Different spectra correspond to 0% TFE (blue), 25% TFE (red), or 40% TFE (green). (A) A known β-
MoRF. (B-C) IDRs with experimentally unverified structural transitions. 
 
Figure 2.3. CD spectra of IDRs with Anchor regions that undergo a TFE-induced helical transition.  
Different spectra correspond to 0% TFE (blue), 25% TFE (red), or 40% TFE (green). (A-C) Known α-
MoRFs. (D-F) IDRs with experimentally unverified structural transitions. 
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Table 2.3. Secondary structure content in consensus IDRs lacking Anchor regions. 
Protein 
(residues in peptide) 
BECN1 
(50-78) 
GOPC 
(255-279) 
ATG2A 
(1244-1273) 
ATG16L1 
(59-84) 
  Average estimated secondary structure content (%) 
Helix 
(%) 
No TFE 1 ± 2 6 ± 2 5 ± 2 4 ± 2 
25% TFE 7 ± 6 12 ± 8 18 ± 1 17 ± 1 
40% TFE 1 ± 1 6 ± 3 16 ± 1 3 ± 2 
Strand 
(%) 
No TFE 16 ± 10 32 ± 1 19 ± 5 16 ± 6 
25% TFE 14 ± 11 28 ± 4 24 ± 2 17 ± 2 
40% TFE 8 ± 3 35 ± 4 25 ± 1 35 ± 2 
Coil 
(%) 
No TFE 81 ± 8 61 ± 1 76 ± 2 79 ± 8 
25% TFE 80 ± 17 59 ± 4 58 ± 2 65 ± 3 
40% TFE 89 ± 3 58 ± 1 58 ± 2 60 ± 6 
Table 2.4. Secondary structure content in known MoRFs. 
Protein 
(residues in peptide) 
GRIM 
(1-15) 
TRAP220 
(637-654) 
BECN1 
(105-130) 
p53 
(367-388) 
Type of MoRF β-MoRF α-MoRF α-MoRF α- & β- MoRF 
Average estimated secondary structure content (%) 
Helix 
(%) 
No TFE 0 ± 1 7 ± 3 2 ± 1 6 ± 4 
25% TFE 0 ± 4 62 ± 10 48 ± 2 34 ± 10 
40% TFE 7 ± 7 50 ± 3 55 ± 2 31 ± 1 
Strand 
(%) 
No TFE 9 ± 8 29 ± 5 28 ± 7 31 ± 2 
25% TFE 19 ± 14 6 ± 3 12 ± 1 12 ± 4 
40% TFE 22 ± 16 7 ± 6 8 ± 1 18 ± 2 
Coil 
(%) 
No TFE 89 ± 7 62 ± 6 65 ± 6 63 ± 2 
25% TFE 72 ± 7 32 ± 11 40 ± 2 54 ± 7 
40% TFE 70 ± 20 43 ± 10 36 ± 2 50 ± 4 
Table 2.5. Secondary structure content in IDRs with Anchor regions with unidentified binding partners. 
Protein 
(residues in peptide) 
ATG3 
(129-158) 
ATG9A 
(810-839) 
BECN1 
(76-105) 
AMBRA1 
(527-541) 
GOPC 
(248-277) 
Average estimated secondary structure content (%) 
Helix 
(%) 
No TFE 3 ± 5 3 ± 2 1 ± 1 2 ± 1 3 ± 1 
25% TFE 4 ± 1 5 ± 4 20 ± 3 37 ± 1 4 ± 1 
40% TFE -3 ± 6 4 ± 0 33 ± 3 50 ± 4 20 ± 1 
Strand 
(%) 
No TFE 27 ± 8 20 ± 4 4 ± 2 4 ± 4 19 ± 4 
25% TFE 26 ± 3 28 ± 2 8 ± 6 10 ± 5 17 ± 6 
40% TFE 22 ± 9 18 ± 5 7 ± 4 8 ± 5 20 ± 4 
Coil 
(%) 
No TFE 63 ± 15 76 ± 2 95 ± 4 95 ± 5 79 ± 4 
25% TFE 67 ± 5 59 ± 15 53 ± 5 53 ± 5 78 ± 4 
40% TFE 76 ± 10 78 ± 5 43 ± 8 43 ± 9 60 ± 4 
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2.3.4. IDRs lacking Anchor regions fail to undergo disorder-to-helix transitions  
The secondary structure estimated from the CD spectra indicates that addition of TFE causes 
varying fluctuations in β-content of the different IDRs lacking Anchor regions (Table 2.3).  In BECN1 
residues 50-78, addition of 40% TFE, results in a decrease in the number of residues in β-conformation 
from five to two, clearly insufficient for the formation of stable β-strands. However, GOPC residues 255-
279 and ATG2A residues 1244-1273 show marginal increases of residues in β-content at 25% and 40% 
TFE, that would enable them to form short stable β-sheets. Finally, β-content in ATG16L (residues 59-84) 
remains constant at four residues upon addition of 25% TFE, but in 40% TFE, the number of residues in β 
-conformation increases to nine residues, which is sufficient for formation of stable β-strands. 
Strikingly, the secondary structure content estimated from the CD spectra indicates that addition 
of TFE does not induce stable helical structure in the four IDRs lacking Anchor regions (Figure 2.1, Table 
2.3). Helical content peaks in the presence of 25% TFE and is maintained or slightly decreased in 40% 
TFE; however, neither condition results in the six-residue minimum required for a stable helix.  Thus, the 
changes in coil content estimated from the CD spectra of the four IDRs lacking Anchor regions appear to 
simply reflect fluctuations in helix and strand content (Table 2.3).  
2.3.5. IDRs that bear Anchor regions, yet do not undergo TFE-induced helical transitions, may be 
β- or σ- MoRFs  
GRIM residues 1-15, which include a known β-MoRF and bear an Anchor region, do not become 
helical in the presence of TFE (Figure 2.2A, Table 2.4). The helical content, none at 0% and 25% TFE, 
and one residue at 40% TFE, is insufficient to stabilize a minimal helix, which requires at least six 
residues. However, while the number of residues in β-conformations increases marginally in 25% and 
40% TFE, the three residues estimated to be in extended conformation in the presence of TFE, are also 
insufficient to form a stable β-strand, which requires six residues. These results demonstrate that TFE 
does not induce helicity in β-MoRFs, nor does it appear to support formation of stable β-structure.  
Two of the Anchor region-containing IDRs for which binding partners have not yet been identified, 
ATG3 residues 129-158 and ATG9A residues 810-839, also do not undergo a disorder-to-helix transition 
in either 25% or 40 % TFE (Figure 2.2). These IDRs contain two or fewer helical residues (Table 2.5) 
even in 25% and 40% TFE, which is insufficient for the formation of a single stable helical turn. This 
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failure to induce helicity indicates that ATG3 residues 129-158 and ATG9A residues 810-839 are not α-
MoRFs. In contrast, in both these IDRs, there is sufficient β-content in TFE concentrations ranging from 
0%-40% to permit the formation of β-strand structure; with the β-content increasing marginally at 25% 
TFE, then decreasing marginally at 40% TFE. Thus, TFE causes a marginal increase in the β-content, 
similar to that observed for the known β-MoRF, GRIM residues 1-15. However, as this increase is 
marginal, and given the limited number of known β-MoRFs available for testing, we cannot suggest that 
this method is a reliable way of identifying β-MoRFs. 
2.3.6. IDRs that bear Anchor regions and undergo TFE-induced helical transitions are α-MoRFs  
TRAP220 residues 637-654, BECN1 residues 105-130, and p53 residues 367-388 are all known 
α-MoRFs with known binding partners. Consistent with this, addition of TFE induces helicity in each IDR 
(Figure 2.3 A-C). Although none of these IDRs have a helical content sufficient for formation of a stable 
helix in the absence of TFE, addition of TFE induces a significant disorder-to-helix transition in all three 
IDRs (Table 2.4). TFE-induced helical content peaks upon addition of 25% TFE, with 40% TFE inducing 
slight fluctuations. In TRAP220 residues 637-653, a maximum of eleven helical residues are stabilized at 
25% and nine are maintained at 40% TFE. In BECN1 residues 105-130, 25% and 40% TFE induces the 
stabilization of thirteen and fourteen helical residues respectively. And finally, in p53 residues 367-388, 
25% and 40% TFE stabilize eight and seven helical residues respectively.  In each of these IDRs, the 
number of residues in β- and coil conformations decreases upon addition of TFE, suggesting that TFE 
destabilizes β-structure in these α-MoRFs.  
All known α-MoRFs become helical in the presence of 25% and 40% TFE; however, the 
maximum number of helical residues induced is not always comparable to the number of helical residues 
actually observed in the corresponding crystal structures. Of the three known α-MoRFs, only in p53 does 
TFE induce a number of helical residues (Table 2.4) comparable to that observed in the crystal structure. 
Residues 378-384 (seven residues) of p53 become helical upon binding Ca2+-bound S100B(ββ) 131, which 
is equal to those stabilized by 40% TFE and just one less than the maximum observed (eight helical 
residues) in 25% TFE. However, in BECN1 residues 105-130, a maximum of fourteen residues are 
stabilized in helical conformations by 40% TFE, while upon binding to BCL2 homologs, BECN1 residues 
108-126 (nineteen residues) form a helix43, 44, 46, indicating that for this IDR the number of residues that 
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undergo helical transformation may be underestimated by this method. Conversely, this method appears 
to slightly overestimate the number of TRAP220 residues that become helical upon binding. Only 
TRAP220 residues 643-648 (six residues) form a helix upon binding the retinoid receptor (RAR/RXR) 
ligand binding domain heterodimer127; however, eleven and nine helical residues are stabilized by 25% 
and 40% TFE respectively. Therefore, although this method stabilizes helical structure in α-MoRFs, the 
number of helical residues induced upon binding cannot be directly inferred from the secondary structure 
content estimations.   
Amongst the Anchor-containing IDRs with unknown binding partners (Table 2.2), three IDRs: 
BECN1 residues 76-105, AMBRA1 residues 527-541, and GOPC residues 248-277, appear to undergo a 
TFE-induced disorder-to-helix transition. Helical content in BECN1 residues 76-105 increases from none 
in the absence of TFE, to six and ten, in 25% and 40% TFE respectively (Table 2.5, Figure 2.3D-F). In 
AMBRA1 residues 527-541, helical content increases from nothing in the absence of TFE to five and 
eight, in 25% and 40% TFE respectively. This increase occurs at the expense of residues in coil 
conformation, as both contain just one residue in β-conformation in the absence of TFE. Like the known 
α-MoRFs, the increase in helical content of BECN1 residues 76-105 and AMBRA1 residues 527-541 is 
observed in both 25% and 40% TFE. However, unlike the known α-MoRFs and BECN1 residues 76-105, 
for AMBRA1 residues 527-541, a stable helix comprising at least six residues is induced only in 40% TFE 
(Table 2.5); while in GOPC residues 248-277, 25% TFE is insufficient for inducing the disorder-to-helix 
transition, which occurs only upon addition of 40% TFE (Figure 2.3F, Table 2.5). Further, unlike the 
known α-MoRFs, the increase in helicity occurs only at the expense of residues in coil conformation, and 
residues in β-conformation do not appear to be destabilized by the addition of TFE (Table 2.4-2.5).  
2.3.7. Effect of amino acid content on response to TFE 
Amino acid composition of the various IDRs used in this study was analyzed (Figure 2.4). 
Relative to the average frequency of 37% hydrophobic residues and 51% polar or charged amino acids in 
proteins137, all but one of the selected IDRs have a lower content of hydrophobic residues and a greater 
content of polar or charged residues, as is expected for typical intrinsically disordered regions (Figure 
2.4). The known β-MoRF, GRIM residues 1-15, is an exception as 67% of this IDR is comprised of 
hydrophobic residues, which is higher than average; while only 30% of the residues are polar or charged, 
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which is lower than average. All but two of the selected IDRs also have a lower proline content (Figure 
2.4), compared to the average frequency of 5% found in proteins137. While the proline content of GRIM 
residues 1-15 is similar to the average; ATG2A residues 1244-1273 contain 33% prolines, which is 
substantially higher than the average proline content. Neither of these IDRs undergoes a transition to 
helix. Lastly, the glycine content of all the selected IDRs is approximately 7% (Figure 2.4), similar to that 
of average proteins137. However, while the amino acid composition of these peptides is consistent with 
these regions being IDRs, there does not appear to be a correlation between the amino acid composition 
of the IDRs and the TFE-induced helical transitions, beyond the absence of prolines in IDRs that do 
undergo a helical transition. This is consistent with findings that indicate that the accuracy of ANCHOR in 
predicting disordered binding regions is independent of amino acid content113, and may also explain the 
ambiguity in the JPred predictions for these regions. Thus, beyond the lack of proline residues, the amino 
acid composition does not appear to be a direct predictor of potential transitions. 
 
Figure 2.4. Amino acid content of the selected IDRs. 
Amino acid content of: (A) Anchor-containing IDRs that undergo TFE-induced helical transitions, (B) 
Anchor-containing IDRs that fail to undergo TFE-induced helical transitions, and (C) IDRs lacking 
Anchors. 
2.4. Discussion and conclusions 
All but one of the sequences selected for this study were predicted to be entirely disordered by at 
least one, and often all three of the disorder predictors, IUPred, IsUnstruct, or PONDR-FIT, as none of 
these sequences contained contiguous non-disordered stretches that were long enough to form stable 
secondary structure. The only exception was BECN1 105-130, which has short regions that are not 
predicted to be disordered, but this sequence was included in our analysis as BECN1 residues 105-130 
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have previously been experimentally shown to be disordered even in the context of adjacent BECN1 
domains30. Additionally, many of the IDRs selected for this study are preceded by long regions, which are 
also predicted to be disordered30, 127-131. Lastly, our CD analysis verifies that, in solution, each of these 
IDRs is largely disordered. 
We used ANCHOR and DisoRDPbind to predict regions that may fold upon binding but found 
little agreement between predictions by these different programs. DisoRDPbind also did not accurately 
predict binding regions within known MoRFs. Interestingly, we find that JPred4 often predicts secondary 
structure of sufficient length to permit formation of stable secondary structure that overlap or lie within 
predicted Anchor regions, rather than predicting these regions as disordered. However, the actual 
predictions of the type of secondary structure were not always accurate, nor did the lengths of the 
predicted folded structures always agree with experimental observations, perhaps due to the 
conformational flexibility of these regions.    
Our results indicate that the combined approach described in this report, of performing sequence-
based predictions using programs like ANCHOR followed by experimental assessment of structural 
transitions in the presence of TFE, is suitable for identifying IDRs that are α-MoRFs. Strikingly, we show 
that while TFE induces helicity in known α-MoRFs, it does not induce disorder-to-helix transitions in IDRs 
lacking Anchor regions, or in known β-MoRFs. This combined predictive and experimental approach did 
not produce any false positives or false negatives, i.e. we were able to use this approach to successfully 
identify all the α-MoRFs we tested, and no known β-MoRFs were misidentified as α-MoRFs. Thus, this 
approach appears to reliably identify α-MoRFs, and distinguish between these and β- or σ-MoRFs. 
Although p53 residues 367-388 can be either a α- or β-MoRF depending on its binding partner 130, 
131, it behaves as an α-MoRF in the presence of TFE where a helical transition is induced at the expense 
of β- and coil content. This is distinct from GRIM, the β-MoRF, in which β-content slightly increases while 
helical content is not increased by TFE.  Therefore, this method can identify IDRs that are α-MoRFs even 
if they can adopt different conformations upon binding to different partners. Conversely, identification of 
an IDR as an α-MoRF does not preclude it from undergoing other disorder-to-order transitions upon 
binding to a different partner.  
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We have used the method proposed in this study to identify three new potential α-MoRFs: 
BECN1 residues 76-105, AMBRA1 residues 527-541, and GOPC residues 248-277; from amongst the 
IDRs for which binding partners have not yet been identified. Like the known α-MoRFs, the helical content 
of each of these IDRs increases in the presence of TFE. However, unlike the known α-MoRFs, in GOPC 
residues 248-277 an increase in helicity is seen only in 40% TFE and in AMBRA1 residues 527-541, 
although an increase in helical content is observed in 25% TFE, stable helical content is achieved only in 
40% TFE. BECN1 residues 76-105 and AMBRA1 residues 527-541 lack significant β-content, hence their 
TFE-induced helical transition occurs at the expense of coil conformation. GOPC residues 248-277 
contain β-structure; however, unlike the known α-MoRFs with β-content, the TFE-induced increase in 
helicity in GOPC residues 248-277 occurs at the expense of the coil-content, and the β-content is not 
affected by TFE. Therefore, although GOPC residues 248-277 may become helical upon binding to one 
partner, perhaps the lack of destabilization of β-structure, which is similar to that seen for β-MoRFs, 
suggests that it may adopt β-conformations upon binding to other partners.  
We also identify two potential Anchor-containing IDRs that do not undergo helical transition in the 
presence of TFE. It is possible that these might be β- or σ-MoRFs. Based on the similarity in TFE-induced 
behavior to the known β-MoRFs, it is tempting to speculate that ATG3 residues 129-158 and ATG9A 
residues 810-839 are also β-MoRFs. 
In this study we included two overlapping IDRs from GOPC: the first comprised of residues 248-
277 and the second comprising residues 255-279. GOPC residues 248-257 comprise a ten-residue 
Anchor region, thus the first GOPC IDR includes the Anchor while the second contains only the last three 
residues of the Anchor.  Strikingly, loss of the first seven Anchor residues abrogates the ability of the 
latter GOPC IDR to undergo the TFE-induced helical transition observed in GOPC residues 248-277. 
Identification of the Anchor region-containing GOPC residues 248-277 as a α-MoRF, demonstrates that 
the TFE-induced helical transition requires the presence of an Anchor region. This is reminiscent of an 
earlier study wherein residues within the Anchor region was demonstrated to be essential for nucleation 
of a binding-induced disorder-to-helix transition in the case of BECN1 residues 105-130104. 
Thus, we propose that ANCHOR predictions combined with assessment of TFE-induced helicity 
serves to identify α-MoRFs. However, we cannot use this method to generally exclude the possibility that 
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these regions may also form either σ- or β-MoRFs in the context of other binding partners. It would be 
interesting to eventually compare the predictions in this report to experimental structural transitions upon 
binding to different partners.   
It is useful to have a convenient experimental diagnostic to identify IDRs that are α-MoRFs as 
that would help better identify disordered regions with a potential biological function in mediating 
macromolecular interactions. Further, a tool to identify α-MoRFs may help identify a potential binding 
partner for the IDR from a wider list of potential interaction partners for the full-length protein, by providing 
information about the IDR conformation and residues most likely to be involved in the interaction. This, in 
turn, would lead to a better mechanistic understanding of the function of proteins involved in IDR-
mediated interactions. For example, within the BECN1 residues 76-105 shown by this study to be a α-
MoRF, residue S90 has previously been shown to be phosphorylated by MK2 (members of the p38 
mitogen-activated protein kinase signaling pathway PAPKAPK2), which binds helical substrates and is 
essential for the tumor suppressor function of BECN1138. Identification of BECN1 residues 76-105 as a α-
MoRF supports the hypothesis that MK2 binds directly to this region to phosphorylate and activate 
BECN1. This information may permit the analysis of MK2 structure to determine the binding determinants 
for interaction with, and phosphorylation of, BECN1.  
Information regarding binding-associated structural transitions in IDRs would not only provide a 
basis for understanding these interactions but may also be useful for developing therapeutics targeting 
these proteins. For instance, a potential therapeutic was recently discovered that specifically binds p27, 
an IDR-containing protein that regulates the cell cycle via interaction with Cdk2/cyclinA. This molecule 
traps the disordered kinase binding domain of p27 in a conformation that prevents folding and binding to 
Cdk2/cyclin A139.  
An example of an IDR that was shown to be an α-MoRF and subsequently targeted for 
therapeutic development is the BECN1 BH3 domain (BECN1 105-130). An Anchor region within the 
BECN1 BH3 domain nucleates a helical transition upon binding BCL2 homologs, resulting in down-
regulation of autophagy, a cellular homeostasis pathway important for innate immune defenses30, 140. An 
understanding of these structural transitions and the role of the Anchor region, enabled development of a 
peptide that selectively inhibits the interaction of BECN1 with the murine γ-herpesvirus68 BCL2 M11, to 
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prevent viral down-regulation of autophagy, while leaving cellular regulation unaffected140. However, 
unlike p27 and the BECN1 BH3 domain, binding partners for many Anchor regions remain unknown.  
In a separate, parallel study, we used X-ray crystallography, CD spectroscopy, small angle X-ray 
scattering (SAXS), and electron paramagnetic resonance (EPR) to demonstrate that the BECN1 flexible 
helical domain (FHD) is partially disordered and partially helical (forming a 2.5 turn helix), when not in 
complex with other proteins, even in larger BECN1 fragments containing adjacent BECN1 domains33. 
Further, we found that although a binding partner for this region had not been identified, the FHD contains 
an Anchor region and undergoes TFE-induced helical transitions suggesting that it is a α-MoRF. 
Subsequently, in a 4.4 Å crystal structure (PDB 5DFZ) of the full-length yeast 
VPS34:VPS15:VPS30:VPS38 complex (VPS30 is the yeast homolog of BECN1), it was shown that 
VPS38, which binds primarily via the VPS30/BECN1 coiled-coil domain, also interacts in a coiled-coil 
manner with the BECN1 FHD (labeled CC1 in this structure)17. Therefore, in this complex the FHD is 
completely helical, forming an eight-turn helix, verifying our prediction that the FHD is a α-MoRF. Thus, 
our method has successfully identified an IDR to be a α-MoRF; which was then confirmed by studies 
wherein a binding partner for this region was established, and the co-complex structure determined. 
Identification of IDRs that are α-MoRFs by our method may enable development of therapeutics 
targeting interactions mediated by these IDRs by similar methods. Many of the IDR-containing proteins 
included in this study are implicated in diverse diseases. For instance, GOPC, which binds and modulates 
membrane proteins, including several oncogenes, is associated with glioblastoma and other cancers, as 
well as cystic fibrosis141, 142. Although a binding partner for the selected GOPC IDR remains to be 
identified, the GOPC α-MoRF identified here could potentially be targeted for therapeutic treatment by 
designing molecules that prevent helix formation or bind very tightly to the helical conformation of the 
GOPC α-MoRF, preventing interactions that facilitate oncogenesis. Thus, this study provides a useful tool 
toward better understanding IDRs and their conformational transitions.  
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 CHAPTER 3. STRUCTURAL TRANSITIONS IN CONSERVED, ORDERED BECN1 DOMAINS 
ESSENTIAL TO REGULATING AUTOPHAGY 
3.1. Introduction 
Co-immunoprecipitation assays show that the BECN1 homodimer exists in cells143. BECN1 self-
associates via its CCD to form a homodimer in the absence of other binding partners. However, the last 
18 residues of the CCD (residues 248-265) form a helical region that we have named the “overlap helix” 
(OH), because it has been crystallized in two differently-packed states: (i) as part of the anti-parallel CCD 
homodimer33, 34, constituting the C-terminal four turns of each CCD; or (ii) packed against the BARAD36. 
Notably, in the structure of the quaternary complex of yeast VPS34/PI3KC3, VPS15, VPS30/BECN1 and 
VPS38/UVRAG, VPS30 residues 304-327 (equivalent to residues 248-271 of the human BECN1 OH and 
BARAD) are part of the VPS30/BECN1 CCD and pack against the CCD of VPS38/UVRAG, stabilizing the 
parallel CCD heterodimer17. This led to the assumption that the OH is part of the CCD in the context of 
full-length BECN1.  
The OH and BARAD appear to undergo conformational changes upon binding membranes. The 
BARAD bears an aromatic finger comprised of residues 359-361 (residues 430-432 of yeast VPS30) that 
is required for BARAD binding to membranes36. Hydrogen-deuterium exchange mass spectrometry 
(HDX-MS) experiments show that this aromatic finger likely directly interacts with membranes when 
BECN1 is part of the PI3KC3 complex17. The HDX-MS experiments also indicate that VPS30 residues 
312-327 (equivalent to BECN1 residues 256-271), which comprise the latter half of the OH, undergo 
membrane-binding induced conformational changes but do not directly bind membranes17. Inclusion of 
the OH as part of the anti-parallel CCD homodimer would greatly increase stability of the autophagy-
inactive homodimer. However, it has not been shown whether the BECN1 OH is part of the CCD or the 
BARAD when BECN1 is not part of PI3KC3 complexes. Therefore, different conformational states of the 
BECN1 OH likely play important roles in regulating protein:membrane or protein:protein interactions. 
Thus, understanding BECN1 conformational flexibility is key to understanding varied BECN1 interactions, 
which in turn, will improve our understanding of the role of BECN1 in autophagy. Ultimately this is 
essential to better understand how eukaryotic organisms respond to and survive cellular stressors.  
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Therefore, in order to determine the packing state of the OH in the absence of heterologous 
binding partners, we investigated the solution structure, stability, and self-dissociation of purified CCD, 
OH+BARAD, and a two-domain CCD-BARAD BECN1 fragment, as well as the impact the impact of 
mutating OH residues that pack against either the partner helix of the CCD or against the BARAD. The 
solution structure was established using CD spectroscopy and size-exclusion chromatography (SEC) in 
tandem with SAXS, self-dissociation using ITC, and stability of the CCD, OH+BARAD, and CCD-BARAD 
by monitoring thermal denaturation by CD. Lastly, we assessed the impact of the OH mutations on 
cellular autophagy by evaluating the change in the number of autophagosomes per cell.   
3.2. Materials and methods 
3.2.1. Structural superimposition and calculation of buried surface area 
The crystal structures of the human BECN1 CCD homodimer (PDB ID: 5HHE) and the human 
BECN1 BARAD containing the OH (OH+BARAD) (PDB ID: 4DDP) were superimposed using the align 
function of the PyMOL Molecular Graphics System (Schrodinger, LLC)144. The PDBePISA145 server 
(http://www.ebi.ac.uk/pdbe/pisa/) was used to calculate interface buried surface areas. 
3.2.2. Plasmid preparation 
Human BECN1 residues 175-265 (CCD), residues 175-450 (CCD-BARAD), or residues 248-450 
(OH+BARAD) were cloned between the NcoI and NotI restriction enzyme sites of the pMBP-Parallel-1 
bacterial expression vector146. The BECN1 OH+BARAD was also cloned between the XhoI and BamHI 
restriction enzyme sites of the pET-15b bacterial expression vector encoding an N-terminal His6 tag 
(Table 3.1). The OH Tetrad mutation (V250A, M254A, L261A, and L264A) and AFM (F359D, F360D, and 
W361D) were generated via site-directed mutagenesis. A pcDNA3.1 mammalian expression vector 
encoding full-length, human wild-type (WT) BECN1 was subjected to site-directed mutagenesis to 
generate the OH Tetrad mutation (V250A, M254A, L261A, and L264A). 
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Table 3.1. Protein constructs used in this study. 
 Label Description BECN1 Residues 
1 MBP-BECN1 CCD-BARAD MBP-BECN1 CCD-BARAD 
fusion protein 
175-450 
2 MBP-BECN1 CCD-
BARADTETRAD 
MBP-BECN1 CCD-BARAD 
fusion protein OH Tetrad Mutant 
175-450 
(V250A,M254A,L261A,L264A) 
3 BECN1 OH+BARAD His6-BECN1 OH+BARAD 248-450 
4 MBP-BECN1 OH+BARAD MBP-BECN1 OH+BARAD fusion 
protein 
248-450 
5 MBP-BECN1 
OH+BARADTETRAD 
MBP-BECN1 OH+BARAD fusion 
protein OH Tetrad Mutant  
248-450, 
(V250A,M254A,L261A,L264A)  
6 MBP-BECN1 CCD MBP-BECN1 CCD fusion protein 175-265 
7 * BECN1 CCD BECN1 CCD  175-265 
8 MBP-BECN1 CCDTETRAD MBP-BECN1 CCD fusion protein 
OH Tetrad Mutant 
175-265, 
(V250A,M254A,L261A,L264A) 
9 * BECN1 CCDTETRAD BECN1 CCD OH Tetrad Mutant 175-265, 
(V250A,M254A,L261A,L264A) 
10 MBP-BECN1 CCD-
BARADAFM 
MBP-BECN1 CCD-BARAD 
fusion protein Aromatic Finger 
Mutant 
175-450 
(F359D,F360D,W361D) 
11 * BECN1 CCD-BARADAFM BECN1 CCD-BARAD Aromatic 
Finger Mutant 
175-450, 
(F359D,F360D,W361D) 
12 MBP-BECN1 CCD-
BARADAFM,TETRAD 
MBP-BECN1 CCD-BARAD 
fusion protein Aromatic Finger 
Mutant +OH Tetrad Mutant 
175-450 
(V250A,M254A,L261A,L264A) 
13 * BECN1 CCD-
BARADAFM,TETRAD 
BECN1 CCD-BARAD Aromatic 
Finger Mutant + OH Tetrad 
Mutant 
175-450, 
(F359D,F360D,W361D), 
(V250A,M254A,L261A,L264A) 
14 MBP-BECN1 
OH+BARADAFM 
MBP-BECN1 OH+BARAD fusion 
protein Aromatic Finger Mutant 
248-450,  
(F359D,F360D,W361D) 
15 * BECN1 OH+BARADAFM His6-BECN1 OH+BARAD 
Aromatic Finger Mutant 
248-450,  
(F359D,F360D,W361D) 
16 MBP-BECN1 
OH+BARADAFM,TETRAD 
MBP-BECN1 OH+BARAD fusion 
protein Aromatic Finger Mutant + 
OH Tetrad Mutant  
248-450, 
(F359D,F360D,W361D), 
(V250A,M254A,L261A,L264A)  
17 * BECN1 OH+BARADAFM, 
TETRAD 
His6-BECN1 OH+BARAD 
Aromatic Finger Mutant + OH 
Tetrad Mutant  
241-450, 
(F359D,F360D,W361D), 
(V250A,M254A,L261A,L264A)  
* Denotes constructs used for our final published analyses since the AFM dramatically reduces 
aggregation and permits large-scale purification of high-quality, homogenous, BARAD-containing 
constructs, and also does not appear to impact secondary or tertiary structure of these fragments as 
described in subsequent sections. 
For preliminary analyses with maltose binding protein (MBP)-tagged fusion protein, the flexible 
long linker (LL) between the MBP-tag and N-terminus of the BECN1 domains was replaced with a short, 
triple alanine linker (SL) via site-directed mutagenesis (primer: 5’ GCC CTG AAA GAC GCG CAG ACT 
AAT GCA GCA GCA CTG TAT TTT CAG GGC GCC 3’) in order to reduce flexibility of the linker region to 
facilitate analyses of the effect of the Tetrad mutant on protein structure and flexibility. 
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3.2.3. Protein expression and purification 
For the BECN1 CCD and CCDTETRAD, Escherichia coli (E. coli) BL21(DE3)·pLysS cells were 
transformed and grown in LB media with 100 µg/mL ampicillin at 37 °C to an OD600 of ~0.8 prior to 
equilibrating the temperature to 20 °C. For WT and mutant BECN1 CCD-BARAD and His6-BECN1 
OH+BARAD, E. coli Arctic Express cells were transformed and grown in LB media with 100 µg/mL 
ampicillin at 30 °C to an OD600 of ~0.6 prior to equilibrating the temperature to 10 °C. In each case, cells 
were grown to an OD600 of 0.8-1.2. Expression of the CCD and CCD-BARAD was induced by addition of 
0.5 mM isopropyl thio-β-D-galactoside (IPTG). His6-OH+BARAD constructs were induced with 0.3 mM 
IPTG. All constructs were expressed overnight. One protease inhibitor tablet (Bimake, Houston, TX, US) 
per liter of cell culture was added during lysis for all protein constructs. At each stage of purification, 
protein purity was evaluated by SDS-PAGE stained with Coomassie Blue. In each case, the final purified 
protein was estimated to be >90% pure by Coomassie Blue stained SDS-PAGE.  
For all cleaved BECN1 CCD and BECN1 CCD-BARAD constructs, soluble MBP-tagged fusion 
protein was purified from clarified crude cell lysate by amylose affinity chromatography on Amylose Resin 
(NEB BioLabs, Ipswich, US). The column was washed with 10 column volumes of Wash Buffer 1 and 
then 10 column volumes of Wash Buffer 2 (Wash Buffer 1: 25 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM 
EDTA, 2 mM Dithiothreitol (DTT), 10% glycerol; Wash Buffer 2: 25 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 
mM EDTA, 2 mM DTT) and subjected to overnight, on-column cleavage by glutathione S-transferase – 
tobacco etch virus (GST-TEV) protease at 4 °C. Cleaved protein was washed from the column with Wash 
Buffer 2 and further purified by anion exchange chromatography on a 5/50 GL MonoQ (Pharmacia 
Biotech – GE Life Sciences, Pittsburgh, US) (MonoQ Buffer A: 50mM Tris-HCl pH 7.5, 2mM DTT; MonoQ 
Buffer B: 50mM Tris-HCl pH 7.5, 2mM DTT, 1M NaCl). BECN1 protein fragments were purified to 
homogeneity by size exclusion chromatography (SEC), using a 10/30 Superdex 200 (GE Life Sciences, 
Pittsburgh, US) column (SEC buffer: 25 mM Tris-HCl pH 7.5, 300 mM NaCl, 2 mM DTT). The cleaved 
proteins were concentrated in a 10 kD Amicon Ultra-0.5 centrifugal concentrator (EMD Millipore, Billerica, 
MA, US). 
For WT His6-BECN1 OH+BARAD, fusion protein was purified from clarified crude cell lysate by 
nickel immobilized affinity chromatography (IMAC) using a HisTrap column (GE Life Sciences, Pittsburgh, 
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US). The column was washed with 10 column volumes of Wash Buffer (Wash Buffer: 25 mM Tris HCl pH 
8.0, 150 mM NaCl, 10% v/v glycerol, 25 mM imidazole) and protein was eluted with Wash Buffer 
containing 350 mM imidazole. WT BECN1 OH+BARAD was subsequently purified by SEC, using a 10/30 
Superdex 200 in tandem with a 10/30 Superdex 75 column (GE Life Sciences, Pittsburgh, US) (SEC 
buffer: 25 mM Tris-HCl pH 7.5, 300 mM NaCl, 2 mM DTT) and concentrated to a maximum of 2 mg/mL in 
a 10 kD Amicon Ultra-0.5 centrifugal concentrator (EMD Millipore, Billerica, MA, US). 0.4 % (w/v) β-octyl 
glucoside was added during lysis and concentration stages (except final protein concentration) to prevent 
aggregation. 
For His6-BECN1 OH+BARADAFM constructs, fusion protein was purified from clarified crude cell 
lysate by nickel immobilized affinity chromatography (IMAC) using Ni Sepharose High Performance 
nickel-charged IMAC resin (GE Life Sciences, Pittsburgh, US). The column was washed with 10 column 
volumes of Wash Buffer (Wash Buffer: 50 mM HEPES acid pH 7.5, 300 mM NaCl, 10% v/v glycerol, 25 
mM imidazole) and protein was eluted with Wash Buffer containing 350 mM imidazole. BECN1 
OH+BARAD constructs were subsequently purified to homogeneity by SEC, using a 10/30 HR Superdex 
200 column (GE Life Sciences, Pittsburgh, US) (SEC buffer: 25 mM Tris-HCl pH 7.5, 300 mM NaCl, 2 mM 
DTT) and concentrated to a maximum of 6 mg/mL in a 10 kD Amicon Ultra-0.5 centrifugal concentrator 
(EMD Millipore, Billerica, MA, US).  
For preliminary analyses with MBP-tagged fusion proteins, E. coli Arctic Express(DE3) cells were 
transformed by the WT MBP-SL-BECN1 CCD-BARAD, MBP-SL-BECN1 CCD-BARADAFM, MBP-SL-
BECN1 CCD-BARADTETRAD, MBP-SL-BECN1 OH+BARADAFM, MBP-SL-BECN1 OH+BARADTETRAD, or 
MBP-SL-BECN1 OH+BARADAFM,TETRAD expression vectors and grown in LB media with 100 µg/mL 
ampicillin at 30 °C to an OD600 of ~0.6 prior to allowing the temperature to equilibrate to 10 °C. 
Recombinant protein expression was then induced by addition of 0.3 mM IPTG upon an OD600 of 1.0-1.2 
and expressed overnight. E. coli BL21(DE3)pLysS cells were transformed by the MBP-SL-BECN1 CCD  
and MBP-SL-BECN1 CCDTETRAD expression vectors and grown in LB media with 100 µg/mL ampicillin at 
37 °C to an OD600 of ~0.8 when recombinant protein expression was induced by addition of 0.5 mM 
IPTG and expressed for two hours. 
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For WT and mutant MBP-BECN1 CCD-BARAD constructs, fusion protein was purified from 
clarified crude cell lysate by amylose affinity chromatography on Amylose Resin (NEB BioLabs, Ipswich, 
US). The column was washed with 10 column volumes of Wash Buffer (25 mM Tris-HCl pH 8.0, 300 mM 
NaCl, 10% v/v glycerol, 1 mM EDTA, 2 mM DTT) and eluted with Wash Buffer plus 20 mM maltose. 
Subsequently, the WT protein was loaded onto a 5/50 GL MonoQ (Pharmacia Biotech - GE Life 
Sciences, Pittsburgh, US) at 50 mM NaCl and eluted at 300 mM NaCl, which concentrated the protein to 
7mg/mL. Lastly, the protein was purified to homogeneity by SEC, using a 16/60 Superdex 200 or 10/30 
Superdex 200 (GE Life Sciences, Pittsburgh, PA, US) column (SEC buffer: 25 mM Tris-HCl pH 8.0, 300 
mM NaCl, 2 mM DTT) and concentrated to 5 mg/mL in a 50 kD Amicon Ultra-0.5 centrifugal concentrator 
(EMD Millipore, Billerica, MA, US). The amylose affinity elutions of the remaining MBP-SL fusion 
constructs were directly purified to homogeneity by SEC, using a 16/60 Superdex 200 or 10/30 Superdex 
200 (GE Life Sciences, Pittsburgh, PA, US) column (SEC buffer: 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 
mM DTT).  
I would like to thank Yue Li for her significant contribution to the expression and purification of the 
CCD, CCD-BARADAFM, CCD-BARADAFM,TETRAD, MBP-CCD-BARADAFM,TETRAD, MBP-OH+BARADAFM, 
MBP-OH+BARADTETRAD, MBP-OH+BARADAFM,TETRAD. 
3.2.4. CD spectroscopy 
Continuous scanning CD spectra were recorded from 190 to 240 nm at 4 °C in a 300 µL quartz 
cell (0.1 cm path length) on a Jasco J-815 spectropolarimeter equipped with a Peltier thermoelectric 
temperature control for each protein sample at concentrations of 3-20 µM in 5 mM Na phosphate dibasic, 
5 mM Na phosphate monobasic pH 7.4, 100 mM (NH4)2SO4. Secondary structure content was estimated 
by analyzing CD data using the SDP48 reference protein database and three programs, SELCON3, 
CDSSTR, and CONTIN, from the CDpro suite within the Jasco software78, 125, 126. For each spectrum, the 
average secondary structure was calculated by averaging estimated secondary structure content 
obtained from the three CD data analysis programs. 
Variable temperature CD spectra were recorded at 222 nm at 1 °C intervals, with a ramp rate of 1 
°C/min after dilution of protein samples to 2-20 µM in 5 mM Na phosphate dibasic, 5 mM Na phosphate 
monobasic pH 7.4, 100 mM (NH4)2SO4. Spectra were recorded for BECN1 OH+BARAD and BECN1 
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CCD-BARAD proteins from 4-75 °C, and for BECN1 CCD proteins from 4-55 °C or 55-4 °C for reverse 
measurements. Data were analyzed using OriginPro 8 (OriginLab), where mean residue molar ellipticity 
was plotted against temperature, and the Tm was calculated by fitting the data to the Boltzmann or Double 
Boltzmann algorithm included in OriginPro 8. 
3.2.5. ITC  
BECN1 CCD, CCDTETRAD, CCD-BARADAFM, and CCD-BARADAFM,TETRAD protein samples were 
dialyzed against 50 mM HEPES base pH 8.0, 150 mM NaCl, and 2 mM β-mercaptoethanol (BME). ITC 
experiments were performed in triplicate at 20 °C using a Low Volume Gold Nano isothermal titration 
calorimeter (TA Instruments, New Castle, US). 65 µM CCD-BARADAFM, 100 µM CCD-BARADAFM,TETRAD, 
350 µM CCD, and 100 µM CCDTETRAD were separately titrated into dialysis buffer using 20 injections of 
2.5 µL each. Data were analyzed with the NanoAnalyze Software (TA Instruments, New Castle, US), 
using a dimer dissociation model to calculate the dimer dissociation constants. 
3.2.6. SAXS data collection and analysis  
SAXS data were recorded at the BioCAT beamline (ID18) (Advanced Photon Source, Argonne, 
IL, US) on a Pilatus 3 1M detector at a sample to detector distance of 3.5 m at a wavelength of 1.03 Å. 
For all constructs, SEC was performed in tandem with SAXS to ensure that all SAXS data were collected 
from a homogenous sample eluting from the SEC column (10/300 GL Superdex 200 Increase). SEC-
SAXS data were recorded by exposing the column eluate to the X-ray beam for 1 second with a 
periodicity of 3 seconds. Scattering data were normalized to the incident X-ray beam intensity and 
scattering from buffer was subtracted using the BioCAT beamline pipeline based on the ATSAS suite of 
programs, prior to further analysis. Data were analyzed with the ATSAS program suite147, including 
PRIMUS148 to calculate Guinier extrapolations to estimate the Rg and Kratky plots to evaluate disorder 
within the samples. The P(r) function plotted from the Fourier inversion of the scattering intensity, I(q) 
using GNOM149, was used to calculate the Rg and Dmax, and to reconstruct ab initio envelopes by applying 
ten cycles in DAMMIF85 with subsequent analysis by DAMSEL, DAMSUP, DAMAVER and DAMFILT86 to 
compare and identify the most probable model, align all models to the most probable model, average 
aligned models and compute a probability map, and filter the averaged model.  
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The EOM, as encoded within EOM 2.1150, was used to generate an ensemble of models that 
included the flexible and disordered elements for each protein fragment. For the CCDTETRAD, we modeled 
the OH and its partner helix (BECN1 residues 175-193) as flexible using PDB ID: 5HHE, after removing 
OH and partner helix residues (ShortCCD), as a rigid body. For the BARADAFM and BARADAFM,TETRAD, we 
modeled the flexible His6 tag using PDB ID: 4DDP (OH+BARAD) as a rigid body. For the CCD-
BARADAFM, we generated two-domain models using i) the ShortCCD and the OH+BARAD as rigid 
bodies, or ii) PDB ID: 5HHE and 4DDP, after removing OH residues (BARAD), as rigid bodies. For the 
CCD-BARADAFM,TETRAD, we generated two-domain models using i) the ShortCCD and the OH+BARAD as 
rigid bodies, or ii) the ShortCCD and BARAD as rigid bodies. Models were obtained using native-like 
chain options and P2 symmetry was imposed on CCD-containing fragments by fixing the original 
coordinates of the PDB ID: 5HHE or ShortCCD. The theoretical scattering data calculated from each 
model in the ensemble was fitted to the averaged scattering data using CRYSOL 151. The EOM model 
that best agreed with the experimentally derived Rg and Dmax and best fit the averaged scattering curves 
was then fitted into the molecular envelopes using SUPCOMB87.  
3.2.7. Autophagy assays 
Cellular autophagy levels were quantified by monitoring cellular localization of GFP-tagged LC3 
protein152. Each chamber of an 8-well culture slide (Nunc™ Lab-Tek™ Chambered Coverglass) was 
seeded with 3.0 x 105 MCF7 cells and cultured overnight in Dulbecco modified eagle medium (DMEM) 
with 10% fetal bovine serum (FBS) until 80-90% confluent. The cells were co-transfected with 500 ng total 
plasmid per well, comprising of 200 ng GFP-LC3 and 300 ng FLAG-BECN1 WT or mutant expression 
plasmids, using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. After transfection and incubation at 37 °C for 24 hours, the cells were cultured in either rich 
(DMEM, 10% FBS, 2x essential amino acids and 2x nonessential amino acids) or starvation (Earle’s 
balanced salt solution) media for 4 hours. Cells were counterstained with DAPI to visualize nuclei and 
facilitate total cell counts, fixed to slides with 4% v/v paraformaldehyde, and then stored in 70% v/v 
glycerol. Cells were washed with PBS between the counterstaining, fixation, and storage stages. GFP-
LC3-positive puncta were observed under a fluorescent microscope (Zeiss AxioObserver Z1) and 
quantified by counting a minimum of 50 cells for duplicate samples per condition using Imaris software 
 43 
(Bitplan AG, Zurich, Switzerland) in three independent experiments. The significance of alterations in 
autophagy levels was determined by a two-tailed, heteroscedastic student’s t-test, wherein p ≤ 0.05 is 
considered significant. I would like to thank Shreya Mukhopadhyay for performing these autophagy 
assays. 
Expression levels of WT FLAG-BECN1 and mutants were verified by Western blot using 
commercial mouse monoclonal anti-FLAG M2-peroxidase antibody (MilliporeSigma). As a loading control, 
Actin levels in MCF7 cell lysates were detected with mouse anti-Actin (MilliporeSigma).  
3.3. Results  
3.3.1. The BECN1 OH cannot simultaneously pack against the CCD homodimer partner helix and 
the BARAD 
Superimposition of the human BECN1 OH of the OH+BARAD (PDB ID: 4DDP) and one chain of 
the CCD homodimer (PDB ID: 5HHE) reveals the OH cannot simultaneously be within the CCD and 
packed against the BARAD, as there are extensive steric conflicts between the BARAD and the partner 
helix of the CCD (Figure 3.1). Further, the same five OH residues; V250, M254, A257, L261, and L264, 
involved in the CCD homodimer interface also pack against the BARAD (Figure 3.1). Thus, the OH in the 
CCD and OH+BARAD crystal structures represent mutually exclusive conformations of BECN1.  
Approximately 1359 Å2 of surface area are buried upon OH packing against the BARAD, 
significantly more than the 937 Å2 buried when the OH packs within the CCD. Within the CCD, OH 
residues are only involved in paired interactions. However, OH residues pack against the first β-sheet and 
third α-helix of the BARAD (Figure 3.1) resulting in more extensive packing.  
Each of the OH interface residues is largely conserved from yeast to human (Figure 3.2A). The 
position equivalent to human Met254 is least well conserved, although all examined vertebrates have an M 
or V at equivalent positions. In comparison to the OH, residues of the partner BECN1 CCD that pack 
against the OH are not as well conserved (Figure 3.2B). Based on this preliminary analysis, we 
hypothesized that simultaneous alanine mutagenesis of four of the common OH interface residues; 
V250A, M254A, L261A, and L264A (Tetrad mutant) would differently impact structure and stability of the 
CCD and BARAD. Structural and thermodynamic analyses of these differences would allow us to 
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determine whether the OH is part of the CCD, packs against the BARAD, or transitions between the two 
states. 
 
Figure 3.1. The OH has two different packing states. 
The BECN1 CCD (magenta) and BARAD (green) are shown in ribbon. The OHs in the CCD and BARAD 
structures are superimposed. Boxes indicate regions that are rotated 30° about the x-axis and enlarged to 
show the mutually exclusive packing arrangement of interacting OH side chains displayed as sticks. The 
first β-sheet and third helix of the BARAD, against which the OH side chains pack, are labeled β1 and α3 
respectively. This and other molecular figures were made using PyMOL (v.1.5.0.2; Schrödinger)144. 
 
Figure 3.2. Sequence alignment of the OH and partner helix in BECN1 orthologs. 
Increasing background color intensity corresponds to increasing residue conservation: with red 
corresponding to invariant residues of the A) Overlap helix and B) Partner helix with NES boxed. Interface 
residues are indicated with black arrows. 
3.3.2. Expression and purification results of BECN1 protein fragments 
In order to obtain enough pure and homogenous WT and OH mutant BECN1 protein fragments 
for usage in the various biophysical and structural analyses in this study, we attempted to express 
untagged and MBP fusion protein constructs of the BECN1 CCD, CCDTETRAD, OH+BARAD, 
OH+BARADTETRAD, CCD-BARAD, and CCD-BARADTETRAD (Table 3.1). Representative purification results 
are reported below, which highlight the difficulty in obtaining high quality, homogenous proteins containing 
the WT BARAD. 
Figure 1: The OH has two different packing tates. 
V250 M254 A257 L261 
L264 V250 M254 A257 L261 
L264 
S177 L180 L184 L187 E191 
BECN1 CCD 
BECN1  
OH+BARAD 
BECN1  
OH+BARAD 30° x 30° x 
β1 α3 
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For MBP-BECN1 CCD-BARAD, MBP-SL-BECN1 CCD-BARAD was expressed in E. coli Arctic 
Express cells, and soluble protein in the cell lysate from a 6 L expression culture was purified to 
homogeneity by affinity chromatography using a 3 mL amylose resin gravity column, followed by anion 
exchange chromatography using a 1mL 5/50 GL MonoQ column (load and wash at 50 mM NaCl, step 
elution at 300 mM NaCl), and finally by SEC using a 10/30 HR Superdex 200 column. The single peak on 
SEC and single band on SDS-PAGE indicate the MBP-SL-BECN1 CCD-BARAD was pure and 
homogenous (Figure 3.3). The apparent molecular weight of MBP-SL-BECN1 CCD-BARAD calculated 
based on the elution volume from SEC is 245.4 kD, which is 1.7-times greater than the theoretical 
molecular weight of 147.2 kD for the MBP-SL-BECN1 CCD-BARAD dimer calculated from the amino acid 
sequence. This is consistent with the MBP-SL-BECN1 CCD-BARAD forming rod-shaped dimer. The final 
yield of the purified MBP-SL-BECN1 CCD-BARAD obtained from one liter of bacterial culture was 0.3 mg. 
The MBP tag; however, could not be cleaved from the fusion protein without causing severe precipitation. 
 
 
Figure 3.3. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 CCD-
BARAD.  
The elution positions of SEC standards are indicated by arrows. 
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For MBP-BECN1 CCD-BARADTETRAD, MBP-SL-BECN1 CCD-BARADTETRAD was expressed in E. 
coli Arctic Express cells, and soluble protein in the cell lysate from a 6 L expression culture was purified to 
homogeneity by affinity chromatography using a 4 mL amylose resin gravity column followed by SEC 
using a 10/30 HR Superdex 200 column. The single peak on SEC and single band on SDS-PAGE 
indicate the MBP-SL-BECN1 CCD-BARADAFM was pure and homogenous (Figure 3.4). The apparent 
molecular weight of MBP-SL-BECN1 CCD-BARADAFM calculated based on the elution volume from SEC 
is 114.0 kD, which is similar to the theoretical molecular weight of 146.8 kD for the MBP-SL-BECN1 CCD-
BARADTETRAD dimer calculated from the amino acid sequence. This is consistent with the MBP-SL-
BECN1 CCD-BARADTETRAD forming dimer. The final yield of the purified MBP-SL-BECN1 CCD-
BARADTETRAD obtained from one liter of bacterial culture was 4 mg. The MBP tag; however, could not be 
cleaved from the fusion protein without causing severe precipitation. 
 
 
Figure 3.4. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 CCD-
BARADTETRAD.  
The elution positions of SEC standards are indicated by arrows. 
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For BECN1 OH+BARAD, His6-BECN1 OH+BARAD was expressed in E. coli Arctic Express cells. 
Soluble protein in the cell lysate from a 2 L expression culture was purified by affinity chromatography 
using a 5 mL HisTrap column, followed by anion exchange chromatography using a 1mL 5/50 GL MonoQ 
column, and finally SEC using a 10/30 Superdex 200 in tandem with a 10/30 Superdex 75 column. Most 
of the BECN1 OH+BARAD and lingering contaminants eluted from SEC in the void volume (16.4 and 
18.3 mL peaks) (Figure 3.5), which is indicative of protein aggregation. A small peak with an elution 
volume of 26.1 mL containing BECN1 OH+BARAD with an apparent molecular weight of 44.7 kD, which 
is 1.7-times larger than the theoretical molecular weight of 26.1 kD for the BECN1 OH+BARAD monomer 
calculated from the amino acid sequence, was obtained. However, the 44.7 kD apparent molecular 
weight BECN1 OH+BARAD could not be concentrated beyond 1 mg/mL without precipitating. The final 
yield of the purified OH+BARAD obtained from one liter of bacterial culture was 0.5 mg. Therefore, pure 
and homogenous protein of sufficient quantity and concentrations could not be obtained to permit the 
various biophysical and structural analyses in this study. 
 
 
Figure 3.5. Size exclusion chromatogram and the corresponding SDS-PAGE of BECN1 OH+BARAD.  
The elution positions of SEC standards are indicated by arrows. 
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For MBP-BECN1 OH+BARAD, MBP-SL-BECN1 OH+BARAD was expressed in E. coli Arctic 
Express cells, and soluble protein in the cell lysate from a 1 L expression culture was purified by affinity 
chromatography using a 2 mL amylose resin gravity column, followed by anion exchange 
chromatography using a 1mL 5/50 GL MonoQ column, and finally by SEC using a 10/30 HR Superdex 
200 column. Most of the MBP-BECN1 OH+BARAD eluted from SEC in the void volume (8.2 mL peak) 
(Figure 3.6), which is indicative of protein aggregation. The fusion protein was intended for comparison 
with the MBP-tagged WT and OH mutant BECN1 protein fragments. However, MBP-SL-BECN1 
OH+BARAD pure and homogenous protein of sufficient quantity and concentrations could not be 
obtained to permit the various biophysical and structural analyses in this study. 
 
 
Figure 3.6. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 
OH+BARAD.  
The elution positions of SEC standards are indicated by arrows. 
 
For MBP-BECN1 OH+BARADTETRAD, MBP-SL-BECN1 OH+BARADTETRAD was expressed in E. 
coli Arctic Express cells, and soluble protein in the cell lysate from a 2.5 L expression culture was purified 
to homogeneity by affinity chromatography using a 10 mL amylose resin gravity column followed by SEC 
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using a 16/60 HiLoad Superdex 200 column. The single peak on SEC and single band on SDS-PAGE 
indicates the MBP-SL-BECN1 OH+BARADTETRAD was pure and homogenous (Figure 3.7). The apparent 
molecular weight of MBP-SL-BECN1 OH+BARADTETRAD calculated based on the elution volume from SEC 
is 37.2 kD, which is 1.7-times smaller than the theoretical molecular weight of 62.8 kD for the MBP-SL-
BECN1 OH+BARADTETRAD monomer calculated from the amino acid sequence. This is consistent with the 
MBP-SL-BECN1 OH+BARADTETRAD forming a monomer. The final yield of the purified MBP-SL-BECN1 
OH+BARADTETRAD obtained from one liter of bacterial culture was 4.5 mg. The fusion protein was included 
for comparison with the MBP-tagged WT and OH mutant BECN1 protein fragments. 
 
 
Figure 3.7. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 
OH+BARADTETRAD.  
The elution positions of SEC standards are indicated by arrows. 
 
For MBP-BECN1 CCD, MBP-SL-BECN1 CCD was expressed in E. coli BL21(DE3)pLysS cells, 
and soluble protein in the cell lysate from a 1 L expression culture was purified to homogeneity by affinity 
chromatography using a 5 mL amylose resin gravity column followed by SEC using a 16/60 HiLoad 
Superdex 200 column. The single peak on SEC and single band on SDS-PAGE indicates the MBP-SL-
BECN1 CCD was pure and homogenous (Figure 3.8). The apparent molecular weight of the MBP-SL-
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BECN1 CCD calculated based on the elution volume from SEC is 110.6 kD, which is similar to the 
theoretical molecular weight of 104.3 kD for the MBP-SL-BECN1 CCD dimer calculated from the amino 
acid sequence. This is consistent with the MBP-SL-BECN1 CCD forming a dimer. The final yield of the 
purified MBP-SL-BECN1 CCD obtained from one liter of bacterial culture was 8 mg. The fusion protein 
was intended for comparison with the MBP-tagged WT and OH mutant BECN1 protein fragments. 
 
 
Figure 3.8. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 CCD.  
The elution positions of SEC standards are indicated by arrows. 
 
For BECN1 CCD, MBP-BECN1 CCD was expressed and purified in a manner similar to that 
previously reported33, except that an anion exchange chromatography step was added to remove 
contaminating MBP after off-column cleavage, which afforded improved cleavage and yield compared to 
on-column cleavage. The MBP-BECN1 CCD was expressed in E. coli BL21(DE3)·pLysS cells, and 
soluble fusion protein in the cell lysate from a 6 L expression culture was purified to homogeneity by 
affinity chromatography using a 10 mL amylose resin gravity column, followed by off-column cleavage 
using 16 mg GST-TEV protease, to remove the MPB tag. The cleaved protein was further purified to 
homogeneity by anion exchange chromatography using a 1mL 5/50 GL MonoQ column, and finally by 
SEC using a 10/30 HR Superdex 200 column. The single peak on SEC and single band on SDS-PAGE 
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indicate the CCD was pure and homogenous (Figure 3.9). The apparent molecular weight of CCD 
calculated based on the elution volume from SEC is 39.8 kD, which is 1.8-times greater than the 
theoretical molecular weight of 22.3 kD for the CCD dimer calculated from the amino acid sequence. This 
is consistent with the CCD forming rod-shaped dimer. The final yield of the purified CCD obtained from 
one liter of bacterial culture was 0.83 mg. 
 
 
Figure 3.9. Size exclusion chromatogram and the corresponding SDS-PAGE of BECN1 CCD.  
The elution positions of SEC standards are indicated by arrows.  
 
For MBP- BECN1 CCDTETRAD, MBP-SL-BECN1 CCDTETRAD was expressed in E. coli 
BL21(DE3)pLysS cells, and soluble protein in the cell lysate from a 2 L expression culture was purified to 
homogeneity by affinity chromatography using a 2 mL amylose resin gravity column followed by anion 
exchange chromatography using a 5/50 GL MonoQ column (gradient elution from 50-500 mM NaCl over 
100 mL) where MBP-SL-BECN1 CCDTETRAD eluted from MonoQ in two peaks, one at 150mM NaCl and 
another at 200mM NaCl. Each MonoQ elution peak was loaded separately onto SEC using a 10/30 HE 
Superdex 200 column. Both MonoQ elution peaks eluted from SEC as a single peak and yielded a single 
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band on SDS-PAGE, indicating that the MBP-SL-BECN1 CCDTETRAD was pure and homogenous (Figure 
3.10). The apparent molecular weight of MBP-SL-BECN1 CCDTETRAD calculated based on the elution 
volume from SEC is 96.1 kD, which is similar to the theoretical molecular weight of 104.0 kD for the MBP-
SL-BECN1 CCDTETRAD dimer calculated from the amino acid sequence. This is consistent with the MBP-
SL-BECN1 CCDTETRAD forming a dimer. The final yield of the purified MBP-SL-BECN1 CCD obtained from 
one liter of bacterial culture was 0.2 mg. The fusion protein was intended for comparison with the MBP-
tagged WT and OH mutant BECN1 protein fragments. 
 
 
Figure 3.10. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 
CCDTETRAD.  
The elution positions of SEC standards are indicated by arrows. 
 
For BECN1 CCDTETRAD, MBP-BECN1 CCDTETRAD was expressed in E. coli BL21(DE3)·pLysS 
cells, and soluble fusion protein in the cell lysate from a 2 L expression culture was purified to 
homogeneity by affinity chromatography using a 5 mL amylose resin gravity column with on-column 
cleavage using 6.6 mg GST-TEV protease, to remove the MBP tag. The cleaved protein was further 
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purified to homogeneity by anion exchange chromatography using a 1mL 5/50 GL MonoQ column and 
finally by SEC using a 10/30 HR Superdex 200 column. The single peak on SEC and single band on 
SDS-PAGE indicate the CCDTETRAD was pure and homogenous (Figure 3.11). The apparent molecular 
weight of CCDTETRAD calculated based on the elution volume from SEC is 55.4 kD, which is 2.5-times 
greater than the theoretical molecular weight of 21.8 kD for the CCDTETRAD dimer calculated from the 
amino acid sequence. This is consistent with the CCDTETRAD forming a rod-shaped dimer. The final yield of 
the purified CCDTETRAD obtained from one liter of bacterial culture was 1 mg. 
 
 
Figure 3.11. Size exclusion chromatogram and the corresponding SDS-PAGE of BECN1 CCDTETRAD.  
The elution positions of SEC standards are indicated by arrows. 
  
3.3.3. MBP affects homodimerization of the BECN1 CCD 
Since the MBP tag could not be removed from the MBP-BECN1 CCD-BARAD, we sought to 
characterize homodimerization of the WT and OH mutant CCD-containing constructs as MBP-fusion 
proteins. The presence of MBP appears to affect homodimerization of BECN1 via the CCD. Dissociation 
was not detected at both 10 and 20 °C for the MBP-BECN1 CCD (Table 3.2), unlike the untagged CCD, 
which has a Kd of ~48 µM18 at 20 °C. This could indicate either that the MBP-BECN1 CCD fails to form a 
homodimer, or that the Kd of the MBP-BECN1 CCD homodimer is tighter than the ~10 nM detection limit. 
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The presence of MBP also affects the homodimerization of the CCDTETRAD wherein the Kd of the MBP-
BECN1 CCDTETRAD is ~28 µM at 10 °C and ~113 µM at 20 °C, while that of the untagged CCDTETRAD is 
~27 µM at both 10 and 20 °C (Table 3.2). 
Table 3.2. Thermodynamics of dissociation of MBP-BECN1 fusion proteins and BECN1 proteins at 
variable temperatures. 
BECN1 Fragment Temperature 
(°C) 
Kd 
(µM) 
ΔH 
(kJ/mol) 
ΔS 
(J/K·mol) 
MBP-CCD 10 & 20 No dissociation detected 
MBP-CCDTETRAD 10 28 46 248 
MBP-CCDTETRAD 20 113 137 541 
CCDTETRAD 10 26 35 210 
CCDTETRAD 20 29 129 526 
Performed in 25 mM Tris HCl pH 8.0, 300mM NaCl, 2mM BME. Replicates were not performed. 
3.3.4. Secondary structure and melting temperature analyses of the fusion proteins are 
complicated by the presence of MBP 
Since the MBP tag could not be removed from the MBP-BECN1 CCD-BARAD, we also sought to 
characterize the structure and thermal stability of the WT and OH mutant BECN1 fragments as MBP-
fusion proteins. The secondary structure content and melting temperatures of MBP-BECN1 fusion 
proteins were estimated from CD spectra analyses of cleaved MBP-LL, MBP-LL-CCD, MBP-SL-CCD, and 
MBP-SL-BECN1 OH+BARADAFM. Since maltose has been reported to stabilize MBP153, 50 mM maltose 
was used to increase the Tm of MBP and permit separation of the MBP melting curve from that of the 
BECN1 OH+BARADAFM.  
CD spectra analysis for the MBP-LL after cleavage indicates that the MBP-LL contains ~129 α-
helical residues, ~94 β-strand residues, and ~169 coil residues in the absence of maltose and ~277 α-
helical residues, ~26 β-strand residues, and ~90 coil residues (Figure 3.12A, Table 3.3). Therefore, 
maltose increases helical content by ~98 residues, decreases strand content by 68, and decreases coil 
content by 79 residues. The cooperative, although irreversible, melting curves indicate that the Tm of ~57 
°C of MBP increases to ~71 °C in the presence of 50 mM maltose (Figure 3.12B, Table 3.3), which is 
indicative of maltose stabilizing MBP.   
A comparison of the secondary structure content estimated from CD spectra analysis for the 
MBP-SL-BECN1 CCD and MBP-LL-BECN1 CCD indicates that the MBP-SL-BECN1 CCD contains ~249 
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α-helical residues, ~47 β-strand residues, and ~168 coil residues while the MBP-LL-BECN1 CCD 
contains ~202 α-helical residues, ~68 β-strand residues, and ~220 coil residues (Figure 3.12C, Table 
3.3). Therefore, despite containing 18 fewer total residues, the MBP short linker increases α-helical 
content by ~52 residues while reducing β-strand content by ~23 residues and coil content by a 
concomitant ~47 residues as compared to the MBP long linker. The MBP-SL-BECN1 CCD in 50 mM 
maltose contains ~241 α-helical residues, ~43 β-strand residues, and ~182 coil residues (Figure 3.12C, 
Table 3.3); therefore, maltose does not significantly alter the secondary structure of MBP-SL-BECN1 
CCD. 
Although the MBP-LL-BECN1 CCD contains ~202 α-helical residues, ~68 β-strand residues, and 
~220 coil residues (Table 3.3), CD spectra analysis for the MBP-LL and BECN1 after cleavage indicates 
that the MBP-LL contains ~129 α-helical residues, ~94 β-strand residues, and ~169 coil residues (Figure 
3.12A, Table 3.3) while the BECN1 CCD contains ~83 α-helical residues, ~2 β-strand residues, and ~8 
coil residues (Figure 3.31B, Table 3.3). This indicates that the MBP-LL-BECN1 CCD fusion protein 
contains ~10 fewer α-helical, ~28 fewer β-strand, and ~43 more coil residues than the sum of each type 
of secondary structure content in the cleaved MBP-LL and BECN1 CCD proteins. 
The MBP-SL-BECN1 CCD displays a cooperative melting curve from 5-55 °C that indicates a Tm 
of ~31 °C in the presence of 50 mM maltose (Figure 3.12D, Table 3.3), which corresponds to that of the 
cleaved CCD (Tm = 33 °C) (Table 3.5 and 3.8). CD data were only collected up to 55 °C; therefore, the 
MBP transition that begins at 65 °C in the presence of 50 mM maltose (Figure 3.12B) is not observed. 
The MBP is therefore likely still folded at 55 °C based on the lingering ellipticity observed at 222 nm 
(Figure 3.12D). 
A comparison of the secondary structure content estimated from CD spectra analysis for the 
MBP-SL-BECN1 OH+BARADAFM indicates that the MBP-SL-BECN1 OH+BARADAFM contains ~215 α-
helical residues, ~79 β-strand residues, and ~287 coil residues in the absence of 50 mM maltose but 
contains ~ 300 α-helical residues, ~ 39 β-strand residues, and ~ 248 coil residues in the presence of 50 
mM maltose (Figure 3.12E, Table 3.3). 
As expected for a two-domain protein, the cooperative melting curve for the MBP-SL-BECN1 
OH+BARADAFM contains two well separated transitions (Figure 3.12F), indicating the presence of two 
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independently folded domains. The higher Tm of ~71°C corresponds well with that of MBP in the presence 
of maltose (Tm = 71 °C); while the lower Tm of ~46°C corresponds to that of the OH+BARADAFM (Tm = 48 
°C) (Table 3.3 and 3.8).  
Table 3.3. CD analysis: Estimated secondary structure content and melting temperatures of MBP-
BECN1 fusion proteins. 
Protein # residues Average estimated secondary structure 
content (%) 
Melting 
temperature 
(°C) 
Helix Strand Coil Forward 
MBP-LL 393 32.7 ± 5.4 23.9 ± 3.1 42.9 ± 2.7 57 
MBP-LL + Maltose 393 70.6 ± 6.8 6.7 ± 2.9 23.0 ± 9.0 71 
MBP-LL-BECN1 CCD  484 41.7 ± 7.4 14.0 ± 6.6 45.5 ± 8.9 Not collected 
MBP-SL-BECN1 CCD 466 53.4 ± 6.9 10.0 ± 5.2 36.1 ±6.8 Not collected 
MBP-SL-BECN1 CCD + 
Maltose 
466 51.7 ± 1.7 9.3 ± 7.4 39.1 ± 9.1 31 
MBP-SL-BECN1 
OH+BARADAFM 
578 37.2 ± 1.9 13.6 ± 1.4 49.6 ± 1.4 Not collected 
MBP-SL-BECN1 
OH+BARADAFM + 
Maltose 
578 51.9 ± 3.3 6.8 ± 1.5 42.9 ± 4.9 46 & 71 
Proteins precipitated; therefore, reverse Tm could not be determined. 
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Figure 3.12. MBP-BECN1 fusion protein CD spectra and melting curves. 
A) MBP (dark red) and MBP plus maltose (red). B) MBP (dark red) and MBP plus maltose (red) melting 
curve. C) MBP-LL-BECN1 CCD (light purple), MBP-SL-BECN1 CCD (magenta), MBP-SL-BECN1 CCD 
plus maltose (dark purple). D) MBP-SL-BECN1 CCD plus maltose (dark purple) melting curve. E) MBP-
SL-BECN1 BARADAFM (dark green) and MBP-SL-BECN1 BARADAFM plus maltose (light green). F) MBP-
SL-BECN1 BARADAFM plus maltose (light green) melting curve.  
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3.3.5. Tertiary structure analyses of the fusion proteins are complicated by the presence of MBP  
We used SEC-SAXS to investigate the tertiary and quaternary structure of MBP-LL, MBP-SL-
BECN1 CCD, MBP-SL-BECN1 CCDTETRAD, and MBP-SL-BECN1 OH+BARADTETRAD (Figures 3.13-3.16, 
Table 3.4).  
Table 3.4. Summary of SEC-SAXS data for MBP, MBP-BECN1 CCD, and MBP-BECN1 BARAD 
proteins. 
Protein 
MWT 
(kD) 
Guinier P(r) 
Rg (Å) Rg  (Å) Dmax (Å) 
MBP-LL 43.1 (monomer) 24 25 86 
MBP-SL-BECN1 CCD 104.4 (dimer) 62 69 245 
MBP-SL-BECN1 CCDTETRAD 104.0 (dimer) 40 43 165 
MBP-SL-BECN1 OH+BARAD Insufficient protein available for data collection 
MBP-SL-BECN1 OH+BARADTETRAD 64.6 (monomer) 39 42 200 
 
For MBP-LL, the Rg estimated from the Guinier plot and P(r) distribution is ~25 Å, (Figure 3.13A 
and B, Table 3.4) and the shape of the P(r) distribution curves and the Kratky plots indicates that it is a 
well-folded, globular protein (Figure 3.13B and C).  
 
Figure 3.13. SAXS analysis of MBP-LL. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. 
For MBP-SL-BECN1 CCD, the Rg estimated from the Guinier plot and P(r) distribution is ~66 Å, 
(Figure 3.14A and B, Table 3.4) and the shape of the P(r) distribution curves and the Kratky plots 
indicates that it is a well-folded, dumbbell-shaped protein (Figure 3.14B and C).  
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Figure 3.14. SAXS analysis of MBP-SL-BECN1 CCD. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. 
For the MBP-SL-BECN1 CCDTETRAD, the Rg estimated from the Guinier plot and P(r) distribution is 
~42 Å, (Figure 3.15A and B, Table 3.4) and the shape of the P(r) distribution curves and the Kratky plots 
indicates that it is a well-folded, rod-shaped protein (Figure 3.15B and C). Comparison of the Rg and Dmax 
of the MBP-SL-BECN1 CCD and MBP-SL-BECN1 CCDTETRAD indicates that the MBP-SL-BECN1 
CCDTETRAD is more compact than the WT. This is unexpected since the ITC data that indicates that the 
MBP-SL-BECN1 CCDTETRAD homodimerizes more weakly than the MBP-SL-BECN1 CCD at 20 °C (Table 
3.2), which suggests that the MBP-SL-BECN1 CCDTETRAD would be more flexible than the WT. As a more 
flexible protein, the MBP-SL-BECN1 CCDTETRAD would be expected to have a larger Rg and Dmax than the 
WT. However, one possible explanation is that the MBP is positioned around the flexible regions of the 
MBP-SL-BECN1 CCDTETRAD in such a manner that its overall tertiary structure is more compact. 
 
Figure 3.15. SAXS analysis of MBP-SL-BECN1 CCDTETRAD. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. 
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For the MBP-SL-OH+BARADTETRAD, the Rg estimated from the Guinier plot and P(r) distribution is 
~41 Å, (Figure 3.16A and B, Table 3.4) and the shape of the P(r) distribution curves and the Kratky plots 
indicates that it is a well-folded, globular protein (Figure 3.17B and C). This fusion protein fragment was 
intended for comparison to the MBP-SL-OH+BARAD in order to assess the effect of the OH mutant on 
tertiary structure of the BARAD; however, attempts to purify adequate WT MBP-SL-OH+BARAD for SEC 
SAXS analyses were unsuccessful.  
 
Figure 3.16. SAXS analysis of MBP-SL-BECN1 OH+BARADTETRAD. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. 
In summary, the presence of the MBP tag on the BECN1 fusion protein fragments renders the 
analysis of the effect of the OH on protein structure and stability ambiguous. Furthermore, the presence 
of the MBP tag is insufficient to obtain sufficient quantities of high quality protein for each fragment (i.e. 
the WT MBP-SL-OH+BARAD) required for biophysical analysis. 
3.3.6. An Aromatic Finger in the BARAD may decrease solubility of BARAD-containing BECN1 
fragments  
Based on the above described purification results, we find that the WT BECN1 OH+BARAD and 
CCD-BARAD proteins aggregate during purification. However, the structural and stability analyses 
described above indicate that the presence of the MBP tag, which aids in purification of soluble protein, 
affects the structure and stability of the multi-domain protein constructs and; therefore, hinders 
comparison of the WT and OH mutant BECN1 protein fragments. Therefore, it was imperative to identify 
a different method to permit expression and purification of pure, homogenous protein without affecting 
protein structure and stability. Analysis of the OH+BARAD crystal structure (PDB ID: 4DDP) indicates that 
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the OH+BARAD molecules are arranged in a head-to-tail manner in the crystal lattice, stabilized by the 
aromatic finger, consisting of Phe359, Phe360, and Trp361, of one OH+BARAD molecule being buried within 
a hydrophobic pocket formed partly by the OH in the next OH+BARAD molecule 36 (Figure 3.17). We 
hypothesized that this interaction may be the cause of protein aggregation during purification of WT 
OH+BARAD-containing constructs. Therefore, we decided to create an aromatic finger mutant (AFM), 
wherein the aromatic finger residues (Phe359, Phe360, and Trp361) are mutated to Asp.  
 
Figure 3.17. The aromatic finger of the OH+BARAD buried in the hydrophobic pocket of another molecule. 
The aromatic finger is shown in yellow and hydrophobic pocket is shown in grey. 
3.3.7. Expression and purification results of BECN1 protein fragments with the AFM mutation 
In order to obtain enough pure and homogenous WT OH and OH mutant BECN1 protein 
fragments for usage in the various biophysical and structural analyses in this study, we expressed AFM-
containing, untagged and MBP fusion protein constructs of the BECN1 OH+BARAD, OH+BARADTETRAD, 
CCD-BARAD, and CCD-BARADTETRAD (Table 3.1). Representative purification results are reported below, 
which demonstrate that the AFM permits acquisition of high quality, homogenous proteins containing the 
BARAD. 
For MBP-BECN1 CCD-BARADAFM, MBP-SL-BECN1 CCD-BARADAFM was expressed in E. coli 
Arctic Express cells, and soluble protein in the cell lysate from a 4 L expression culture was purified to 
homogeneity by affinity chromatography using a 3 mL amylose gravity column followed by SEC using a 
10/30 HR Superdex 200 column. The single band on SDS-PAGE indicates the MBP-SL-BECN1 CCD-
BARADAFM was pure (Figure 3.18). The apparent molecular weight of MBP-SL-BECN1 CCD-BARADAFM 
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calculated based on the elution volume from SEC is 249.5 kD, which is 1.7-times greater than the 
theoretical molecular weight of 146.8 kD for the MBP-SL-BECN1 CCD-BARAD dimer calculated from the 
amino acid sequence. This is consistent with the MBP-SL-BECN1 CCD-BARADAFM forming rod-shaped 
dimer. The final yield of the purified MBP-SL-BECN1 CCD-BARAD obtained from one liter of bacterial 
culture was 2 mg. This fusion protein was used for structural comparisons with the WT MBP-BECN1 
CCD-BARAD to verify that the AFM does not affect the secondary and tertiary structure of the CCD-
BARAD. 
 
 
Figure 3.18. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 CCD-
BARADAFM. 
The elution positions of SEC standards are indicated by arrows. 
 
For BECN1 CCD-BARADAFM, MBP-BECN1 CCD-BARADAFM was expressed in E. coli Arctic 
Express cells, and soluble fusion protein in the cell lysate from a 6 L expression culture was purified to 
homogeneity by affinity chromatography using a 10 mL amylose resin gravity column, followed by off-
column cleavage using 30 mg GST-TEV protease, to remove the MBP tag. The cleaved protein was 
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further purified to homogeneity by anion exchange chromatography using a 1mL 5/50 GL MonoQ column, 
and finally by SEC using a 10/30 HR Superdex 200 column. The single peak on SEC and single band on 
SDS-PAGE indicate the CCD-BARADAFM was pure and homogenous (Figure 3.19). The apparent 
molecular weight of CCD-BARADAFM calculated based on the elution volume from SEC is 120.0 kD, which 
is 1.9-times greater than the theoretical molecular weight of 64.6 kD for the CCD-BARADAFM dimer 
calculated from the amino acid sequence. This is consistent with the CCD-BARADAFM forming a long rod-
shaped dimer. The final yield of the purified CCD-BARADAFM obtained from one liter of bacterial culture 
was 2.2 mg. 
 
 
Figure 3.19. Size exclusion chromatogram and the corresponding SDS-PAGE of BECN1 CCD-
BARADAFM. 
The elution positions of SEC standards are indicated by arrows. 
 
For MBP-BECN1 CCD-BARADAFM,TETRAD, MBP-SL-BECN1 CCD-BARADAFM,TETRAD was expressed 
in E. coli Arctic Express cells, and soluble protein in the cell lysate from a 4 L expression culture was 
purified to homogeneity by affinity chromatography using a 3 mL amylose gravity column followed by SEC 
using a 10/30 HR Superdex 200 column. The single band on SDS-PAGE indicates the MBP-SL-BECN1 
CCD-BARADAFM,TETRAD was pure (Figure 3.20). The apparent molecular weight of MBP-SL-BECN1 CCD-
BARADAFM calculated based on the elution volume from SEC is 208.0 kD, which is 1.4-times greater than 
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the theoretical molecular weight of 146.5 kD for the MBP-SL-BECN1 CCD-BARAD dimer calculated from 
the amino acid sequence. This is consistent with the MBP-SL-BECN1 CCD-BARADAFM,TETRAD forming rod-
shaped dimer. The final yield of the purified MBP-SL-BECN1 CCD-BARAD obtained from one liter of 
bacterial culture was 4 mg. This fusion protein was used for structural comparisons with the MBP-BECN1 
CCD-BARADTETRAD to verify that the AFM does not affect the secondary and tertiary structure of the CCD-
BARADTETRAD. 
 
 
Figure 3.20. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 CCD-
BARADAFM,TETRAD. 
The elution positions of SEC standards are indicated by arrows. 
 
For BECN1 CCD-BARADAFM,TETRAD, MBP-BECN1 CCD-BARADAFM,TETRAD was expressed in E. coli 
Arctic Express cells, and soluble fusion protein in the cell lysate from a 6 L expression culture was 
purified to homogeneity by affinity chromatography using a 10 mL amylose resin gravity column, followed 
by off-column cleavage using 30 mg GST-TEV protease, to remove the MBP tag. The cleaved protein 
was further purified to homogeneity by anion exchange chromatography using a 1mL 5/50 GL MonoQ 
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column, and finally by SEC using a 10/30 HR Superdex 200 column. The single peak on SEC and single 
band on SDS-PAGE indicate the CCD-BARADAFM,TETRAD was pure and homogenous (Figure 3.21). The 
apparent molecular weight of CCD-BARADAFM,TETRAD calculated based on the elution volume from SEC is 
69.0 kD, which is similar to the theoretical molecular weight of 64.8 kD for the CCD-BARADAFM,TETRAD 
dimer calculated from the amino acid sequence. This is consistent with the CCD-BARADAFM,TETRAD forming 
a dimer. The final yield of the purified CCD-BARADAFM,TETRAD obtained from one liter of bacterial culture 
was 1.8 mg. 
 
 
Figure 3.21. Size exclusion chromatogram and the corresponding SDS-PAGE of BECN1 CCD-
BARADAFM,TETRAD. 
The elution positions of SEC standards are indicated by arrows. 
 
For MBP-BECN1 OH+BARADAFM, MBP-SL-BECN1 OH+BARADAFM was expressed in E. coli 
Arctic Express cells, and soluble protein in the cell lysate from a 3 L expression culture was purified to 
homogeneity by affinity chromatography using a 10 mL amylose resin gravity column followed by SEC 
using a 10/30 HR Superdex 200 column. The single peak on SEC and single band on SDS-PAGE 
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indicates the MBP-SL-BECN1 OH+BARADAFM was pure and homogenous (Figure 3.22). The apparent 
molecular weight of MBP-SL-BECN1 OH+BARADAFM calculated based on the elution volume from SEC is 
61.8 kD, which is similar to the theoretical molecular weight of 62.9 kD for the MBP-SL-BECN1 
OH+BARADAFM monomer calculated from the amino acid sequence. This is consistent with the MBP-SL-
BECN1 OH+BARADAFM forming a monomer. The final yield of the purified MBP-SL-BECN1 
OH+BARADAFM obtained from one liter of bacterial culture was 9.2 mg. This fusion protein was used for 
structural comparisons to verify that the AFM does not affect the secondary and tertiary structure of the 
OH+BARAD. 
 
 
Figure 3.22. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 
OH+BARADAFM. 
The elution positions of SEC standards are indicated by arrows. 
 
For BECN1 OH+BARADAFM, His6-BECN1 OH+BARADAFM was expressed in E. coli Arctic Express 
cells, and soluble protein in the cell lysate from a 3 L expression culture was purified to homogeneity by 
affinity chromatography using a 3 mL nickel affinity resin gravity column followed by SEC using a 10/30 
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HR Superdex 200 column. The single peak on SEC and single band on SDS-PAGE indicate the 
OH+BARADAFM was pure and homogenous (Figure 3.23). The apparent molecular weight of 
OH+BARADAFM calculated based on the elution volume from SEC is 20.6 kD, which is similar to the 
theoretical molecular weight of 26.0 kD for the OH+BARADAFM monomer calculated from the amino acid 
sequence. This is consistent with the OH-BARADAFM forming a globular monomer. The final yield of the 
purified OH+BARADAFM obtained from one liter of bacterial culture was 2 mg. 
 
 
Figure 3.23. Size exclusion chromatogram and the corresponding SDS-PAGE of BECN1 OH+BARADAFM. 
The elution positions of SEC standards are indicated by arrows. 
 
For MBP-BECN1 OH+BARADAFM,TETRAD, MBP-SL-BECN1 OH+BARADAFM,TETRAD was expressed 
in E. coli Arctic Express cells, and soluble protein in the cell lysate from a 3 L expression culture was 
purified to homogeneity by affinity chromatography using a 10 mL amylose resin gravity followed by SEC 
using a 10/30 HR Superdex 200 column. The single peak on SEC and single band on SDS-PAGE 
indicates the MBP-SL-BECN1 OH+BARADAFM,TETRAD was pure and homogenous (Figure 3.24). The 
apparent molecular weight of MBP-SL-BECN1 OH+BARADAFM,TETRAD calculated based on the elution 
volume from SEC is 35.3 kD, which is 1.8-times smaller than the theoretical molecular weight of 62.7 kD 
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for the MBP-SL-BECN1 OH+BARADAFM,TETRAD monomer calculated from the amino acid sequence. This is 
consistent with the MBP-SL-BECN1 OH+BARADAFM,TETRAD forming a monomer. The final yield of the 
purified MBP-SL-BECN1 OH+BARADAFM,TETRAD obtained from one liter of bacterial culture was 6.5 mg. 
This fusion protein was used for structural comparisons to verify that the AFM does not affect the 
secondary and tertiary structure of the OH+BARAD. 
 
 
Figure 3.24. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-SL-BECN1 
OH+BARADAFM,TETRAD. 
The elution positions of SEC standards are indicated by arrows. 
 
For BECN1 OH+BARADAFM,TETRAD, His6-BECN1 OH+BARADAFM,TETRAD was expressed in E. coli 
Arctic Express cells, and soluble protein in the cell lysate from a 4 L expression culture was purified to 
homogeneity by affinity chromatography using a 3 mL nickel affinity resin gravity column followed by SEC 
using a 10/30 HR Superdex 200 column. The single peak on SEC and single band on SDS-PAGE 
indicate the OH+BARADAFM,TETRAD was pure and homogenous (Figure 3.25). The apparent molecular 
weight of OH+BARADAFM.TETRAD calculated based on the elution volume from SEC is 19.6 kD, which is 1.4 
 69 
times smaller than the theoretical molecular weight of 26.7 kD for the OH+BARADAFM,TETRAD monomer 
calculated from the amino acid sequence. This is consistent with the OH+BARADAFM,TETRAD forming a 
globular monomer. The final yield of the purified OH+BARADAFM,TETRAD obtained from one liter of bacterial 
culture was 2 mg. 
 
 
Figure 3.25. Size exclusion chromatogram and the corresponding SDS-PAGE of BECN1 
OH+BARADAFM,TETRAD. 
The elution positions of SEC standards are indicated by arrows. 
3.3.8. The AFM does not impact secondary and tertiary structure of the CCD+BARAD constructs  
The AFM, wherein the aromatic finger residues (F359, F360, and W361) are mutated to Asp, 
dramatically reduces aggregation and permits large-scale purification of homogenous, high-quality 
protein. Therefore, we next sought to demonstrate that the AFM has no effect on the secondary structure 
content estimated from CD of the CCD+BARAD constructs (Figure 3.26, Table 3.5). Secondary structure 
content estimated by analysis of CD spectra for the MBP-BECN1 CCD-BARAD and the MBP-BECN1 
CCD-BARADAFM indicates that the AFM does not change the secondary structure content of the BECN1 
CCD-BARAD, regardless of the presence of the Tetrad mutation (Figure 3.26, Table 3.5). The MBP-
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BECN1 CCD-BARAD contains 269 helical, 82 strand, and 296 coil residues while the MBP-BECN1 CCD-
BARADAFM contains 263 helical, 89 strand, and 299 coil residues and the MBP-BECN1 CCD-
BARADTETRAD contains 300 helical, 74 strand, and 282 coil residues while the MBP-BECN1 CCD-
BARADAFM,TETRAD contains 293 helical, 73 strand, and 288 coil residues (Table 3.5). Since for each class 
of secondary structure, secondary structure content does not vary beyond 10% between MBP-BECN1 
CCD-BARAD and MBP-BECN1 CCD-BARADAFM, we conclude the AFM does not alter the secondary 
structure of these proteins. 
 
Figure 3.26. The AFM does not alter CD spectra of MBP-BECN1 CCD-BARAD. 
A) MBP-BECN1(175-450) and B) MBP-BECN1(175-450)TETRAD. 
Table 3.5. Average Estimated Secondary Structure Content in MBP-BECN1 CCD-BARAD Proteins. 
Protein # Residues Helix (%) Beta (%) Coil % 
MBP-BECN1(175-450) 651 41.3 ± 2.9 12.6 ± 1.0 45.5 ± 1.6 
MBP-BECN1(175-450)AFM 651 40.5 ± 1.3 13.7 ± 0.9 46.0 ± 0.9 
MBP-BECN1(175-450)TETRAD 651 46.0 ± 2.9 11.4  ± 0.8 43.3 ± 2.1 
MBP-BECN1(175-450)AFM,TETRAD 651 45.1 ± 2.2 11.2  ± 1.6 44.3 ± 0.6 
 
The AFM also has no effect on the SEC-SAXS profiles of the CCD-BARAD constructs (Figure 
3.27, Table 3.6). SEC-SAXS data were recorded for the MBP-BECN1 CCD-BARAD (Figure 3.27A) and 
MBP-BECN1 CCD-BARADAFM proteins (Figure 3.27E). An Rg of 68 ± 2 Å (Table 3.6) is estimated from 
the Guinier plots and P(r) plots of MBP-BECN1 CCD-BARAD (Figure 3.27B and D), as well as MBP-
BECN1 CCD-BARADAFM (Figure 3.27F and H). Similarly, a Dmax of 250 Å is estimated from the P(r) 
distribution for both samples (Figure 3.27D and H; Table 3.6). Further, the P(r) plots (Figure 3.27D and H) 
and Kratky plots (Figure 3.27C and G) indicate that both the MBP-BECN1 CCD-BARAD and MBP-
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BECN1 CCD-BARADAFM are well folded. The P(r) plots (Figure 3.27D and H) also suggest a dumbbell-
shaped envelope for both samples. This similarity in size and shape of the WT and AFM mutant MBP-
BECN1 CCD-BARAD indicates that the tertiary structure of the BARAD is unaffected by the AFM. 
Table 3.6. Summary of SEC-SAXS data for MBP-BECN1 CCD-BARAD proteins.  
Protein MWT 
(KD) 
Guinier P(r) 
Rg (Å) Rg  (Å) Dmax (Å) 
MBP-BECN1(175-450) 147.2 (dimer) 66 71 250 
MBP-BECN1(175-450)AFM 146.9 (dimer) 63 71 250 
MWT, theoretical molecular weight. 
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Figure 3.27. SEC-SAXS analysis of MBP-BECN1 CCD-BARAD proteins. 
For the MBP-BECN1 CCD-BARAD, the A) scattering data, B) Guinier, C) Kratky, and D) P(r) pairwise 
distribution. For the MBP-BECN1 CCD-BARADAFM, the E) scattering data, F) Guinier, G) Kratky, and H) 
P(r) pairwise distribution. 
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For the MBP-SL-BECN1 OH+BARADAFM, the Rg estimated from the Guinier plot and P(r) 
distribution is ~30 Å, (Figure 3.28A and B, Table 3.7) and the shape of the P(r) distribution curves and the 
Kratky plots indicates that it is a well-folded, globular protein (Figure 3.28B and C). This fusion protein 
was intended for comparison to the MBP-SL-OH+BARAD in order to assess the effect of the AFM mutant 
on tertiary structure of the BARAD. However, as explained in section 3.3.2, attempts to purify adequate 
WT MBP-SL-OH+BARAD for SEC SAXS analyses were unsuccessful.   
 
Figure 3.28. SAXS analysis of MBP-SL-BECN1 OH+BARADAFM. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. 
The AFM also does not appear to significantly affect the tertiary structure of the MBP-SL-BECN1 
OH+BARADTETRAD. SEC-SAXS data were recorded for the MBP-BECN1 OH+BARADTETRAD (Figure 3.16, 
Table 3.4) and the MBP-BECN1 OH+BARADAFM,TETRAD (Figure 3.29, Table 3.7). An Rg of 37 ± 2 Å (Table 
3.4) is estimated from the Guinier plots and P(r) plots of MBP-BECN1 OH+BARADTETRAD (Figure 3.16A 
and B), as well as MBP-BECN1 OH+BARADAFM,TETRAD (Figure 3.28A and B). Similarly, a Dmax of 163 ± 37 
Å is estimated from the P(r) distribution for both samples (Figures 3.16B and 3.29B; Table 3.4 and 3.7). 
Further, the P(r) plots (Figures 3.16B and 2.28B) and Kratky plots (Figure 3.16C and 3.28C) indicate that 
both the MBP-BECN1 OH+BARADTETRAD and MBP-BECN1 OH+BARADAFM,TETRAD are well folded. The 
asymmetric curve P(r) plots with a maximum at distances less than Dmax/2 (Figures 3.16B and 3.28B) also 
both suggest a slightly elongated protein, which is consistent with two globular domains linked by a short 
linker. This similarity in size and shape of the WT and AFM mutant MBP-BECN1 OH+BARADTETRAD 
indicates that the tertiary structure of the BARADTETRAD is unaffected by the AFM. 
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Figure 3.29. SAXS analysis of MBP-SL-BECN1 OH+BARADAFM,TETRAD. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. 
Table 3.7. Summary of SEC-SAXS data for MBP-BECN1 OH+BARAD proteins.  
Protein MWT 
(KD) 
Guinier P(r) 
Rg (Å) Rg  (Å) Dmax (Å) 
MBP-SL-BECN1 
OH+BARADAFM 
64.6 
(monomer) 
30 30 100 
MBP-SL-BECN1 
OH+BARADAFM,TETRAD 
64.4 
(monomer) 
32 33 125 
MWT, theoretical molecular weight. 
These results indicating that the AFM does not affect the secondary structure content or SEC-
SAXS profiles of the CCD-BARAD constructs are consistent with previously published analyses that 
showed that the AFM does not change the overall secondary structure or thermal stability of the BECN1 
OH+BARAD36. Thus, since the AFM dramatically improves the yield of soluble homogeneous protein for 
both the OH+BARAD and the CCD+BARAD fragments and also does not appear to impact secondary or 
tertiary structure of these fragments; all BARAD-containing proteins used for subsequent analysis bear 
the AFM. 
3.3.9. BECN1 CCD structure is destabilized by the OH Tetrad mutation 
The BECN1 CCD interface is composed of 26 interacting pairs comprised of 13 unique pairs 
related by two-fold homodimer symmetry. Only six of these thirteen unique pairs comprise residue pairs 
that form good hydrophobic interactions; while for each of the remaining seven pairs, one residue has a 
polar and/or bulky side-chain resulting in non-ideal packing 33, 34. At the termini of each set of 13 
interacting pairs within the CCD homodimer, each OH contributes to five pairs of interactions; V250:E191, 
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M254:L187, A257:L184, L261:L180, and L264:S177 (Figure 3.1). This includes three of the six good 
hydrophobic interacting pairs. Thus, the OH contributes half the hydrophobic interactions that stabilize the 
BECN1 CCD homodimer. 
In order to assess the effect of the Tetrad mutation on CCD homodimerization, we compared 
dimer self-dissociation Kd of the CCD and CCDTETRAD, as quantified by ITC. At 20 °C, self-association of 
the CCDTETRAD is ~1.5 fold weaker than that of the WT CCD (Figure 3.30, Table 3.8). A comparison of the 
secondary structure content estimated by analysis of CD spectra for the CCD and CCDTETRAD indicates 
that the Tetrad mutation reduces helicity by ~9.5 residues with a concomitant increase of ~9 residues in 
coil content of the CCD but does not impact β-strand content (Figure 3.31A, Table 3.9). Therefore, the 
Tetrad mutation destabilizes CCD secondary structure. The cooperative, reversible melting curves 
indicate that the melting temperature (Tm) of ~33.5 °C of the WT CCD (Figure 3.31B, Table 3.9) 
decreases substantially to 22.5 °C for the CCDTETRAD (Figure 3.31C, Table 3.9), which is also indicative of 
the Tetrad mutation destabilizing the CCD structure.  
Table 3.8. Thermodynamics of self-dissociation of CCD-containing proteins. 
BECN1 Fragment Kd (µM) ΔH (kJ/mol) ΔS (J/K mol) 
CCD 44.8 ± 2.0 45.0 ± 10.5 236.6 ± 36.2 
CCDTETRAD 70.7 ± 3.1 157.0 ± 8.8 615.1 ± 30.0 
CCD-BARADAFM 61.0 ± 8.1 207.1 ± 21.5 787.1 ± 73.0 
CCD-BARADAFM,TETRAD 134.2 ± 4.9 143.0 ± 10.3 561.9 ± 34.9 
Performed at 20 °C in 25 mM HEPES salt pH 8.0, 150mM NaCl, 2mM BME. 
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Figure 3.30. Homodimer dissociation ITC profiles of the BECN1 CCD and CCDTETRAD. 
A) BECN1 CCD. B) BECN1 CCDTETRAD. 
 
Figure 3.31. BECN1 CCD CD spectra and melting curves. 
A) BECN1 CCD (magenta) and BECN1 CCDTETRAD (purple). B) BECN1 CCD melting curve. C) BECN1 
CCDTETRAD melting curve. The Boltzmann fits of the melting curves are shown in black. 
 
 
 
Figure 2: BECN1 CCD CD spectra and melting curves.  
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Table 3.9. CD analysis: Estimated secondary structure content and melting temperatures. 
Protein Average estimated secondary 
structure content (%) 
Melting temperature 
(°C) 
Helix  Strand  Coil  Forward Reverse 
BECN1 CCD 89.8 ± 6.1 1.9 ± 1.1 8.6 ± 6.4 33.9 ± 0.1 33.3 ± 0.1 
BECN1 CCDTETRAD 80.4 ± 4.8 1.9 ± 1.6 17.6 ± 6.8 23.2 ± 0.2 21.6 ± 0.2 
BECN1 OH+BARADAFM 46.1 ± 7.9 20.2 ± 3.0 34.2 ± 9.8 47.7 ± 0.1 NAa 
BECN1 OH+BARADAFM,TETRAD 46.3 ± 3.8 10.6 ± 2.6 44.0 ± 3.2 41.4 ± 0.1 NA 
BECN1 CCD-BARADAFM 65.2 ± 6.7 5.3 ± 1.6 29.9 ± 7.4 23.9 ± 0.6; 
49.0 ± 0.3 
NA 
BECN1 CCD-BARADAFM,TETRAD 56.2 ± 4.1 7.5 ± 0.2 36.7 ± 3.7 22.1 ± 0.6; 
45.1 ± 0.2 
NA 
a NA, not available; Proteins containing the BARAD precipitated, even upon heating just to the melting 
temperature; therefore, reverse Tm could not be determined. 
We used SEC-SAXS to investigate the impact of the Tetrad mutation on size, shape, and 
structure of the CCD. The Rg of the CCDTETRAD, estimated from the Guinier plot and P(r) distribution, is 
~39 Å (Figure 3.32A and B; Table 3.10), which is similar to the Rg of ~36 Å reported for the WT CCD33. 
However, the Dmax of the CCDTETRAD obtained from the P(r) distribution is 155 Å, which is about 30% 
longer than the Dmax reported for the CCD33 (Figure 3.32B, Table 3.10). Further, the Kratky plot indicates 
that the CCDTETRAD is largely unfolded (Figure 3.32C), in contrast to the CCD which is well-folded33. The 
increase in the Dmax observed in the CCDTETRAD is consistent with the destabilization of the CCD by the 
Tetrad mutation, observed in secondary structure estimations and melting temperature calculations by 
CD, since increased disorder would result in polypeptides transiently sampling a larger volume in solution.  
Table 3.10. SAXS data analysis of OH-containing BECN1 protein fragments. 
 BECN1 Domain 
 CCD 33 
CCD 
TETRAD 
OH+BARAD 
AFM 
OH+BARAD 
AFM,TETRAD 
CCD-
BARAD
AFM 
CCD-
BARAD 
AFM,TETRAD 
Fr
om
 
se
qu
en
ce
 
MWT 
(KD) 
24.4 
(dimer) 
21.8 
(dimer) 
26.0 
(monomer) 
26.7 
(monomer) 
64.6  
(dimer) 
64.8  
(dimer) 
SA
XS
 
pa
ra
m
et
er
s Rg (Å) 34 37 20 22 45 47 
P(r) Rg 
(Å) 37 40 20 23 53 53 
Dmax (Å) 121 155 77 92 195 229 
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Figure 3.32. SAXS analysis of BECN1 CCDTETRAD. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. D) Theoretical scattering curve calculated from 
the selected EOM model of the BECN1 CCD with flexible OH fitted to the experimental data. E) Selected 
EOM model (magenta cartoon, flexible residues as spheres) superimposed into the filtered SAXS 
envelope (sand). F) Rg (left panel) and Dmax (right panel) distribution of initial pool and selected ensemble 
of models. 
The theoretical scattering data calculated from the selected EOM model of the CCDTETRAD fits the 
experimental SAXS data poorly with a χ2 of 7.4 (Figure 3.32D and E); which supports the conclusion that 
the CCDTETRAD is highly flexible and may further indicate that the Tetrad mutation destabilizes more of the 
CCD than just the OH since the Kratky plot suggests the CCDTETRAD is largely unfolded (Figure 3.32C). In 
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contrast, the theoretical scattering calculated from the WT CCD crystal structure fits the WT SAXS data 
very well33. Analysis using EOM150 further confirms that the CCDTETRAD is highly flexible. EOM generates a 
random pool of models and selects an ensemble of models from the pool that best fit the scattering data, 
providing an Rg and Dmax distribution for both the pool and selected ensemble of models150. A narrow Rg 
and Dmax distribution for the ensemble compared to the pool suggests that the molecule is rigid; whereas 
an Rg and Dmax distribution for the ensemble that is as broad as the pool suggests that the molecule is 
flexible154. The Rg and Dmax distribution for the CCDTETRAD pool and ensemble are equally broad (Figure 
3.32F), suggesting that the CCDTETRAD is highly flexible.  
Taken together; the secondary structure and melting temperature estimations by CD, homodimer 
association affinity quantified by ITC, solution size and shape parameter determinations by SEC-SAXS, 
and assessment of flexibility by the Kratky plot and EOM, all indicate that CCD secondary, tertiary and 
quaternary structure stability is significantly disrupted by the OH Tetrad mutation. 
3.3.10. The OH Tetrad mutation impacts the BECN1 OH+BARAD structure less than that of the 
CCD 
The crystal structure of the human BARAD36 includes the OH packed against the BARAD, but the 
OH was not included in the yeast VPS30 BARAD crystal structure35. In each case, the crystal structure as 
well as solution data indicate that the BARAD is a monomer. Therefore, the OH does not mediate 
homodimerization of the BARAD, nor does it appear to be required for stability of the BARAD structure in 
all VPS30/BECN1 homologs.  
A comparison of the secondary structure content estimated from CD spectra analysis for the 
OH+BARADAFM and OH+BARADAFM,TETRAD indicates that the Tetrad mutation reduces β-strand content by 
~21 residues with a concomitant increase of ~25 residues in coil content of the OH+BARAD, but does not 
impact α-helical content (Figure 3.33A, Table 3.9). This suggests that although the Tetrad mutation does 
not disrupt the OH itself, it does distort BARAD secondary structure. Reversible melting curves were not 
obtained for any construct containing the BARAD, as the proteins precipitated even when heated only to 
the Tm. However, melting is cooperative for the OH+BARADAFM and OH+BARADAFM,TETRAD (Figure 3.33B 
and C), enabling us to assess Tm. The Tetrad mutation decreases the Tm of the BARAD by only 7 °C 
(Table 3.9). Thus, the BARAD is less affected by the Tetrad mutation than the CCD.  
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Figure 3.33. BECN1 OH+BARAD CD spectra and melting curves. 
A) BECN1 OH+BARADAFM (green) and BECN1 OH+BARADAFM,TETRAD (light green). B) BECN1 
OH+BARADAFM melting curve. C) OH+BARADAFM,TETRAD melting curve. The Boltzmann fits of the melting 
curves are shown in black. 
Next, we used SEC-SAXS to investigate the impact of the Tetrad mutation on size, shape, and 
structure of the OH+BARAD. The Rg of the OH+BARADAFM estimated from the Guinier plot and P(r) 
distribution is ~20 Å (Figure 3.34A and B, Table 3.10). Further, the shape of the P(r) distribution curve 
and the Kratky plots indicates that the OH+BARADAFM is a well-folded, globular domain (Figure 3.34B and 
C). EOM was used to generate an ensemble of OH+BARAD models to account for the flexible, N-terminal 
His6 tag. The best fit of the experimental SAXS data to the theoretical scattering data calculated from an 
EOM model had a χ2 of 1.3 (Figure 3.34D and E), indicative of a very good fit. 
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Figure 3.34. SAXS analysis of BECN1 OH+BARADAFM. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. D) Theoretical scattering curve calculated from 
the selected EOM model of BECN1 OH+BARADAFM, with OH modeled against the BARAD and a flexible 
His6 tag, fitted to the experimental data. E) Selected EOM model (green cartoon, flexible residues as 
spheres) superimposed into the filtered SAXS envelope (sand). F) Rg (left panel) and Dmax (right panel) 
distribution of initial pool and selected ensemble of models. 
The Rg of the OH+BARADAFM,TETRAD estimated from the Guinier plot and P(r) distribution is ~23 Å 
(Figure 3.35A and B, Table 3.10), which is similar to that of the OH+BARADAFM. Similarly, the shape of 
the P(r) distribution curve and the Kratky plot reveals that the OH+BARADAFM,TETRAD is also well-folded 
and globular (Figure 3.35B and C). However, the 15 Å increase in Dmax and the extended tail on the P(r) 
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distribution of the OH+BARADAFM,TETRAD, (Figure 3.35B) relative to the OH+BARADAFM (Figure 3.34B) 
suggest the presence of a more flexible region in the OH+BARADAFM,TETRAD. Indeed, the normalized 
Kratky 83 shows that although the OH+BARADAFM,TETRAD is well folded, it is slightly more flexible than the 
OH+BARADAFM (Figure 3.36). This is consistent with the increased coil content estimated by CD. 
EOM was used to generate an ensemble of OH+BARADAFM,TETRAD models to account for the 
flexible, N-terminal His6 tag of the OH+BARAD fragments. The best fit of the experimental SAXS data to 
the theoretical scattering data calculated from an EOM model had a χ2 of 3.2 (Figure 3.35D and E). 
Lastly, for both the OH+BARADAFM and OH+BARADAFM,TETRAD, EOM analysis shows that the Rg and Dmax 
distribution for the selected ensemble is narrower than that of the initial pool of ensembles generated 
(Figure 3.34F and 3.35F), indicating that both constructs are relatively conformationally homogeneous in 
solution.  
Taken together, the secondary structure and Tm estimations by CD, solution size and shape 
parameter determinations by SEC-SAXS analyses, and assessment of flexibility by the Kratky plot and 
EOM, all demonstrate that the OH Tetrad mutation impacts OH+BARAD structure and stability 
significantly less than it does the CCD. 
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Figure 3.35. SAXS analysis of BECN1 OH+BARADAFM,TETRAD. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. D) Theoretical scattering curve calculated from 
the selected EOM model of BECN1 OH+BARADAFM,TETRAD, with OH modeled against the BARAD and a 
flexible His6 tag, fitted to the experimental data.  E) Selected EOM model (green cartoon, flexible residues 
as spheres) superimposed into the filtered SAXS envelope (sand). F) Rg (left panel) and Dmax (right panel) 
distribution of initial pool and selected ensemble of models. 
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Figure 3.36. The BECN1 OH+BARADAFM,TETRAD is more flexible than the BECN1 OH+BARADAFM. 
Normalized Kratky plot of the OH+BARADAFM (green) and BECN1 OH+BARADAFM,TETRAD (light green). 
3.3.11. The OH preferentially packs against the BARAD rather than with the CCD homodimer, but 
transiently samples both conformations  
A comparison of the secondary structure content estimated from the CD spectra for the BECN1 
CCD-BARADAFM and CCD-BARADAFM,TETRAD indicates that the Tetrad mutation decreases helical content 
by 25 residues and increases strand and coil content by ~4 and ~9 residues respectively (Figure 3.37A, 
Table 3.9). Thus, secondary structure of the two-domain construct is impacted by the Tetrad mutation.  
 
Figure 3.37. BECN1 CCD-BARAD CD spectra and melting curves. 
A) CCD-BARADAFM (orange) and CCD-BARADAFM,TETRAD (light orange). B) CCD-BARADAFM melting curve. 
C) CCD-BARADAFM,TETRAD melting curve. The Boltzmann fits of the melting curves are shown in black. 
In order to determine whether the CCD-BARAD also forms a homodimer like the CCD, we used 
ITC to quantify the dimer Kd. At 20 °C, self-association of the CCD-BARADAFM is 1.4-fold weaker than that 
of the WT CCD, but slightly tighter than that of the CCDTETRAD (Figure 3.30, Figure 3.38A, Table 3.8). 
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Notably, self-association of the CCD-BARADAFM,TETRAD  is approximately 2-fold weaker than the CCD-
BARADAFM (Figure 3.38, Table 3.8). Taken together, these ITC data indicate that the Tetrad mutation 
destabilizes both the CCD and CCD-BARAD homodimer. Equally importantly, compared to the WT CCD 
homodimer, the CCD-BARAD homodimer is substantially dissociated, with a Kd comparable to the 
CCDTETRAD rather than the CCD, suggesting that the OH helix does not stabilize the homodimer as much 
in the two-domain fragment. 
 
Figure 3.38. Homodimer dissociation ITC profiles of the BECN1 CCD-BARAD and CCD-BARADTETRAD. 
A) CCD-BARADAFM. B) CCD-BARADAFM,TETRAD. 
In order to assess the thermostability of the CCD-BARAD, we used CD to measure the melting 
temperature of the two-domain fragment. Although protein precipitation prevented acquisition of 
reversible curves, melting curves for both the CCD-BARADAFM and CCD-BARADAFM,TETRAD contain two 
well-separated transitions (Figure 3.37B and C), indicating that each construct contains two 
independently folded domains. The higher Tm of 49 °C for the CCD-BARADAFM corresponds well with that 
of the OH+BARADAFM (Tm = 48 °C); but notably, the lower Tm of 24 °C corresponds to that of the 
CCDTETRAD (Tm = 23 °C) rather than the WT CCD (Tm = 33 °C) (Table 3.9). This suggests that in the CCD-
BARAD construct, the OH is not part of the CCD homodimer, but rather, packs against the BARAD.  
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This is further corroborated by the melting temperatures of 22 °C and 45 °C observed for the 
CCD-BARADAFM,TETRAD (Table 3.9), as the 22 °C transition temperature is comparable to that of the lower 
Tm of the CCD-BARADAFM as well as that of the CCDTETRAD, whereas the 45 °C transition is a little less 
than the second Tm of 49 °C for the CCD-BARADAFM or the Tm of 48 °C for the OH+BARADAFM, albeit 
slightly higher than the Tm of 41 °C for the OH+BARADAFM,TETRAD (Table 3.9). Therefore, the Tetrad 
mutation does not impact stability of the CCD in the CCD-BARAD construct, but rather appears to 
marginally destabilize the OH+BARAD, consistent with the disruption of packing of the OH against the 
BARAD in the two-domain construct. 
Thus, the melting temperature analysis indicates that the OH packs against the BARAD in the 
BECN1 homodimer. However, self-dissociation measurements by ITC indicate that the CCD-BARAD 
homodimerizes slightly better than the CCDTETRAD and that disruption of the OH packing interface 
weakens CCD-mediated homodimerization of the CCD-BARAD, although not as much as in the CCD 
alone. Taken together, these data suggest that in solution, the OH transitions between packing as part of 
the CCD or against the BARAD, with the predominant state comprising the OH packed against the 
BARAD. 
3.3.12. SAXS indicates the OH packs against the BARAD in the CCD-BARAD protein fragment 
We used SEC-SAXS to further investigate the conformation of the OH in the CCD-BARADAFM and 
CCD-BARADAFM,TETRAD. In each case, the Rg estimated from the Guinier plot and P(r) distribution is ~50 Å, 
(Figure 3.39A and B, Figure 3.40A and B; Table 3.10) and the shape of the P(r) distribution curves and 
the Kratky plots indicates that both are well-folded, dumbbell-shaped proteins (Figure 3.39B and C, 
Figure 3.40B and C).  
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Figure 3.39. SAXS analysis of BECN1 CCD-BARADAFM. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. D) Theoretical scattering data calculated from 
the selected EOM model of the BECN1 CCD-BARADAFM, with the OH modeled as packed against the 
BARAD, fitted into the experimental data. E) Theoretical scattering data calculated from the selected 
EOM model of the BECN1 CCD-BARADAFM, with the OH modeled as part of the CCD, fitted into the 
experimental data. 
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Figure 3.40. SAXS analysis of BECN1 CCD-BARADAFM,TETRAD. 
A) Guinier plot. B) P(r) pairwise distribution. C) Kratky plot. D) Theoretical scattering data calculated from 
the selected EOM model of the BECN1 CCD-BARADAFM,TETRAD, with the OH modeled as packed against 
the BARAD, fitted into the experimental data. E) Theoretical scattering data calculated from the selected 
EOM model of the BECN1 CCD-BARADAFM,TETRAD, with the overlap region as flexible loop, fitted into the 
experimental data. 
EOM was used to generate the best ensemble of CCD-BARADAFM homodimer models. Two 
separate sets of ensembles were generated: one with the OH modeled within the CCD and the other with 
the OH modeled as packed against the BARAD. The average Rg of the ensemble wherein the OH is 
packed against the BARAD (53 Å) is more similar to the experimental data (~50 Å) (Table 3.10) than the 
ensemble wherein the OH is part of the CCD (65 Å). The theoretical scattering curves calculated from 
each selected EOM model were also fit to the experimental SAXS data. The theoretical scattering curves 
calculated from the selected EOM model wherein the OH is packed against the BARAD agrees better 
with the experimental SAXS data (χ2 = 6.9) (Figure 3.39D), compared to the theoretical scattering curves 
calculated from the selected EOM model wherein the OH is part of the CCD (χ2 = 11.7) (Figure 3.39E), 
although neither ensemble fits particularly well. Thus, while the EOM analysis also suggests that the OH 
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likely packs against the BARAD rather than within the CCD in the BECN1 CCD-BARAD homodimer, the 
poor fits of both modeled states suggest that different conformations are transiently occupied in solution. 
EOM was used to generate the best ensemble of CCD-BARADAFM,TETRAD homodimer models. 
Two separate sets of ensembles were generated: one with the OH modeled packed against the BARAD 
and the other with the OH modeled as completely flexible. The theoretical scattering curves calculated 
from each selected EOM model were also fit to the experimental SAXS data. The theoretical scattering 
curve calculated from the selected EOM model wherein the OH is packed against the BARAD agrees 
better with the CCD-BARADAFM,TETRAD experimental SAXS data (χ2 = 14.2) (Figure 3.40D), compared to 
the theoretical scattering curves calculated from the selected EOM model wherein the OH is completely 
flexible (χ2 = 41.8) (Figure 3.40E), but worse compared to the CCD-BARADAFM experimental SAXS data 
(χ2 = 6.9) (Figure 3.40D). These results suggest that the Tetrad mutation partially destabilizes the OH in 
the CCD-BARAD homodimer. 
3.3.13. The Tetrad mutant decreases starvation-induced autophagy 
Lastly, we investigated the impact of destabilization of the OH on cellular autophagy levels 
mediated by exogenously-expressed full-length BECN1, by quantifying and comparing the impact of 
either WT or the Tetrad mutant (V250A, M254A, L261A, and L264A) BECN1. Since BECN1 is known to 
be required for autophagosome nucleation, we evaluated cellular autophagy by monitoring and 
comparing levels of puncta labeled with GFP-tagged LC3, an autophagosome-specific marker, in cells 
grown in either nutrient-rich or starvation media. Expression of WT and Tetrad mutant BECN1 was 
comparable in starvation and nutrient-rich conditions (Figure 3.41A). We used human breast 
adenocarcinoma MCF7 cells as they lack detectable endogenous expression of BECN1, resulting in very 
low basal levels of autophagy 4, 26, 44 even in starvation conditions unless BECN1 is ectopically expressed 
(Figure 3.41B and C). This allows the effect of BECN1 mutants to be assayed in the absence of 
endogenous BECN1. 
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Figure 3.41. Effect of the OH Tetrad mutation on autophagy. 
A) Western blot of MCF7 cell extracts showing comparable expression levels of WT and mutant FLAG-
BECN1 in nutrient rich (R) and starvation (S) conditions, with Actin as a loading control. B) Light 
microscopy quantification of discrete GFP-LC3 puncta per cell in GFP-positive MCF7 cells co-transfected 
with GFP-LC3 and WT or mutant FLAG-BECN1 as indicated below the x-axis. Bars represent the number 
of puncta per cell. Error bars represent standard deviation. C) Representative images of GFP-LC3 
(green) and DAPI (blue) staining in cells grown in starvation or nutrient rich media and transfected with 
mutant FLAG-BECN1 as indicated. 
Transient expression of BECN1 in MCF7 cells did not increase autophagy levels in nutrient-rich 
conditions (p = 0.951 for BECN1 expression versus no expression; Figure 3.41B); but led to a marked 
increase in autophagy upon starvation (p = 0.005 for starved versus nutrient-rich cells; Figure 3.41B). We 
find that the BECN1 Tetrad mutation does not impact autophagy levels in nutrient rich media (p = 0.836 
for mutant versus WT; Figure 3.41B); consistent with the lack of impact of BECN1 expression on basal 
autophagy levels in nutrient-rich conditions. Strikingly however, the BECN1 Tetrad mutation decreases 
autophagy levels in starvation media (p = 0.004 versus WT; Figure 3.41B), indicating that these residues 
are essential for up-regulating starvation-induced autophagy. This is consistent with the established 
importance of other conserved regions of BECN1 in starvation-triggered autophagy, rather than basal 
autophagy levels18, 33. 
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3.4. Discussion and conclusions 
Our observation that the short linker consisting of three alanines promotes helical content as 
compared to the long linker in the MBP-BECN1 CCD fusion proteins is consistent with previous 
observations that the short linker can adopt a helical structure in MBP-fusion proteins155, 156. Since this 
short linker directly precedes the N-terminus of the CCD, which can pack against the conformationally 
flexible OH, it is possible that the presence of a helical short linker stabilizes helical content of the CCD 
within the MBP-SL-BECN1 CCD fusion protein. Thus, since the AFM dramatically reduces aggregation 
and permits large-scale purification of high-quality, homogenous, BARAD-containing constructs that do 
not require the MBP tag, and also does not appear to impact secondary or tertiary structure of these 
fragments; all experiments for our final published analyses used AFM-containing BARAD fragments. 
Utilization of the AFM-containing BARAD constructs eliminated the ambiguities in structural analyses 
caused by the presence of MBP. 
Regarding the main objectives of our study, based on the biophysical and structural analyses 
reported here, we conclude that the BECN1 C-terminal domains, the CCD and BARAD, are linked by a 
conformationally-labile helix. Structural superimposition unambiguously demonstrates that the OH 
residues present in the crystal structure of both the CCD18, 34 and OH+BARAD36, cannot simultaneously 
pack as part of the CCD and against the BARAD. Melting temperature measurements by CD 
spectroscopy and analyses by SEC-SAXS indicate that mutation of OH residues that are key components 
of the interface with the CCD partner helix and the BARAD, disrupts CCD structure more than the 
BARAD. Indeed, these mutations substantially diminish CCD homodimer association. Furthermore, the 
comparative melting temperature analyses, together with the weakened self-association of the CCD-
BARAD relative to the CCD, indicate that the OH preferentially packs against the BARAD in the two-
domain CCD-BARAD protein fragment. This preference is supported by our buried surface area 
calculations, which identify a larger interface between the OH and BARAD than between the OH and the 
partner helix within the CCD. However, self-dissociation measurements by ITC indicate that the OH also 
contributes to CCD-BARAD homodimerization. Therefore, contrary to currently established ideas, the OH 
preferentially packs against the BARAD in the absence of heterologous binding partners but appears to 
also transiently sample conformations where it forms part of the CCD and contributes to 
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homodimerization. This is consistent with the recent discovery in full-length BECN1 that mutations 
analogous to the Tetrad mutant weaken the homodimer, indicating that the OH also contributes to 
homodimerization of full-length BECN1157.  
We further show that the BECN1 homodimer is unstable at physiological temperatures. Our 
melting temperature analyses show that nearly half the CCD is unfolded in the two-domain CCD-BARAD 
fragment at 37 °C. Together, the weak self-association and instability of the CCD-BARAD homodimer 
suggest that BECN1 likely does not exist in a stable homodimeric state at physiological temperatures, 
unless stabilized in that state by other protein partners such as the BCL2 proteins. BECN1 
homodimerization likely serves as an important means of regulating autophagy in cells. Notably, this may 
be a regulatory mechanism that evolved in higher eukaryotes such as vertebrates, as yeast do not 
encode BCL2 proteins, and it is unknown whether yeast VPS30 homodimerizes. 
This is significant because upregulation of autophagy by BECN1 requires either ATG14 or 
UVRAG to displace one molecule of the BECN1 homodimer, which would be facilitated by a weak 
BECN1 homodimer. The 4.4 Å crystal structure (PDB ID: 5DFZ) of full-length yeast VPS30/BECN1 in 
complex with VPS34/PI3KC3, VPS15/p150, and VPS38/UVRAG17, shows that the OH is part of a parallel 
VPS30:VPS38 CCD heterodimer essential for stabilizing this complex. The 28 Å reconstruction of the 
quaternary complex of human PI3KC3, p150, BECN1 and ATG1416, indicates that BECN1 and ATG14 
interact in an analogous manner. A SAXS data-constrained model of the BECN1:ATG14 heterodimer 
indicates that four of the OH interface residues identified in the homodimer also contribute to the 
heterodimer coiled-coil interface (V250:I165, M254:N169, A257:L172, L261:V176)18. Notably, these OH 
residues are largely conserved, especially in vertebrates (Figure 3.2A); and are predicted to pack against 
ATG14 residues that are also conserved. Indeed amongst these interacting pairs, the least conserved 
BECN1 residue, M254, is paired with N169, the least conserved paired residue in ATG1418. Thus, the OH 
contributes critical binding determinants to the parallel CCD heterodimers required for formation of 
VPS34/PI3KC3 complexes essential for autophagy. Consistent with this, we show that the Tetrad 
mutation of the OH interface residues abrogates the starvation-induced up-regulation of autophagy but 
has no effect on basal levels of autophagy.  
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Our experimental evidence showing that the OH preferentially packs against the BARAD in the 
BECN1 homodimer suggests a mechanism wherein homodimerization via the CCD results in BECN1 
conformations that prevents the BARAD aromatic finger from associating with membranes, while BECN1 
heterodimerization with ATG14 or UVRAG disrupts this inhibitory conformation. The crystal structure and 
HDX-MS experiments of the yeast PI3KC3:p150:BECN1:UVRAG ternary complex show that the aromatic 
finger interacts with membranes when the OH participates in the CCD interface of the heterodimer 17. 
However, formation of a BECN1 homodimer, wherein the OH preferentially packs against the BARAD, 
would shorten the CCD and involve reorientation of the BARAD relative to that observed in the yeast 
PI3KC3:p150:BECN1:UVRAG ternary complex. This would reposition the BARAD such that the aromatic 
finger is no longer able to interact with membranes, thereby inhibiting BECN1-mediated autophagy. 
Another important implication of the OH being preferentially packed against the BARAD in the 
homodimer is that this would release the N-terminal region of the partner helix within the anti-parallel 
CCD homodimer. The N-terminal region of the human BECN1 CCD (Figure 3.2B) contains a leucine-rich 
nuclear export signal (NES) that binds the chromosomal protein 1 (CRM1) to enable nuclear export of 
BECN1158, 159. A functional NES is comprised of the sequence motif: Lx(2-3)Lx(2-3)LxL. NES residues L184 
and L187 are essential for BECN1 nuclear export, BECN1-mediated autophagy, and tumor 
suppression158, 159. In the CCD homodimer, NES residues L184 and L187 pack against OH interface 
residues, A257 and M254 respectively18. Therefore, in order to bind CRM1, the BECN1 NES cannot be 
packed against the BECN1 OH. Thus, our results showing that the OH preferentially packs against the 
BARAD in the homodimeric state provide a mechanism of how the NES may be exposed for CRM1-
binding to enable nuclear export. Indeed, interaction with CRM1 may stabilize BECN1 conformations 
wherein the OH is packed against the BARAD. Interestingly, unlike vertebrates, lower eukaryotes do not 
have a NES located at the N-terminus of the CCD (Figure 3.2B). Therefore, this conformational switch is 
likely not needed for nuclear export in yeast, as the NES is located between yeast VPS30 residues 12-
21158, which is part of the IDR, rather than the CCD. 
In summary, previous studies have established the BECN1 CCD and BARAD as structurally well-
defined domains, but here we show that these domains include a region, now termed the overlap helix 
(OH), that can adopt two distinct, mutually-exclusive packing states, emphasizing overall BECN1 
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conformational flexibility. Further, in the absence of heterologous partners, the OH transitions between 
these states with a preference to packing against the BARAD, rather than the CCD as has been 
commonly assumed. This region likely serves to regulate BECN1 function in autophagy and nuclear 
transport, and interactions with different partners likely stabilize one packing state or the other to promote 
these different functions. Understanding how different interactions stabilize different BECN1 
conformational states is the next critical step toward understanding the regulation of BECN1-mediated 
autophagy. 
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CHAPTER 4. INVESTIGATING THE HIV NEF INTERACTION WITH BECN1 
4.1. Introduction 
The human immunodeficiency virus (HIV), the virus responsible for the global acquired immune 
deficiency syndrome (AIDS) epidemic, is highly resilient to therapeutic intervention due to its remarkable 
ability to mutate and adapt to evolutionary pressure160, 161. Patients infected with Negative Factor (Nef)-
defective strains of HIV-1 tend to either not progress, or progress very slowly, towards AIDS66. This 
critical role in HIV-1 pathogenesis makes Nef a particularly interesting therapeutic target. 
Nef is a small, polymorphic in length (200-215 residues), myristoylated protein primarily localized 
in the paranuclear region that has been demonstrated to subvert a variety of host cell proteins to promote 
viral replication162, 163. Nef molecules incorporated into virion progeny are commonly cleaved by the viral 
protease, freeing the C-terminal Core domain from the myristoylated N-terminus164, 165. 
Notably, cellular assays in human cells indicate that Nef is essential for enhancing HIV virion 
yields in response to autophagy induction, causes accumulation of early autophagic markers, inhibits 
autophagosome maturation, blocks autophagic degradation of HIV, co-localizes with autophagosome 
maturation factors including BECN1, and immunoprecipitates from cell lysates with BECN1-containing 
complexes68, 69. This suggests that Nef subverts the autophagy machinery to promote HIV replication. 
Immunoprecipitation assays from cell lysates with Nef mutants revealed that Nef residues D174 
and D175 in the C-terminal Core domain are required for interaction with BECN1 and autophagosome 
maturation inhibition68. Separate immunoprecipitation assays from cell lysates indicate that BECN1 
residues 267-284 of the BARAD are crucial for the BECN1:Nef interaction, but are not required for the 
BECN1:PI3KC3 interaction166. However, the mechanism of the Nef interaction with BECN1-containing 
complexes is unknown. Therefore, we utilized affinity pull-down assays and ITC with purified protein to 
determine if BECN1 is sufficient for a direct interaction with Nef. 
4.2. Materials and methods 
4.2.1. Plasmid preparation 
Human BECN1 residues 175-450 (CCD-BARAD) were cloned between the NcoI and NotI 
restriction enzyme sites of the pMBP-Parallel-1 bacterial expression vector146. The full length Nef SF2 
allele residues 1-210 (FL Nef) and Nef SF2 allele residues 62-210 Core domain (Nef Core) prepared as 
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published previously167, were kindly provided by Dr. John Jeff Alvarado (University of Pittsburgh School of 
Medicine, Pittsburgh, USA).   
4.2.2. Protein expression and purification 
FL Nef and Nef Core were expressed and purified as previously described167. This involved 
expression of FL Nef in Rosetta(DE3)pLysS E. coli cells. Soluble protein in the cell lysate (Lysis Buffer: 
25 mM Tris pH 8.0, 1 mM EDTA, 8% (v/v) glycerol, 2 mM DTT, 50 mM NaCl, 0.4 % (w/v) β-octyl 
glucoside) from a 1 L expression culture was purified to homogeneity using a 10/100 MonoQ anion 
exchange column chromatography (MonoQ Buffer A: 25 mM Tris pH 8.0, 1 mM EDTA, 8% (v/v) glycerol, 
2 mM DTT, 50 mM NaCl; MonoQ Buffer B: MonoQ Buffer A plus 1 mM NaCl). 0.4 % (w/v) β-octyl 
glucoside was subsequently added to minimize aggregation; protein was then concentrated to 5 mg/mL, 
dialyzed against MonoS Buffer A (MonoS Buffer A: 25 mM HEPES sodium salt pH 7.5, 1 mM EDTA, 1 
mM DTT, 8% (v/v) glycerol; MonoS Buffer B: MonoS Buffer A plus 1 mM NaCl), and further purified by 
cation exchange chromatography on a 10/100 GL MonoS column. 0.4 % (w/v) β-octyl glucoside was 
subsequently added; then protein was concentrated to 5 mg/mL and purified by SEC using a 16/60 
HiLoad Superdex 200 column in 20 mM Tris HCl pH 8.0, 150 mM NaCl, 8% (v/v) glycerol, 2 mM DTT. 
Nef Core was expressed in Rosetta(DE3)pLysS E. coli cells. Soluble protein in the cell lysate 
(Lysis Buffer: 25 mM Tris pH 8.0, 1 mM EDTA, 8% (v/v) glycerol, 2 mM DTT, 50 mM NaCl, 0.2 % (w/v) β-
octyl glucoside) from a 1 L expression culture was purified using a 10/100 MonoQ anion exchange 
column (MonoQ Buffer A: 25 mM Tris pH 8.0, 1 mM EDTA, 8% (v/v) glycerol, 2 mM DTT, 50 mM NaCl; 
MonoQ Buffer B: MonoQ Buffer A plus 1mM NaCl). 0.2 % (w/v) β-octyl glucoside was subsequently 
added to minimize aggregation; then protein was concentrated to 5 mg/mL and purified to homogeneity 
by SEC using a 16/60 HiLoad Superdex 200 column in 20 mM Tris HCl pH 8.0, 150 mM NaCl, 8% (v/v) 
glycerol, 2 mM DTT. 
For the MBP-LL-BECN1 CCD-BARAD, E. coli Arctic Express DE3 cells were transformed and 
grown in LB medium with 100 µg/ml ampicillin at 37 °C to an A600 of ~ 0.7 before equilibrating the 
temperature to 13 °C. Once the cells achieved an A600 of ~ 1.2, they were induced by the addition of 0.5 
mM IPTG and expressed overnight. Fusion protein in the cell lysate (Lysis buffer: 25 mM Tris HCl pH 8, 
150 mM NaCl, 10% (v/v) glycerol, 1mM EDTA, 2 mM DTT, and 1 cOmplete, EDTA-free protease inhibitor 
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cocktail tablet (MilliporeSigma)) from a 1 L expression culture was purified by amylose affinity 
chromatography using a 10 mL amylose resin gravity column, washed with 10 column volumes of wash 
buffer (wash buffer: 25 mM Tris HCl pH 8, 150 mM NaCl, 10% (v/v) glycerol, 1mM EDTA, 2 mM DTT), 
and eluted with wash buffer plus 20 mM maltose. The protein was then purified by anion exchange 
chromatography on a 5/50 GL MonoQ column (GE Life Sciences, Pittsburgh, US) (MonoQ Buffer A: 25 
mM Tris HCl pH 8, 10% (v/v) glycerol, 1 mM EDTA, 1mM DTT; MonoQ Buffer B: MonoQ Buffer A plus 1M 
NaCl). Protein was eluted from the MonoQ column via step elutions at 190 mM and 220 mM NaCl. The 
protein was then purified to homogeneity by SEC using a 16/60 Superdex 200 column (GE Life Sciences, 
Pittsburgh, US) in 20 mM Tris HCl pH 8, 150 mM NaCl, 10% glycerol, 2mM DTT. 
4.2.3. Pull-down  
For a 1:1 molar ratio, 0.9 mg of FL Nef and 0.3 mg MBP-BECN1 CCD-BARAD were added to 250 
µL amylose resin, washed with Wash Buffer (25 mM Tris pH 8.0, 50 mM NaCl, 5% (v/v) glycerol, 1 mM 
EDTA, 2 mM DTT) until the A280 = 0, and finally eluted with wash buffer plus 20 mM maltose. Fractions 
were evaluated by SDS-PAGE stained with Coomassie Blue. As a control, 0.9 mg of FL Nef was added to 
250 µL amylose resin and treated in the same manner. 
4.2.4. ITC 
Protein samples were co-dialyzed against 25 mM HEPES sodium salt pH 7.5, 150 mM NaCl, 10 % 
(v/v) glycerol, and 2 mM TCEP. ITC experiments were performed at 20 °C using a Low Volume Gold 
Nano isothermal titration calorimeter (TA Instruments, New Castle, US). 100 µM Nef Core was titrated 
into 40 µM MBP-BECN1 CCD-BARAD. Data were analyzed with the NanoAnalyze Software (TA 
Instruments, New Castle, US). 
4.3. Results  
4.3.1. Protein expression and purification 
FL Nef was purified by sequential anion exchange chromatography, cation exchange 
chromatography, and SEC. The single peak on SEC and single band on SDS-PAGE indicate the FL Nef 
was pure and homogenous (Figure 4.1). The apparent molecular weight of FL Nef calculated based on 
the elution volume from SEC is 20 kD, which is 1.2-times smaller than the theoretical molecular weight of 
24 kD for the FL Nef monomer calculated from the amino acid sequence. This is consistent with the FL 
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Nef forming a monomer. The final yield of the purified FL Nef obtained from one liter of bacterial culture 
was 6 mg. 
 
Figure 4.1. Size exclusion chromatogram and the corresponding SDS-PAGE of FL Nef.  
The elution positions of SEC standards are indicated by arrows. 
 
Nef Core was purified by sequential anion exchange chromatography and SEC. The apparent 
molecular weight of Nef Core calculated based on the elution volume from SEC of the 71.9 mL peak is 
106 kD, which is ~6 times greater than the theoretical molecular weight of 18 kD for the Nef Core 
monomer calculated from the amino acid sequence (Figure 4.2), indicating oligomerization. The final yield 
of the purified Nef Core obtained from one liter of bacterial culture was 5 mg.  
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Figure 4.2. Size exclusion chromatogram and the corresponding SDS-PAGE of Nef Core.  
The elution positions of SEC standards are indicated by arrows. 
 
MBP-LL-BECN1 CCD-BARAD was purified by sequential amylose chromatography, anion 
exchange chromatography, and SEC. The single peak on SEC and single band on SDS-PAGE indicate 
the MBP-LL-BECN1 CCD-BARAD was pure and homogenous (Figure 4.3). The apparent molecular 
weight of MBP-LL-BECN1 CCD-BARAD calculated based on the elution volume from SEC is 178 kD, 
which is 1.2-times greater than the theoretical molecular weight of 151 kD for the MBP-LL-BECN1 CCD-
BARAD dimer calculated from the amino acid sequence. This is consistent with the MBP-LL-BECN1 
CCD-BARAD forming rod-shaped dimer. The final yield of the purified MBP-LL-BECN1 CCD-BARAD 
obtained from one liter of bacterial culture was 4 mg. 
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Figure 4.3. Size exclusion chromatogram and the corresponding SDS-PAGE of MBP-LL-BECN1 CCD-
BARAD.  
The elution positions of SEC standards are indicated by arrows. 
4.3.2. Nef and BECN1 do not directly interact via affinity pull-down assays 
In order to determine if Nef interacts directly with BECN1, we performed amylose affinity pull-
downs of purified FL Nef and MBP-BECN1 CCD-BARAD. We first confirmed that FL Nef does not bind 
amylose resin in the absence of an MBP-tagged binding partner. FL Nef from two separate protein preps 
(FL Nef #1 and FL Nef #2) did not bind the amylose resin in the absence of MBP-tagged BECN1 (Figure 
4.4A). 
MBP-BECN1 CCD-BARAD does not pull down FL Nef (Figure 4.4B). MBP-BECN1 CCD-BARAD 
binds well to the amylose resin, with only a small fraction coming off in the flow through, whereas most of 
the FL Nef comes off in the flow through. The remainder of the FL Nef washes off of the amylose resin 
and does not co-elute with MBP-BECN1 CCD-BARAD. This suggests either that Nef and BECN1 do not 
interact directly or that BECN1 is insufficient for a direct interaction with Nef.  
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Figure 4.4. Pull-down assay to assess binding between FL Nef and BECN1 CCD-BARAD. 
A) SDS-PAGE of FL Nef pull-down on amylose resin. FL Nef from two separate protein preps was tested 
(labeled FL Nef #1 and FL Nef #2). B) SDS-PAGE of FL Nef and MBP-BECN1 CCD-BARAD pull-down on 
amylose resin. 
4.3.3. ITC of MBP-BECN1 CCD-BARAD and Nef Core 
Since Nef residues Asp174 and Asp175 in the C-terminal Core domain were found to be required 
for the BECN1 interaction and autophagosome maturation inhibition68, we utilized ITC to determine if a 
direct interaction could be detected between Nef Core and BECN1 by titrating Nef Core into MBP-LL-
BECN1 CCD-BARAD; however, no binding was detected (Figure 4.5). Therefore, consistent with affinity 
pull-down assays performed with purified protein, ITC confirms that Nef and BECN1 either do not interact 
directly or that BECN1 is insufficient for a direct interaction with Nef 
 102 
 
Figure 4.5. ITC profiles of Nef Core titrated into MBP-LL-BECN1 CCD-BARAD. 
 
4.4. Discussion and conclusions 
Based on the in vitro analyses with purified protein reported here, we conclude that the BECN1 
BARAD in the context of the BECN1 homodimer is insufficient to mediate a direct interaction with Nef. 
Previously published cellular co-immunoprecipitation assays indicated that C-terminal residues of the Nef 
Core mediate the interaction with BECN1-containing complexes68 and that BECN1 residues 267-284 of 
the BARAD are crucial for the BECN1:Nef interaction166. However, our affinity pull-down assays and ITC 
indicate that neither FL Nef nor the Nef Core interacts with the MBP-BECN1 CCD-BARAD homodimer. 
Previous studies indicate that Nef is essential for HIV progression towards HIV66 and the 
observed augmentation of HIV virion yields in response to autophagy induction68. Notably, Nef is required 
for accumulation of the early autophagic marker LC3-II, which is typically degraded in autolysosomes, 
and prevents acidification of the autolysomes68. This role in arresting maturation suggests that Nef 
interacts with BECN1 in the context of PI3KC3 Complex II, which consists of BECN1 (VPS30 in yeast), 
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PI3KC3 (VPS34 in yeast), p150 (VPS15 in yeast), and UVRAG (VPS38 in yeast) since Complex II 
mediates autophagosome maturation11, 12, 14, 15, 57. 
BECN1 residues 267-284 (residues 323-340 in yeast VPS30) crucial for the BECN1:Nef 
interaction166, are located at the N-terminus of the BARAD immediately following the OH. The 4.4 Å 
crystal structure (PDB ID: 5DFZ) of full-length yeast VPS30 in Complex II17 shows that the OH is part of a 
parallel VPS30:VPS38 CCD heterodimer such that the critical Nef-binding BECN1 (VPS30) residues are 
largely solvent exposed as part of a coil immediately following the OH and the first β sheet of the BARAD. 
However, a 1.6 Å crystal structure (PDB ID: 4DDP) of the OH+BARAD36 shows that the OH packs against 
one face of the first β sheet of the BARAD. We have shown that the BECN1 homodimer transitions 
between these two mutually exclusive states with a preference to packing against the BARAD, rather than 
the CCD168. It is possible that the BECN1 homodimer preference for packing the OH against the BARAD 
prevents Nef from interacting with the BECN1 homodimer. Therefore, we cannot rule out the possibility 
that Nef interacts directly with the BECN1 BARAD in the context of the BECN1:UVRAG heterodimer 
wherein the Nef-binding BECN1 residues are less occluded.  
Alternatively, perhaps the Nef:BECN1 interaction requires stabilization by interactions with other 
PI3KC3 Complex II proteins in addition to BECN1. The UVRAG (VPS38) BARA2 and p150 (VPS15) 
WD40 domains in Complex II17 create a pocket with a diameter of about 25 Å on the side of the first β 
sheet of the BARAD opposite to where the OH packs in the homodimer. The 3.0 Å crystal structures of 
unbound Nef Core (PDB ID: 1AVV) and the Nef Core bound to the SH3 domain of FYN (PDB ID: 
1AVZ)163, as well as the 1.9 Å crystal structure (PDB ID: 4U5W) of the Nef Core bound to the SH3-SH2 
domains of the kinase Hck167 show that Nef Core is a small globular protein with a diameter of about 30 Å 
comprising an N-terminal ordered coil, followed by 2 α-helices, an ordered coil, a β sheet consisting of 
two strands, and two short C-terminal α-helices. The N-terminal coil and the first and second α-helices of 
the Nef Core interact with the SH3 domains in Nef:FYN and Nef:Hck complexes. The Nef residues Asp174 
and Asp175 in the C-terminal Core domain determined to be required for interaction with BECN1 and for 
autophagosome maturation inhibition68 are located within a region of 31 disordered residues between the 
strands of the β sheet. Therefore, it is also possible that a direct Nef:BECN1 interaction requires 
stabilization by residues the p150 WD40 domain within the PI3KC3 Complex II.  
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In summary, previous studies have established that residues from the BECN1 BARAD and Nef 
Core are essential for the BECN1:Nef interaction, but here we show that these domains are insufficient to 
mediate a direct interaction. Therefore, Nef likely interacts with BECN1 in the context of the PI3CK3 
complex II; although, we cannot rule out a direct interaction between Nef and the BECN1 heterodimer 
observed in this complex. Understanding the mechanism by which Nef interacts with BECN1 in the 
PI3CK3 complex II is the next critical step toward understanding how Nef subverts the autophagy 
machinery to enhance HIV pathogenesis.   
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CHAPTER 5. KSHV V-BCL2 INTERACTION WITH BECN1 AND NOXA BH3DS 
5.1. Introduction 
KSHV is a human ɣHV associated with Kaposi’s sarcoma (KS), primary effusion lymphomas, and 
Castleman’s disease169. KSHV encodes a vBcl-2 mimic that is expressed in KSHV lesions170, which 
promotes survival of KSHV-infected cells and may contribute to tumor development169. Like host cell anti-
apoptotic Bcl-2s, ɣHV Bcl-2s inhibit apoptosis171. Further like host cell and other ɣHV anti-apoptotic Bcl-
2s43-47, 172, KSHV Bcl-2 also appears to down-regulate autophagy by inhibiting autophagosome formation 
by binding the BH3D of BECN126. The solution structure of the KSHV vBcl-2 indicates that the overall fold 
is similar to cellular Bcl-2 proteins173. However, binding affinities for various BH3Ds by the KSHV vBcl-2 
vary widely from the affinities for the same BH3Ds by host cell Bcl-2 proteins44, 174. This suggests that the 
mechanism of binding by the KSHV vBcl-2 to BH3Ds differs from that of host cell proteins.  
A BECN1 BH3D G120E/D121A double mutant has been shown to selectively bind the mouse 
ɣHV Bcl-2 homolog M11, but not cellular Bcl-2 proteins, to down-regulate M11-mediated inhibition of 
autophagy140. Although the KSHV vBcl-2 has previously been demonstrated to bind the wild-type BECN1 
BH3D44, we show via ITC that the BECN1 BH3D G120E/D121A double mutant does not bind the KSHV 
vBcl-2. This suggests that the determinants of binding specificity for BH3Ds differ for the KSHV vBcl-2 
and M11. However, to date, there is no crystal structure deposited in the PDB of KSHV vBcl-2 bound to 
any BH3D. Therefore, solving the KSHV vBcl-2 structure in complex with a pro-apoptotic BH3D may 
permit identification of the molecular determinants that define binding specificity for the KSHV vBcl-2. 
Since mouse NOXA (mNOXA) has been shown to tightly bind KSHV vBcl-2, Mcl-1, and A1, but 
binds weakly or not at all to the other human anti-apoptotic Bcl-2 paralogs174, 175, we quantified the 
thermodynamics of binding between the KSHV vBcl-2 and mNOXA via ITC. However, protein 
precipitation issues hindered acquisition of sufficient quantities of high quality, homogenous protein to 
perform ITC replicates required to obtain reliable thermodynamics parameters and to perform other 
biophysical and structural analyses of the interaction. 
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5.2. Materials and methods 
5.2.1. Plasmid preparation and peptide synthesis 
KSHV residues 1-146 were cloned between the NcoI and NotI restriction enzyme sites of the 
pET21d(+) bacterial expression vector such that the construct included a C-terminal His6 tag. Site-
directed mutagenesis was used to introduce N67D and V117A point mutations to improve protein 
solubility173. Peptides corresponding to the mouse NOXA (mNOXA) BH3D and the BECN1 BH3D 
G120E/D121A mutant were chemically synthesized, HPLC purified to >90% purity, and purity confirmed 
by electrospray mass spectrometry (RS Synthesis). For each peptide, a 3 mM stock solution in 25 mM 
Tris HCl pH 7.8, 2mM BME was prepared. The mNOXA sequence was 
RAELPPEFAAQLRKIGDKVYCTWSAP (2.9 kD, ε280 = 6,990 M-1 cm-1). The BECN1 BH3D G120E/D121A 
sequence was DGGTMENLSRRLKVTEALFDIMSGQT (2.9 kD, ε280 = 0 M-1 cm-1). 
5.2.2. Protein expression and purification 
E. coli BL21-Gold(DE3) cells were transformed and grown in LB medium with 100 µg/mL 
ampicillin at 37 °C to an A600 of 0.350 before equilibrating the temperature to 30 °C. Once the cells 
achieved an A600 of ~1.2, they were induced by the addition of 0.5 mM IPTG and expressed overnight at 
20 °C. Soluble protein in the cell lysate (Lysis Buffer: 20 mM Tris HCl pH 7.8, 150 mM NaCl, 2mM BME, 
40 mM Imidazole, and 1 cOmplete, EDTA-free protease inhibitor cocktail tablet (MilliporeSigma)) from a 1 
L expression culture was by nickel IMAC using a 5 mL HisTrap column (GE Life Sciences, Pittsburgh, 
US), washed with 10 column volumes of nickel wash buffer consisting of 20 mM Tris HCl pH 7.8, 150 mM 
NaCl, 2mM BME, and 40 mM Imidazole, and then eluted with wash buffer containing 200 mM imidazole. 
The protein was then desalted on a HiPrep 16/10 desalt column (GE Life Sciences, Pittsburgh, US) in 50 
mM Tris HCl pH 7.8, 2mM BME and then purified to homogeneity by SEC on a 10/30 Superdex 200 
linked in tandem to a 10/30 Superdex 75 column (GE Life Sciences, Pittsburgh, US) in the same buffer. 
5.2.3. Complex SEC and crystal screening 
300 µL of 170 µM KSHV vBcl-2 was injected onto a 10/30 Superdex 200 linked in tandem to a 10/30 
Superdex 75 SEC column, which was run with SEC buffer consisting of 50 mM Tris HCl pH 7.8, 2mM 
BME. Purified KSHV vBcl-2 and mNOXA were mixed with a 1:2 molar ratio and incubated at 4 °C for one 
hour. 300 µL of the mixture (170 µM complex) was injected onto the same tandem SEC columns using 
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the same SEC buffer. The KSHV vBcl-2:mNOXA complex peak from SEC was concentrated and 
screened for crystallization at 20 °C against Microlytic screens MCSG 1-4 (Anatrace, Maumee, OH, USA) 
using a 1:1, 2:1, or 3:1 mixture of protein stock (1 mg/mL complex in 50 mM Tris HCl pH 7.8 and 2mM 
BME) and well solution using a Gryphon LCP crystal screen dispenser (Art Robbins Instruments). 
5.2.4. ITC 
Protein and peptide samples were co-dialyzed against 50 mM Tris HCl pH 7.8 and 2 mM BME. In 
order to assess the thermodynamics of binding of the KSHV vBcl-2 to the BH3D peptides, ITC 
experiments were performed in duplicate at 14 °C using a Low Volume Gold Nano isothermal titration 
calorimeter (TA Instruments, New Castle, US). 2 mM BECN1 BH3D G120E/D121A or 2 mM mNOXA 
BH3D were separately titrated into 200-250 µM KSHV vBcl-2. Data were blanked against a peptide-into-
buffer titration curve and analyzed with the NanoAnalyze Software (TA Instruments, New Castle, US) 
using an independent binding model.  
5.3. Results  
5.3.1. KSHV vBcl-2 purification 
KSHV vBcl-2 was purified to homogeneity using a 5 mL HisTrap column; however, the protein 
precipitated severely if left overnight in nickel elution buffer. Therefore, elution fractions were immediately 
desalted on a desalt column to minimize precipitation and subsequently purified by SEC. KSHV vBcl-2 
itself elutes as two peaks, one at 16.0 mL likely corresponding to aggregated protein, and another peak at 
27.2 mL (Figure 5.1). The apparent molecular weight of KSHV vBcl-2 calculated based on the elution 
volume of the second SEC peak is 22.2 kD (Figure 5.1), which is 1.3-times greater than the theoretical 
molecular weight of 17.7 kD for the KSHV vBcl-2 monomer calculated from the amino acid sequence. 
This is inconsistent with any oligomerization, indicating the KSHV vBcl-2 is a monomer. The 27.2 mL SEC 
peak could be concentrated to a maximum of 2.5 mg/mL before precipitation was observed. The final 
yield obtained from one liter of bacterial culture was 9.5 mg. 
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Figure 5.1. Size exclusion chromatogram and the corresponding SDS-PAGE of KSHV vBcl-2.  
The elution positions of SEC standards are indicated by arrows. 
5.3.2. The KSHV vBcl-2 binds mNOXA but not the BECN1 BH3D G120E/D121A double mutant 
It has been demonstrated that the KSHV vBcl-2 binds the BECN1 BH3D44 and that the BECN1 
BH3D G120E/D121A double mutant selectively binds the mouse ɣHV Bcl-2 homolog M11, but not cellular 
Bcl-2 proteins, to down-regulate M11-mediated inhibition of autophagy140. We therefore, used ITC to 
determine if the BH3D G120E/D121A double mutant likewise binds the KSHV vBcl-2. However, unlike 
M11, ITC reveals that the BECN1 BH3D G120E/D121A double mutant does not bind the KSHV vBcl-2 
(Table 5.1, Figure 5.2A).  
Since mNOXA has been shown to tightly bind KSHV vBcl-2, Mcl-1, and A1 but weakly or not at all 
to the other anti-apoptotic Bcl-2 paralogs174, 175, we used ITC to quantify the thermodynamics of binding 
between the KSHV vBcl-2 and mNOXA. The KSHV vBcl-2 binds mNOXA with a Kd of ~64.5 µM (Table 
5.1, Figure 5.2B). Although this confirms a direct interaction of moderate affinity, the affinity we 
determined by ITC is significantly less than the reported 0.163 µM affinity determined by fluorescence 
polarization assays174. 
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Figure 5.2. ITC profiles of KSHV vBcl-2 binding to BH3Ds.  
KSHV vBcl-2 binding to the A) BECN1 BH3D G120E/D121A and B) mNOXA BH3D. 
Table 5.1. Thermodynamics of binding of KSHV vBcl-2 to BH3D peptides. 
BH3D Kd (µM) ΔH (kJ/mol) ΔS (J/K mol) 
BECN1 BH3D G120E/D121A No binding detected 
mNOXA BH3D 64.5 ± 27.9 2.4 ± 0.5 89.0 ± 1.2  
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5.3.3. SEC and crystal screening of the KSHV vBcl-2:mNOXA complex 
We used SEC to characterize the oligomeric state of the KSHV vBcl-2:mNOXA complex in 
solution, using a 10/30 Superdex 200 column linked in tandem with a 10/30 Superdex 75 SEC column to 
determine the elution volume of the complex. KSHV vBcl-2 itself elutes as two peaks, one at 16.0 mL 
corresponding to aggregated protein and another at 27.2 mL corresponding to the monomer (Figure 5.3). 
Four peaks were observed in the SEC chromatogram after KSHV vBcl-2 was incubated with mNOXA, two 
of which correspond to the peaks of the SEC chromatogram of the isolated KSHV vBcl-2 (Figure 5.3). 
The aggregation peak (16mL) is diminished, but still present; while the 27.1 mL peak represents the 
KSHV vBcl-2 monomer with an apparent molecular weight of 22.9 kD (theoretical MW = 17.7 kD). The 
two new peaks include a 33.2 mL peak with an apparent molecular weight of 3.0 kD that likely represents 
the mNOXA BH3D monomer (theoretical MW = 2.9 kD) and a 24.2 mL peak with an apparent molecular 
weight of 60.4 kD. The theoretical molecular weight of the KSHV vBcl-2:mNOXA heterodimer complex is 
20.6 kD, so it is unclear what this peak corresponds to, but it may represent a homotrimer of KSHV vBcl-
2:mNOXA BH3D heterodimers. Thus, the KSHV vBcl:mNOXA BH3D mixture appears to elute as a 
combination of complex and monomer species (Figure 5.3). 
 
Figure 5.3. Size exclusion chromatogram of KSHV vBcl-2 (gray) and the KSHV vBcl-2:mNOXA mixture 
(black).  
The elution positions of SEC standards are indicated by arrows. 
 111 
We screened the 24.2 mL SEC peak for crystallization in an attempt to determine conditions 
suitable for crystallization of the KSHV vBcl-2:mNOXA complex. However, the 24.2 mL SEC peak could 
only be concentrated to a maximum of 1 mg/mL before precipitation was observed. Robotic screening of 
the 1 mg/mL KSHV vBcl-2:mNOXA did not yield an crystal hits after observation over the course of two 
months. 
5.4. Discussion and conclusions 
Protein precipitation during nickel IMAC and concentration stages of purification resulted in the 
acquisition of low concentrations of KSHV vBcl-2, wherein a maximum concentration of 2.5 mg/mL, was 
obtained, and KSHV vBcl-2:mNOXA complex, wherein a maximum concentration of 1 mg/mL, was 
obtained. We used these low concentration samples to perform a single ITC experiment to quantify the 
binding affinity for a BECN1 BH3D G120E/D121A double mutant and mNOXA BH3D peptide, as well as 
assess the oligomeric state of the KSHV vBcl-2:mNOXA complex by SEC and screen the complex for 
crystallization. Our ITC results indicate that, unlike M11140, the KSHV vBcl-2 does not bind the BECN1 
BH3D G120E/D121A double mutant. However, consistent with previous reports174, our binding affinity 
measurements by ITC and elution volume determinations by SEC indicate that the KSHV vBcl-2 forms a 
complex with a mNOXA BH3D peptide. Our crystallization screening experiments did not yield any crystal 
hits; however, this may be due to the low concentration of complex (1 mg/mL).  
Our experimental evidence showing that the BECN1 BH3D G120E/D121A double mutant does 
not bind the KSHV vBcl-2 indicates that this peptide is not a suitable candidate for selective inhibition of 
KSHV vBcl-2-mediated autophagy inhibition. The absence of binding suggests that, as expected, there 
are differences in the residues contributing to KSHV vBcl-2 binding to BH3Ds compared to other host cell 
and ɣHV Bcl-2 proteins. This is consistent with the observation that the binding affinity of KSHV vBcl-2 for 
other BH3Ds varies greatly compared to those of other anti-apoptotic Bcl-2 proteins44, 174. However, due 
to the precipitation issues during protein purification, we were unable to obtain sufficient quantities of 
KSHV vBcl-2 at concentrations high enough to permit biophysical and structural analyses to determine 
which residues contribute to binding specificity for the KSHV vBcl-2 by BH3Ds.  
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CHAPTER 6. BHRF1, AN EPSTEIN-BARR VIRUS BCL2 MIMIC, DOWN-REGULATES AUTOPHAGY 
BY NON-CANONICAL BINDING OF BECN1 
6.1. Introduction 
Epstein-Barr virus (EBV) is a widespread ɣHV, infecting more than 95% of the adult population 
worldwide176. EBV, first isolated over 50 years ago in Burkitt’s lymphoma patients177 and the cause of 
infectious mononucleosis, is associated with a variety of other malignancies including post-transplant 
lymphoproliferative disease, AIDS-related central nervous system lymphoma, AIDS-related 
leiomyosarcoma, AIDS-associated peripheral lymphomas, AIDS-associated primary effusion lymphomas, 
nasopharyngeal carcinoma, Hodgkin’s lymphoma, and gastric carcinoma178. Like all ɣHVs, EBV is an 
obligate intracellular pathogen that establishes latent and lytic infections178. During latent infection, only a 
limited number of viral proteins are expressed, allowing the EBV genome to replicate without killing the 
host cell. Upon reactivation, EBV enters the lytic cycle wherein many genes are expressed to facilitate 
viral replication and release of infectious virus progeny, typically resulting in death of the host cell. Latent 
and lytic EBV genes have both been linked to tumorigenesis179. All ɣHVs encode mimics of the anti-
apoptotic cellular BCL2 proteins180, 181, suggesting that vBCL2s play an important role in the pathogenesis 
of these viruses.  
The first BCL2 protein discovered, Bcl-2, was first identified as an oncogene that blocks apoptotic 
cell death182, 183, but has since been established as a member of a family of proteins that also regulates 
autophagy, unfolded protein response, cell cycle progression, calcium signaling, glucose homeostasis, 
mitochondrial dynamics, and transcription184, 185. BCL2 family members are categorized based on their 
Bcl-2 homology (BH) domains and include anti-apoptotic and pro-apoptotic proteins184. Mammalian anti-
apoptotic BCL2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, and A1) contain four BH domains (BH1-4) and 
down-regulate apoptosis by binding the BH3D of pro-apoptotic BCL2 proteins, inhibiting the ability of pro-
apoptotic Bcl-2s to induce apoptosis. All pro-apoptotic proteins (BAD, BAK, BAX, BID, BIM, PUMA) 
contain, at minimum, a single BH3 domain; although, BAX and BAK contain BH1-3184, 186. EBV encodes a 
vBCL2 called BamH1 H fragment rightward reading frame 1 (BHRF1)171. BHRF1 has been implicated in 
the development of various EBV-associated cancers. BHRF1 expression has been detected in clinical 
isolates of nasopharyngeal carcinomas187, 188 and oral hairy leukoplakia188, and promotes survival and 
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proliferation of lytically infected cells by inhibiting apoptotic cell death189. Although BHRF1 is controlled by 
the early lytic cycle BamHI W promoter, it is also constitutively expressed as a latent protein in some 
EBV-positive Burkitt’s lymphoma cell lines and may contribute to Burkitt lymphomagenesis in vivo190-192. 
Therefore, BHRF1 is likely important for both the latent and lytic cycles of EBV. BHRF1 contains three BH 
domains193, 194, which have together also been termed the early antigen protein R domain195, comprising 
residues 1-160 and a C-terminal transmembrane (TM) helix comprising residues 161-191 that, like other 
BCL2 homologs, localizes BHRF1 to mitochondrial, endoplasmic reticulum, and nuclear membranes193, 
194, 196. 
Human cellular anti-apoptotic BCL2 paralogs share about 50% sequence identity and have 
similar three-dimensional structures, consisting of a central hydrophobic α-helix surrounded by six or 
seven amphipathic helices197. The amphipathic, α-helical BH3Ds of pro-apoptotic proteins bind to a 
hydrophobic surface groove on the anti-apoptotic BCL2 paralogs such that the hydrophobic face of the 
BH3D helix is buried in the hydrophobic groove on the BCL2 surface198-204. BHRF1 shares about 24% 
sequence identity with human anti-apoptotic BCL2 proteins. Although the solution structure of the ligand-
free BHRF1 lacks a hydrophobic surface groove205, significant conformational changes occur upon 
binding BAK and BIM206 to create a surface hydrophobic groove that binds the amphipathic α-helical 
BH3D of BAK or BIM. Different viral and human anti-apoptotic BCL2 homologs have a wide range of 
affinities for the BH3Ds of pro-apoptotic proteins44, 174, 175, although the molecular binding determinants 
that dictate these variable specificities are poorly understood. 
Several anti-apoptotic BCL2 homologs also inhibit autophagy by binding the BH3D of BECN1 to 
inhibit autophagosome formation26, 43, 44, 46, 47, 172. Since autophagy contributes to innate immune defenses 
by sequestering and degrading intracellular pathogens, several cellular and ɣHV BCL2 homologs, 
including the KSHV vBCL2 and the ɣHV 68 M11, inhibit autophagosome formation by binding the BH3D 
of BECN1 in order to evade autophagic degradation26, 43, 44. However, the role of BHRF1 in autophagy 
regulation is relatively poorly understood. Cellular autophagy assays have demonstrated that EBV initially 
inhibits autophagy after induction of lytic cycle, then later up-regulates autophagy and incorporates 
autophagic membranes into the final envelope of EBV207, 208 but the mechanism by which EBV modulates 
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autophagy is unknown. The initial inhibition of autophagy could be mediated by an interaction between 
BHRF1 and BECN1.  
We hypothesized that, like other BCL2 homologs, BHRF1 would bind BECN1 and down-regulate 
starvation-induced autophagy. Therefore, we used cellular assays to demonstrate that BHRF1 down-
regulates BECN1-dependent, starvation-induced autophagy and that a cell-permeable version of the BID 
BH3D inhibits BHRF1-mediated down-regulation of autophagy in mammalian cells. We also used yeast 
two-hybrid assays, affinity pull-down assays, and ITC to identify the minimal region of BECN1 required for 
interaction with BHRF1 and quantify the thermodynamics of binding. Further, based on the differential 
affinities between BHRF1 and cellular BCL2s for BID, BIM, PUMA174, 175, we expected that determining 
and comparing the thermodynamic contributions and atomic binding determinants to the BHRF1:BID 
BH3D interaction would illuminate differences in how BHRF1 versus cellular BCL2s bind BID. Therefore, 
we determined the 2.6 Å X-ray crystal structure of the BID BH3D peptide bound to BHRF1, as well as the 
thermodynamics of binding by ITC, to elucidate the mechanism by which the BID BH3D peptide binds to 
BHRF1. Together, these results show for the first time that BHRF1 down-regulates autophagy, that a 
flexible region of BECN1 comprising 15 residues of the IDR preceding the BH3D, the BH3D, and FHD is 
necessary and sufficient for binding to BHRF1, and that a BID BH3D can inhibit BHRF1-mediated down-
regulation of autophagy. This information might facilitate the design of a peptide capable of displacing 
BECN1 in order to bind BHRF1 and selectively inhibit down-regulation of autophagy.  
6.2. Materials and methods 
6.2.1. Expression plasmid preparation 
EBV BHRF1 residues 1-160, which lack the C-terminal transmembrane helix (BHRF1ΔTM) 
(Figure 6.1A), were cloned between the NcoI and NotI restriction enzyme sites of the pET-21d(+) 
bacterial expression vector such that the expression construct included a C-terminal His6 tag. Human 
BECN1 residues 1-450 (FL), residues 1-171, or residues 90-171 were cloned between the NcoI and NotI 
restriction enzyme sites of the pMBP-Parallel-1 bacterial expression vector such that the expression 
construct encoded an N-terminal MBP tag. Site directed mutagenesis was used to generate the FL 
BECN1AFM, which contained a triple mutation (F359D, F360D, and W361D) that improves protein 
solubility168. The bacterial expression construct for Bcl-XL residues 1-208 N52D/N66D, which lacks the C-
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terminal transmembrane helix and contains a double mutant that improves proteins solubility (Bcl-
XLΔTM), was generated as previously described140. 
For the yeast two-hybrid assays, human ɣHV BHRF1 residues 1-191 (FL) or residues 1-160 
(BHRF1ΔTM) were cloned between the SalI and XhoI restriction enzyme sites of the pGAD-GH yeast 
two-hybrid vector in frame with the Gal4 activation domain (AD). UVRAG, another key autophagy protein 
that is an established binding partner of BECN1, was used as a positive control for the yeast two-hybrid 
assays. FL human UVRAG was cloned between the BamHI and XhoI restriction enzyme sites of the 
pGAD-GH yeast two-hybrid vector in frame with the Gal4 AD. Different human BECN1 fragments were 
cloned between the BamHI and PstI restriction enzyme sites of the pGBT8 yeast two-hybrid vector in 
frame with the Gal4 DNA binding domain (DBD). These BECN1 fragments were: BECN1 residues 1-450 
(FL), residues 1-171 (IDR-FHD), residues 90-171, residues 105-265 (BH3D-FHD-CCD), residues 1-140 
(IDR), or residues 1-265 (IDR-FHD-CCD) (Table 6.1, Figure 6.1B). 
Table 6.1. BECN1 constructs used for yeast two-hybrid assays with BHRF1. 
Label BECN1 Residues 
FL BECN1 1-450 
BECN1 IDR-FHD 1-171 
BECN1 residues 90-171 90-171 
BECN1 BH3D-FHD-CCD 105-265 
BECN1 IDR 1-140 
BECN1 IDR-FHD-CCD 1-265 
 
Figure 6.1. The domain architecture of BHRF1 and BECN1.  
A) BHRF1 includes an early antigen protein R domain and transmembrane (TM) helix, and B) BECN1 
includes an N-terminal intrinsically disordered region (IDR), Bcl-2 homology 3 domain (BH3D), flexible 
helical domain (FHD), coiled-coil domain (CCD), and β-α repeated, autophagy-specific domain (BARAD). 
The BARAD contains an aromatic finger comprised of three aromatic residues (FFW). 
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Lastly, for the cellular autophagy assays, FL human BECN1 or FL human ɣHV BHRF1 were 
cloned between the NcoI and XhoI restriction enzyme sites of the pcDNA3.1 mammalian expression 
vector, such that the expressed protein would include an N-terminal FLAG-tag. 
6.2.2. Autophagy assays 
Cellular autophagy levels were quantified by monitoring cellular localization of GFP-tagged LC3 
protein209. Each chamber of an 8-well culture slide (Nunc™ Lab-Tek™ Chambered Coverglass) was 
seeded with 3.0 x 105 MCF7 cells and cultured overnight in Dulbecco modified eagle medium (DMEM) 
with 10% fetal bovine serum (FBS) until 80-90% confluent. The cells were co-transfected with 500 ng total 
plasmid per well. For transfection with BECN1, cells were transfected with 200 ng GFP-LC3 and 300 ng 
FLAG-BECN1, using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. For co-transfection with BHRF1, cells were co-transfected with 200 ng GFP-
LC3, 100 ng FLAG-BECN1, and 200 ng FLAG-BHRF1. After transfection and incubation at 37 °C for 24 
hours, the cells were cultured in either rich (DMEM, 10% FBS, 2x essential amino acids and 2x 
nonessential amino acids) or starvation (Earle’s balanced salt solution) medium for 4 hours. Cells were 
counterstained with DAPI to visualize nuclei, fixed to slides with 4% v/v paraformaldehyde, and then 
stored in 70% v/v glycerol. Cells were washed with PBS between the counterstaining, fixation, and 
storage stages. GFP-LC3-positive puncta were observed under a fluorescent microscope (Zeiss 
AxioObserver Z1) and quantified by counting a minimum of 50 cells for duplicate samples per condition 
using Imaris software (Bitplan AG, Zurich, Switzerland) in three independent experiments. The 
significance of alterations in autophagy levels was determined by a two-tailed, heteroscedastic student’s 
t-test, wherein p ≤ 0.05 is considered significant. The effect of a potential inhibitory TAT-BID BH3D 
peptide was investigated by comparing autophagy levels in the absence or presence of 30 µM peptide. A 
2 mM peptide stock was prepared in water and stored at -80 °C until use. The peptide was diluted to 30 
µM directly into the rich or starvation medium. 
Expression levels of FLAG-BECN1 and FLAG-BHRF1 in MCF7 cells were verified by Western 
blotting using commercial mouse monoclonal anti-FLAG M2-peroxidase antibody (Sigma). As a loading 
control, actin levels in MCF7 cell lysates were detected using commercial mouse monoclonal anti-Actin-
peroxidase antibody (Sigma). 
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6.2.3. Yeast two-hybrid assays 
Several plasmid combinations were co-transformed into the Saccharomyces cerevisiae HF7c 
using a yeast transformation kit (Sigma). A single yeast colony obtained in the co-transformation 
procedure was resuspended in 1 mL of sterile deionized H2O and the optical density of each cell 
suspension was determined at a wavelength A600. A cell suspension of each co-transformant was 
prepared at an A600 value of 0.01 such that the final volume, diluted in sterile deionized H2O, was 500 µL. 
This initial cell suspension (OD600 = 0.01) was serially diluted to 1:5 and 1:25. Five µL of the 1:1, 1:5, and 
1:25 dilutions were spotted on SD/-Leu/-Trp dropout medium to assess transformation efficiency and SD/-
Leu-Trp-His selection medium to test for potential interactions. 1-9 mM 3-amino-1,2,4-trizole (3-AT) was 
used in the SD/-Leu-Trp-His plates to reduce false positives. The culture plates were incubated at 30 °C 
for 2–3 days. Co-transformation of BECN1 and UVRAG served as a positive interaction control 53. Each 
experiment was performed in triplicate. I would like to thank Srinivas Dasanna for performing these yeast 
two-hybrid assays. 
6.2.4. Protein expression and purification 
All proteins were expressed in E. coli cells and purified by chromatography methods. At each 
state of purification, protein purity was evaluated by SDS-PAGE stained with Coomassie Blue. In each 
case, the final purified protein was estimated to be >90% pure by Coomassie Blue-stained SDS-PAGE. 
For BHRF1ΔTM, BL21(DE3)pLysS cells were transformed and grown in LB medium with 100 
µg/ml ampicillin at 37 °C  to an A600 of ~0.8 before equilibrating the temperature to 20 °C. Once the cells 
achieved an A600 of ~1.4, they were induced by the addition of 0.5 mM IPTG and expressed overnight. 
Soluble protein in the cell lysate (Lysis buffer: 25 mM Tris HCl pH 7.5, 100 mM NaCl, 40 mM imidazole, 2 
mM BME, and 1 cOmplete, EDTA-free protease inhibitor cocktail tablet (MilliporeSigma) per liter of cell 
culture) from a 3 L expression culture was purified by nickel IMAC using 10 mL of Ni Sepharose High 
Performance nickel-charged IMAC resin (GE Life Sciences, Pittsburgh, US), washed with 10 column 
volumes of Wash Buffer (25 mM Tris HCl pH 7.5, 100 mM NaCl, 40 mM imidazole, and 2 mM BME), and 
eluted with Wash Buffer containing 250 mM imidazole. The protein was subsequently purified by SEC 
using a 16/60 Superdex 200 column (GE Life Sciences, Pittsburgh, US) in SEC buffer consisting of 25 
 118 
mM HEPES sodium salt pH 7.5, 100 mM NaCl, and 2 mM BME. The BHRF1ΔTM-His6 was quantified via 
UV/Vis using an ε280 of 33,460 M-1 cm-1 and a molecular mass of 19,119 Da. 
For BECN1AFM, Arctic Express(DE3) cells were transformed and grown in LB medium with 100 
µg/ml ampicillin at 37 °C to an A600 of ~0.8 before equilibrating the temperature to 13 °C. Once the cells 
achieved an A600 of ~1.4, they were induced by the addition of 0.5 mM IPTG and expressed overnight. 
Soluble protein in the cell lysate (Lysis buffer: 50 mM Tris HCl pH 8.0, 300 mM NaCl, 2 mM DTT, and 1 
cOmplete, EDTA-free protease inhibitor cocktail tablet (MilliporeSigma) per liter of cell culture) from a 3 L 
expression culture was purified by amylose affinity chromatography on a 10 mL Amylose Resin (NEB 
BioLabs, Ipswich, US) gravity column and washed with 10 column volumes of amylose Wash Buffer (50 
mM Tris HCl pH 8.0, 300 mM NaCl, 2 mM DTT, and 1mM EDTA). Fusion protein was subjected to 
overnight, on-column cleavage using 8 mg GST-TEV at 4 °C to remove the MBP tag. Cleaved protein 
was washed from the column with Wash Buffer and further purified to homogeneity by SEC using a 10/30 
Superose 6 Increase column (GE Life Sciences, Pittsburgh, US) in SEC buffer consisting of 50 mM 
HEPES sodium salt pH 8.0, 150 mM NaCl, and 2 mM BME. The BECN1AFM was quantified via UV/Vis 
using an ε280 of 49,390 M-1 cm-1 and a molecular mass of 52,176 Da. 
For BECN1(90-171), BL21(DE3)pLysS cells were transformed and grown in LB medium with 100 
µg/ml ampicillin at 37 °C  to an A600 of ~0.8 before equilibrating the temperature to 15 °C. Once the cells 
achieved an A600 of ~1.4, they were induced by the addition of 0.5 mM IPTG and expressed overnight. 
Soluble protein in the cell lysate (Lysis buffer: 50 mM Tris HCl pH 7.5, 150 mM NaCl, 2 mM BME, and 1 
cOmplete, EDTA-free protease inhibitor cocktail tablet (MilliporeSigma) per liter of cell culture) from a 6 L 
expression culture was purified by amylose affinity chromatography on a 10 mL Amylose Resin (NEB 
BioLabs, Ipswich, US) gravity column and washed with 10 column volumes of amylose Wash Buffer (50 
mM Tris HCl pH 7.5, 150 mM NaCl, 2 mM BME, and 1mM EDTA). Fusion protein was subjected to 
overnight, on-column cleavage using 8 mg of GST-TEV protease at 4 °C to remove the MBP tag. Cleaved 
protein was washed from the column with wash buffer and further purified by ion exchange 
chromatography on a 5/50 GL MonoQ column (GE Life Sciences, Pittsburgh, US) (MonoQ Buffer A: 50 
mM Tris HCl pH 7.5, 2 mM BME; MonoQ Buffer B: 50 mM Tris HCl pH 7.5, 2 mM BME, 1 M NaCl). The 
protein was loaded and washed at 50 mM NaCl, and then eluted with a gradient elution where it eluted at 
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approximately 100 mM NaCl. The protein was then purified by SEC using a 10/30 Superdex 200 column 
(GE Life Sciences, Pittsburgh, US) in SEC buffer consisting of 25 mM HEPES sodium salt pH 7.5, 150 
mM NaCl, 2 mM BME. The BECN1(90-171) was quantified via UV/Vis using an ε280 of 1,490 M-1 cm-1 , as 
well as using Bradford reagent (BioRad, Hercules, CA) according to the manufacturer’s instructions, and 
a molecular mass of 9,432 Da. 
Bcl-XLΔTM-His6 was expressed and purified as described previously140. This involved 
transformation of BL21(DE3)pLysS and growth in LB medium with 35 µg/ml kanamycin at 37 °C  to an 
A600 of ~0.6 before equilibrating the temperature to 20 °C. Once the cells achieved an A600 of ~0.8, they 
were induced by the addition of 0.5 mM IPTG and expressed overnight. Soluble protein in the cell lysate 
(Lysis buffer: 25 mM Tris HCl pH 7.5, 100 mM NaCl, 40 mM imidazole, 2 mM BME, and 1 cOmplete, 
EDTA-free protease inhibitor cocktail tablet (MilliporeSigma) per liter of cell culture) from a 3 L expression 
culture was purified by nickel IMAC on a 10 mL HisTrap nickel IMAC column (GE Life Sciences, 
Pittsburgh, US), washed with 10 column volumes of Wash Buffer (25 mM Tris HCl pH 7.5, 100 mM NaCl, 
40 mM imidazole, and 2 mM BME), and eluted with Wash Buffer containing 250 mM imidazole. The 
protein was then purified by anion exchange chromatography using an 8 mL 10/10 HR MonoQ column 
(GE Life Sciences, Pittsburgh, US) (MonoQ Buffer A: 25 mM Tris HCl pH 7.5, 2 mM BME; MonoQ Buffer 
B: 50 mM Tris HCl pH 7.5, 2 mM BME, 1 M NaCl) using a step elution with 300 mM NaCl. Finally, the 
protein was purified by SEC using a 16/60 Superdex 200 column (GE Life Sciences, Pittsburgh, US) in 
SEC buffer consisting of 25 mM HEPES sodium salt pH 7.5, 100 mM NaCl, and 2 mM BME. Bcl-XLΔTM-
His6 was quantified via UV/Vis using an ε280 of 41,940 M-1 cm-1 and molecular mass of 24,035 Da. 
6.2.5. Pull-down assays 
The clarified lysate from a 1 L expression culture of MBP-BECN1(90-171) and MBP-BECN1(1-
171) was separately bound to 0.5 mL of Amylose Resin (NEB BioLabs, Ipswich, US) and washed with 10 
column volumes of wash buffer consisting of 50 mM Tris HCl pH 7.5, 150 mM NaCl, 2 mM BME, and 
1mM EDTA. 6 mg of purified BHRF1ΔTM-His6 or Bcl-XLΔTM-His6 was separately incubated with the 
MBP-BECN1(90-171)-bound or MBP-BECN1(1-171)-bound amylose resin for 1 hour at 4 °C and washed 
with wash buffer. Bound protein was eluted with wash buffer plus 20 mM maltose. The amylose elution 
fractions were then loaded onto 100 µL of nickel immobilized metal ion chromatography resin and washed 
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with 10 column volumes of wash buffer. Bound protein was eluted with wash buffer plus 250 mM 
imidazole. Fractions were evaluated by SDS-PAGE stained with Coomassie Blue. 
6.2.6. Peptide synthesis 
Peptides corresponding to BECN1 BH3D residues 105-130, BID BH3D residues 79-104, and BID 
BH3D-derived mutant peptides (Table 6.2) were chemically synthesized, HPLC-purified to >90% purity, 
and purity confirmed by electrospray mass spectrometry (EZBiolab, Carmel, IN). The BID BH3D mutants 
were designed by comparing the sequences of the BID, BAK, and BIM BH3D, which bind BHRF1, and 
the BECN1 BH3D, which does not bind BHRF1, in an effort to discover a peptide that would selectively 
bind BHRF1 but not Bcl-XL. To make the BID BH3D peptide cell-permeable, the transactivating HIV-1 
transcriptional activator protein transduction domain (TAT), which is a cell-penetrating peptide previously 
shown to facilitate entry of extended poly-peptides into mammalian cells under the conditions used 
here166, was attached via a diglycine linker to the N terminus of the BID BH3D peptide (TAT-BID BH3D). 
Table 6.2. Peptide sequences synthesized for BHRF1 interaction analyses. 
Peptide Amino Acid Sequence 
BECN1 BH3D AGGTMENLSRRLKVTGDLFDIMSGQT 
BID BH3D QEDIIRNIARHLAQVGDSMDRSIPPG 
BID BH3D G94A QEDIIRNIARHLAQVADSMDRSIPPG 
BID BH3D Mutant 1 DTMRNIARQLARIGDEFDRSYGRT 
BID BH3D Mutant 2 DTMRNIARHLARIGDEFDRSIGRT 
BID BH3D Mutant 3 DTMRNIARHLAQVGDSMDRSIGRT 
TAT-BID BH3D YGRKKRRQRRR-GG-QEDIIRNIARHLAQVGDSMDRSIPPG 
 
6.2.7. ITC 
Protein and peptide samples were dialyzed against 50 mM HEPES sodium salt pH 8.0, 150 mM 
NaCl, and 2 mM BME. In order to assess the thermodynamics of binding of BHRF1 to BECN1 fragments, 
ITC experiments were performed in triplicate at 20 °C. 1mM BHRF1ΔTM-His6 was separately titrated into 
25 µM FL BECN1 and 50 µM BECN1 (90-171). 1 mM BECN1(105-130) was titrated into 100 mM 
BHRF1ΔTM. In order to assess the thermodynamics of binding of the BID BH3D and BID BH3D mutants 
to BHRF1 and Bcl-XL, ITC experiments were performed in duplicate at 10 °C. 2 mM peptides were 
separately titrated into 200 mM BHRF1ΔTM-His6 and Bcl-XL(1-208, N52D/N66D)-His6. All ITC 
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experiments were performed using a Low Volume Gold Nano isothermal titration calorimeter (TA 
Instruments, New Castle, US) and data were analyzed with the NanoAnalyze Software (TA Instruments, 
New Castle, US) using an independent binding model. 
6.2.8. Crystallization 
The purified BHRF1ΔTM-His6 and BID BH3D peptide were mixed with a 1:1 molar ratio and 
incubated at 4 °C for two hours. The BHRF1:BID BH3D complex was crystalized by hanging drop vapor 
diffusion from a 3:1 mixture of protein stock (5 mg/mL complex in 25 mM HEPES sodium salt pH 7.5, 100 
mM NaCl, 2 mM BME) and well solution (0.1 mM NaC2H3O2 pH 5.0, 1.6 mM HCOONa). Rod-shaped 
crystals were harvested and cryoprotected in a cryosolution consisting of 0.1 M NaC2H3O2 pH 5.0 and 
25% glycerol and then immediately flash-frozen in liquid N2. 
6.2.9. X-ray Data collection, structure solution, and refinement 
Diffraction data were collected at 100 K at a wavelength of 0.97943 Å in one 360° sweep from a 
single crystal on NE-CAT beamline 24-ID-C at the Advanced Photon Source, Argonne National 
Laboratory, Argonne, IL, USA. Diffraction intensities were recorded on a 4 x 4 tiled MAR Mosaic CCD 
detector (Rayonix) at a crystal-to-detector distance of 250 mm over a 0.5° crystal rotation with 1 s 
exposure per image. Diffraction data were processed using the RAPD automated processing web server 
(https://rapd.nec.aps.anl.gov/rapd/). The structure was solved by molecular replacement using Phaser210 
in the PHENIX suite96, using as a model the BHRF1:BIM BH3D complex structure (PDB entry 2WH6) 
modified to remove coordinates pertaining to the BIM BH3D. The structure was refined to 2.61 Å 
resolution using the PHENIX refinement pipeline96,combined with iterations of manual model building 
using Coot211. 
6.2.10. Protein structure analysis 
Since the asymmetric unit contained 5 BHRF1:BID complexes, simultaneous superimposition of 
multiple structures was performed with THESEUS212, which applies a maximum-likelihood method, via the 
PSSweb server (http://pssweb.org)213. The quality of the geometry and fit to the electron density of each 
chain was analyzed via the wwPDB Validation Service (https://validate-rcsb-1.wwpdb.org). The complex 
composed of chains A and B was identified via this validation as having the highest quality. Therefore, 
pairwise structural superimposition of each of the other four complexes was performed against 
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BHRF1:BID chains A and B using PyMOL (v.1.3; Schrödinger). All subsequent analyses were performed 
using BHRF1:BID chains A and B. The BHRF1:BID interface was analyzed in detail using PISA145. 
Pairwise structural superimpositions of the BHRF1:BID complex with other complexes were performed 
using PyMOL (v.1.3; Schrödinger). Molecular figures were created using PyMOL (v.1.3; Schrödinger). 
Multiple sequence alignments of the BH3Ds were performed using Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). 
6.3. Results  
6.3.1. BHRF1 down-regulates starvation-induced autophagy 
We investigated the impact of exogenously expressed BHRF1 on cellular autophagy levels in 
human breast adenocarcinoma MCF7 cells (Figure 6.2). MCF7 cells lack detectable endogenous 
expression of BECN1, resulting in very low basal levels of autophagy26, 44, 214 even in starvation conditions 
unless BECN1 is ectopically expressed (Figure 6.2B,C). Expression of BECN1 and BHRF1 was 
comparable in starvation and nutrient-rich conditions (Figure 6.2A). Since BECN1 is known to be required 
for autophagosome nucleation, we evaluated cellular autophagy by monitoring and comparing levels of 
puncta labeled with GFP-tagged LC3, an autophagosome-specific marker, in cells grown in either 
nutrient-rich or starvation medium (Figure 6.2B,C).  
Transient expression of BECN1 in MCF7 cells did not increase autophagy levels in nutrient-rich 
conditions (p = 0.7800 for BECN1 expression versus no expression; Figure 6.2B); but led to a marked 
increase in autophagy upon starvation (p = 0.0002 for starved versus nutrient-rich cells; Figure 6.2B). 
This is consistent with the established importance of BECN1 in starvation-triggered autophagy, rather 
than basal autophagy215, 216. Strikingly, starvation-induced, BECN1-dependent autophagy is significantly 
down-regulated by co-expression of BHRF1 (Figure 6.2B,C). Furthermore, co-expression of BHRF1 
returns autophagy levels to those consistent with basal autophagy levels (p = 0.2500 for starved BHRF1 
co-expressed with BECN1 versus nutrient-rich BECN1). Therefore, we find that BHRF1 abrogates 
BECN1-mediated, starvation-induced autophagy. 
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Figure 6.2. The effect of BHRF1 and TAT-BID peptide treatment on autophagy. 
A) Western blot of MCF7 cell extracts showing comparable expression levels of FLAG-BECN1 and FLAG-
BHRF1 in nutrient rich (R) and starvation (S) conditions, with Actin as a loading control. B) Light 
microscopy quantification of discrete GFP-LC3 puncta per cell in GFP-positive MCF7 cells co-transfected 
with GFP-LC3 and BECN1 or BHRF1, as indicated below the x-axis, and then treated with either no 
peptide or TAT-BID peptide, as indicated above the graph. Bars represent the number of puncta per cell. 
Error bars represent standard deviation. C) Representative images of GFP-LC3 (green) and DAPI (blue) 
staining in cells grown in starvation or nutrient rich media and transfected with mutant FLAG-BECN1 or 
FLAG-BHRF and treated with TAT-BID peptide, as indicated below the images. 
6.3.2. BECN1 residues 90-171 are required for binding BHRF1 
Since several cellular and ɣHV BCL2 homologs, including the KSHV vBCL2 and the ɣHV 68 M11, 
inhibit autophagosome formation by binding the BH3D of BECN126, 43, 44, we used yeast two-hybrid 
assays to determine whether BECN1 and BHRF1 interact and to identify the minimal BECN1 region 
required for binding to BHRF1. Saccharomyces cerevisiae HF7c cells were co-transformed with BHRF1 
fused to the AD and various combinations of BECN1 domains fused to the DBD.  
Growth is not observed in the 1:5 and 1:25 dilutions under 1 mM 3-AT with empty GAD-GH or 
GBT8 but is observed with FL BHRF1 and FL BECN1 (Figure 6.3), indicating that the reporter vectors do 
not self-associate but that FL BHRF1 and FL BECN1 interact. Failure to grow in the presence of higher 
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concentrations of 3-AT is likely due to association of the expressed proteins with membranes due to the 
presence of the BHRF1 TM helix and the BECN1 aromatic finger, since these assays are not optimized 
for use with membrane-associated proteins. Therefore, subsequent yeast two-hybrid assays tested 
binding of the BHRF1ΔTM fused to the AD, to various combinations of soluble BECN1 domains fused to 
the DBD. 
 
Figure 6.3. BHRF1 interacts with BECN1. 
Yeast two-hybrid analysis in Saccharomyces cerevisiae HF7c. Labels on the left indicate BECN1 fused to 
the DBD (GBT8) that was co-transformed with BHRF1 fused to the AD (GAD-GH), and spotted onto SD/-
Leu/-Trp dropout medium and SD/-Leu/-Trp/-His selection medium, as indicated above the image. Each 
co-transformation was serially diluted as indicated below the image. 
Growth is not observed under 3 or 9 mM 3-AT with empty GAD-GH or GBT8 but is observed with 
BECN1 and UVRAG (Figure 6.4). This indicates that reporter vectors do not self-associate, and that 
interaction by known binding partners, BECN1 and UVRAG53, is detected under the conditions used here. 
Growth under 3 or 9 mM 3-AT of co-transformants of BHRF1ΔTM and the BECN1 IDR-FHD-CCD 
fragment, which contains all non-membrane interacting BECN1 domains, as well as with the BECN1 IDR-
FHD fragment, indicates that the BECN1 BARAD and CCD are not required for interaction with BHRF1. 
However, co-transformation with BHRF1ΔTM and the BECN1 IDR, which includes the BH3D, did not 
enable growth indicating that unlike other interactions between BECN144, 140 and pro-apoptotic BCL2 
proteins199-201, 206, wherein the BH3D is sufficient for interaction, the BECN1 FHD is also required for 
interaction with BHRF1. However, co-transformants of the BHRF1ΔTM and the BECN1 BH3D-FHD-CCD 
also did not grow, indicating that the BH3D and FHD together are also insufficient for interaction with 
BHRF1 and additional regions of the IDR may be required. Indeed, growth is enabled by co-
transformation of BHRF1ΔTM and a BECN1 fragment that includes 15 residues from the BECN1 IDR 
immediately preceding the BH3D, i.e. BECN1 residues 90-171 (Figure 6.4). Thus, we find that BECN1 
residues 90-171 are required and sufficient for interaction with BHRF1. 
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Figure 6.4. Determination of the minimal BECN1 region required for BHRF1 binding. 
Yeast two-hybrid analysis in Saccharomyces cerevisiae HF7c. Labels on the left indicate the various 
BECN1 domains fused to the DBD (GBT8) that were co-transformed with BHRF1 fused to the AD (GAD-
GH), and spotted onto SD/-Leu/-Trp dropout medium and SD/-Leu/-Trp/-His selection medium, as 
indicated above the image. Each co-transformation was serially diluted as indicated below the image. 
6.3.3. Purification of BHRF1ΔTM 
BHRF1ΔTM-His6 was purified by sequential nickel IMAC and SEC. The single peak on SEC and 
single band on SDS-PAGE indicate the BHRF1ΔTM-His6 was pure and homogenous (Figure 6.5). The 
apparent molecular weight of the BHRF1ΔTM-His6 calculated based on the elution volume from SEC is 
12.9 kD, which is 1.4-fold smaller than the theoretical molecular weight of 19.1 kD for the BHRF1ΔTM-
His6 monomer calculated from the amino acid sequence. This is inconsistent with any oligomerization, 
indicating the BHRF1ΔTM-His6 forms a monomer. The final yield of the purified BHRF1ΔTM-His6 obtained 
from one liter of bacterial culture was 20 mg. 
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Figure 6.5. Size exclusion chromatogram and the corresponding SDS-PAGE of BHRF1ΔTM. 
The elution positions of SEC standards are indicated by arrows. 
6.3.4. Purification of BECN1AFM  
MBP-BECN1AFM fusion protein was purified by amylose affinity chromatography followed by on-
column cleavage using GST-TEV protease to remove the MBP tag. BECN1AFM then purified by sequential 
anion exchange chromatography and SEC. The SEC elution profile contains three peaks: an 8.6 mL peak 
in the void volume that likely contains aggregated protein, a 14.3 mL peak that contains BECN1AFM, and a 
17.8 mL peak that contains lower molecular weight contaminants (Figure 6.6). The apparent molecular 
weight of BECN1AFM calculated based on the 14.3 mL elution volume from SEC is 535.4 kD, which is 10-
fold larger than the theoretical molecular weight of 52.4 kD for the BECN1AFM monomer calculated from 
the amino acid sequence. This is consistent with the BECN1AFM forming a rod-shaped dimer via the CCD 
as well as containing a large IDR. The final yield of the purified BECN1AFM obtained from one liter of 
bacterial culture was 1.8 mg.  
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Figure 6.6. Size exclusion chromatogram and the corresponding SDS-PAGE of BECN1AFM. 
The elution positions of SEC standards are indicated by arrows. 
6.3.5. Purification of BECN1 residues 90-171 
MBP-BECN1(90-171) fusion protein was purified by affinity chromatography followed by on-
column cleavage using GST-TEV protease to remove the MBP tag. BECN1(90-171) was purified by 
sequential anion exchange chromatography and SEC. The single peak on SEC and single band on SDS-
PAGE indicate that BECN1(90-171) was pure and homogenous (Figure 6.7). The apparent molecular 
weight of BECN1(90-171) calculated based on the elution volume from SEC is 24.2 kD, which is 2.6-fold 
larger the theoretical molecular weight of 9.4 kD for the BECN1 residues 90-171 monomer calculated 
from the amino acid sequence. This is inconsistent with the formation of a dimer or trimer and could 
indicate that the protein is disordered or partially disordered. The final yield of the purified BECN1 
residues 90-171 obtained from one liter of bacterial culture was 0.3 mg. 
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Figure 6.7. Size exclusion chromatogram and the corresponding SDS-PAGE of BECN1 residues 90-171. 
The elution positions of SEC standards are indicated by arrows. 
6.3.6. Purification of Bcl-XLΔTM  
In order to compare binding of BHRF1 and a mammalian BCL2 protein by BH3Ds, Bcl-XL was 
purified. Bcl-XLΔTM-His6 was purified by sequential nickel IMAC, anion exchange chromatography, and 
SEC. The SEC elution profile contains two peaks: a 46.6 mL peak in the void volume that contains high 
molecular weight contaminants and a 90.1 mL peak that contains Bcl-XLΔTM-His6 (Figure 6.8). The 
apparent molecular weight of the Bcl-XLΔTM-His6 calculated based on the 90.1 mL SEC elution volume is 
16.9 kD, which is 1.4-fold smaller than the theoretical molecular weight of 24.4 kD for the Bcl-XLΔTM-His6 
monomer calculated from the amino acid sequence. This is inconsistent with any oligomerization, 
indicating the Bcl-XLΔTM-His6 forms a monomer. The final yield of the purified Bcl-XLΔTM-His6 obtained 
from one liter of bacterial culture was 6 mg. 
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Figure 6.8. Size exclusion chromatogram and the corresponding SDS-PAGE of Bcl-XL. 
The elution positions of SEC standards are indicated by arrows. 
6.3.7. Purified BHRF1 and BECN1 fragments interact weakly 
We performed affinity pull-downs using His6-tagged BHRF1ΔTM and MBP-tagged BECN1 
fragments to confirm a direct interaction. We used Bcl-XLΔTM which is known to interact with the BECN1 
BH3D 46 as a positive control. Amylose affinity resin-bound MBP-BECN1(1-171) or MBP-BECN1(90-171) 
pull-down of Bcl-XLΔTM-His6 indicates that Bcl-XL interacts directly with both of these BECN1 fragments 
(Figure 6.9A). This direct interaction was further confirmed by nickel affinity pull-down of the amylose 
elution fractions (Figure 6.9B). Similarly, amylose affinity resin-bound MBP-BECN1(1-171) or MBP-
BECN1(90-171) pull-down of BHRF1ΔTM-His6 (Figure 6.9A) indicates that BHRF1 interacts directly with 
both BECN1 fragments. This direct interaction was further confirmed reverse pull-down experiments 
wherein MBP-BECN1(1-171) or MBP-BECN1(90-171) were pulled down by BHRF1ΔTM-His6 bound to 
nickel affinity resin (Figure 6.9B). 
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Figure 6.9. BECN1 interacts directly with BHRF1. 
A) SDS-PAGE of an amylose affinity pull-down of purified BHRF1ΔTM-His6 or Bcl-XL(1-208, N52D/N66D)-
His6 by MBP-BECN1(1-171) or MBP-BECN1(90-171), as indicated above the gel. Amylose resin indicates 
the MBP-BECN1 bound resin after the final wash step. B) SDS-PAGE of nickel affinity pull-down of 
amylose affinity elution fractions from Figure 6.9A. 
We used ITC to quantify and compare binding of BECN1 protein fragments to BHRF1ΔTM. FL 
BECN1AFM binds weakly to BHRF1ΔTM with a Kd of ~118 µM (Table 6.3, Figure 6.10). BECN1(90-171), 
which is the smallest BECN1 fragment shown by yeast two-hybrid and affinity pull-down assays to bind 
BHRF1, binds with a similar Kd of ~127 µM. For both interactions, the favorable ΔG is due to ΔS rather 
than due to ΔH, which are positive each case (Table 6.3). Finally, consistent with yeast two-hybrid 
assays, no binding was detected by ITC between the BECN1 BH3D and BHRF1ΔTM. Therefore, 
qualitative assessment of binding by yeast two-hybrid and affinity pull-downs, as well as quantification of 
binding affinity by ITC, all indicate that BECN1 residues 90-171 are required and sufficient for a direct, 
albeit weak, interaction with BHRF1.  
Table 6.3. Thermodynamics of binding of BHRF1 to BECN1 fragments. 
BECN1 Fragment 
BHRF1ΔTM 
Kd  
(µM) 
ΔH  
(kJ/mol) 
ΔS  
(J/K·mol) 
ΔG 
(kJ/mol) 
BECN1AFM 117.7 ± 15.3 3.6 ± 0.5 87.5 ± 1.4 -22.1 ± 0.2 
BECN1 residues 90-171 126.5 ± 4.6 7.2 ± 2.0 99.3 ± 7.2  -21.9 ± 0.1 
BECN1 BH3D  No binding detected 
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Figure 6.10. ITC profiles of BHRF1 complexes. 
A) BHRF1ΔTM binding to BECN1AFM, B) BHRF1ΔTM binding to BECN1 residues 90-171, C) BHRF1ΔTM 
binding to BECN1 BH3D, D) BHRF1ΔTM titrated into buffer. 
6.3.8. BID binds tightly to BHRF1 and Bcl-XL  
ITC and fluorescence polarization binding assays have previously demonstrated that BHRF1 
binds the pro-apoptotic BH3Ds of BID, BIM, and PUMA174, 206 and competitive binding assays have 
demonstrated that the BID BH3D binds cellular BCL2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, and A1) with 
weaker affinity compared to BIM and PUMA175. Therefore, we selected the BID BH3D to serve as a 
template for designing a selective inhibitor to prevent BHRF1-mediated autophagy down-regulation 
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without inhibiting cellular BCL2-mediated autophagy down-regulation since the WT BID BH3D tightly 
binds BHRF1 but binds the cellular BCL2 proteins more weakly relative to the other pro-apoptotic BH3Ds. 
We quantified the thermodynamics of binding of the BID BH3D to BHRF1ΔTM and Bcl-XLΔTM via 
ITC. We find that the BID BH3D binds BHRF1 tightly with a Kd of ~0.3 µM, which is ~3.6-fold tighter than it 
binds Bcl-XL (Kd ~ 1.1 µM) (Table 6.4), ~400-fold tighter than BHRF1 binding to BECN1 (Kd ~ 118 µM) 
(Table 6.3), and ~6.7-fold tighter than Bcl-XL binding to BECN1 (Kd ~2.0 µM)30. For both the 
BHRF1:BECN1 interaction and the BHRF1:BID BH3D interaction, the favorable ΔG is due to ΔS rather 
than due to ΔH, both of which are positive (Table 6.3, Figure 6.11, and Table 6.4). For the Bcl-XL:BID 
BH3D interaction, contributions by both ΔS, which is positive, and ΔH, which is negative, contribute to the 
favorable ΔG (Table 6.4). For the Bcl-XL:BECN1 BH3D interaction, the favorable ΔG is due to ΔH rather 
than due to ΔS, both of which are negative30. The differing entropic and enthalpic contributions between 
BECN1 or BID binding to BHRF1 or Bcl-XL is consistent with differential modes of binding. Furthermore, 
the tighter binding of BHRF1 to the BID BH3D compared to BECN1 suggests that the BID BH3D can 
displace BECN1 to bind BHRF1. Our measured BHRF1 affinity (Table 6.4) for the BID BH3D is consistent 
with the previously published affinities (Kd = 0.10 µM) determined by ITC206 and fluorescence polarization 
binding assays174, and is similar to the BHRF1 affinity for the BAK BH3D (Kd = 0.15 µM)206 determined by 
ITC. The BHRF1 binding affinity for BID and BAK is ~10-fold weaker than the BHRF1 affinity for the BIM 
BH3D (Kd = 0.020 µM)206 determined by ITC. 
Table 6.4. Thermodynamics of binding of the BID BH3D to BHRF1 and Bcl-XL. 
BID Peptide 
BHRF1ΔTM Bcl-XLΔTM 
Kd  
(µM) 
ΔH 
(kJ/mol) 
ΔS 
(J/K·mol) 
ΔG 
(kJ/mol) 
Kd  
(µM) 
ΔH 
(kJ/mol) 
ΔS 
(J/K·mol) 
ΔG 
(kJ/mol) 
BID BH3D 0.3  
± 0.1 
18  
± 3.1 
189.3  
± 7.2 
-35.6  
± 1.0 
1.1  
± 0.0 
-20.4  
± 0.7 
42.5  
± 2.3 
-32.4  
± 0.0 
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Figure 6.11. ITC profiles of BID BH3D binding to BHRF1 or Bcl-XL. 
A) BID BH3D binding to BHRF1ΔTM, B) BID BH3D binding to Bcl-XLΔTM. 
6.3.9. The hydrophobic surface groove of BHRF1 binds the BID BH3D 
In order to improve our understanding of binding determinants for the BHRF1 interaction with the 
BID BH3D, we determined a 2.6 Å resolution X-ray crystal structure of the BHRF1ΔTM:BID BH3D 
complex (Figure 6.12A,B). The BHRF1:BID BH3D co-crystals belonged to the space group P65, with 5 
complexes per asymmetric unit. Data collection and refinement statistics indicate a good structure 
solution was obtained (Table 6.5). Simultaneous superimposition of multiple structures by THESEUS212 
via the PSSweb server (http://pssweb.org)213 indicates that all five complexes within the asymmetric unit 
superimpose well with an average RMSD of 0.30 ± 0.24 Å for the atomic Cartesian coordinates of the 
backbone atoms over 174 residues. Likewise, pairwise structural superimposition of each complex 
performed against BHRF1:BID BH3D chains A and B using PyMOL (v.1.3; Schrödinger) also indicates 
that each complex superimposes well against BHRF1:BID BH3D chains A and B (Table 6.6). Since all 
five complexes superimpose well, the complex composed of BHRF1:BID BH3D chains A and B was used 
for all structural analyses. The final crystal structure represents residues 2-156 of BHRF1 and residues 
81-98 of BID. The total surface area buried upon formation of the BHRF1:BID BH3D complex is 1552 Å2, 
wherein 857 Å2 is contributed by the BID BH3D and 695 Å2 by BHRF1, as calculated using PISA145. 
Helices α2-5 of BHRF1 form the ligand-binding groove (Figure 6.12A).  
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Table 6.5. X-ray data collection and structure refinement statistics. 
Data collection statistics 
Space group P65 
Unit-cell parameters (Å) a=b=186.8, c=70.5 
Resolution (Å) 161.79-2.61 
Wilson B factor (Å2) 74.21 
Unique reflections 42919 (4267) 
Completeness (%) 99.9 (100.0) 
Multiplicity 11.3 (11.5) 
<I/σ(I)> 19.6 (1.7) 
CC1/2 0.998 (0.611) 
Refinement statistics 
Resolution range 80.89-2.61 (2.70-2.61) 
Completeness (%) 99.85 (99.95) 
Rwork✝ (%) 0.1976 (0.3375) 
Rfree✝☨ (%) 0.2597 (0.3959) 
No. of protein residues 848 
No. of waters 37 
RMSD, bond lengths (Å) 0.009 
RMSD, bond angles (°) 1.19 
Ramachandran outliers (%) 0.0 
Average B factor (Å2) 
Overall 92.4 
Macromolecules 92.5 
Solvent 69.0 
Values in parentheses pertain to the outermost shell of data. 
✝ R factor = ∑hkl||Fobs| - |Fcalc||/∑hkl|Fobs|. 
☨ The test set for Rfree consisted of 5% of the data. 
Table 6.6. Structural superimpositions of complexes in the ASU performed against BHRF1:BID BH3D 
chains A and B. 
BHRF1:BID BH3D Complex RMSD 
BHRF1:BID BH3D chains C and D 0.213 Å over 152 Cα atoms 
BHRF1:BID BH3D chains E and F 0.259 Å over 160 Cα atoms 
BHRF1:BID BH3D chains G and H 0.336 Å over 162 Cα atoms 
BHRF1:BID BH3D chains I and J 0.413 Å over 128 Cα atoms 
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Figure 6.12. Crystal structure of the BHRF1:BID BH3D complex. 
A) The BID BH3D backbone is traced in cyan ribbon while the BHRF1 backbone is traced in a ribbon 
colored in rainbow shades with blue at the N-terminus and red at the C-terminus. BHRF1 helices are 
labeled α1, α1’, and α2-8. B) The BID BH3D backbone is as in (A), while the BHRF1 surface is colored by 
atom type: oxygen, red; nitrogen, blue, carbon, grey; sulfur, yellow. Conserved hydrophobic and salt 
bridge-forming BID BH3D residues that interact with BHRF1 are shown in stick and colored by atom type: 
oxygen, red; nitrogen, blue; carbon, cyan; sulfur, yellow. C) Ligand-free BHRF1205 backbone is traced in a 
ribbon colored in rainbow shades with blue at the N-terminus and red at the C-terminus. Helices are 
labeled as α1-8. All molecular figures are displayed in superimposable views and were made using 
PyMOL (v.1.3; Schrödinger). 
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Analysis of the buried surface area (BSA) of interface residues and electrostatic interactions that 
stabilize the complex indicate that BID interacts with BHRF1 in a manner similar to other interactions 
between pro-apoptotic BH3 only proteins and anti-apoptotic BCL2s. The BSA calculated using PISA145 
indicates that the following BHRF1 residues contribute to the BID BH3D interface: I57, R60, N61, T64, 
F65, E67, T68, R71, F72, H75, D82, S85, V86, E89, I90, R93, S97, L98, G99, R100, L102, A104, W104, 
and W107. BID BH3D residues I82, I83, R84, I86, A87, H89, L90, A91, V93, G94, D95, M97, and D98 all 
contribute to the interface, as calculated using PISA145. Among the BID interface residues, the four 
hydrophobic residues that define the BH3D consensus sequence217 (I86, L90, V93, and M97) are 
significantly buried by the interaction with BHRF1 (Figure 6.12B). Equivalent residues in the BH3D of 
various pro-apoptotic BCL2 proteins are also significantly buried by Bcl-XL201, A1200, Mcl-1199, and M1144. 
Three electrostatic interactions also stabilize the BHRF1:BID BH3D complex. These include a salt bridge 
between BHRF1 E89 and BID BH3D R84, a salt bridge BHRF1 R100 and BID BH3D D95, and a 
hydrogen bond between BHRF1 S97 and BID BH3D D98. Residues equivalent to those forming the salt 
bridge between BHRF1 R100 –and BID BH3D D95 (Figure 6.12B) form a salt bridge in Bcl-XL complexes 
with the BH3D of BID206, BIM202, and BECN146; Mcl-1 complexes with the BH3D of BID199 and BIM218; A1 
complexes with the BH3D of BID200; and M11 complexes with the BH3D of BECN144.  
6.3.10. The BHRF1:BID BH3D complex is structurally similar to complexes of BHRF1 and either 
the BAK or BIM BH3Ds 
The solution structure of ligand-free BHRF1ΔTM has been previously determined by NMR (PDB 
entry 1Q59)205 and superimposes with the BHRF1:BID BH3D complex with a pairwise RMSD of 3.678 Å 
over 148 Cα atoms, indicating the structures are similar but have significant differences. BHRF1 has also 
been previously crystallized in complex with either the BAK or BIM BH3D206. Like the BHRF1:BAK (PDB 
entry 2XPX; 2.05 Å resolution) and BHRF1:BIM (PDB entry 2V6Q; 2.7 Å resolution) complexes206, the 
BHRF1:BID complex has an all α-fold comprising 9 helices in BHRF1 with the BID BH3D forming a single 
helix within a hydrophobic surface groove of BHRF1 (Figure 6.12A,B). We labeled the helices α1, α1’, and 
α2-8, consistent with the BHRF1:BAK and BHRF1:BIM complexes206, because the BHRF1 complexes 
contain an extra helix between the α1 and α2 relative to the ligand free BHRF1205 (Figure 6.12C) and Bcl-
XL:BID complex (PDB entry 4QVE)201. The BHRF1:BID BH3D complex superimposes with a pairwise 
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RMSD of 0.401 Å over 147 Cα atoms of the BHRF1:BAK complex, and with a pairwise RMSD of 0.462 Å 
over 155 Cα atoms of the BHRF1:BIM complex, indicating that all three of these complexes are very 
similar. The formation of these BHRF1:BH3D complexes requires significant rearrangement of α3 and α4 
(Figure 6.12A), which obscure the binding groove in the ligand-free state (Figure 6.12C). 
6.3.11. Interface residues contribute differentially to BHRF1 interactions with the BID, BAK, and 
BIM BH3Ds 
Despite the overall structural similarity between our BHRF1:BID BH3D and the previously 
published BHRF1:BH3D complexes, BSA analysis by PISA145 interface residues differentially contribute 
to the complexes. In our crystal structure, the BHRF1:BID BH3D interaction buries 857 Å2 of the BID 
BH3D and 695 Å2 of BHRF1, for a total of 1552 Å2; with 13 BID residues and 24 BHRF1 residues 
contributing to the interface. The BHRF1:BAK BH3D interaction buries 956 Å2 of the BAK BH3D and 783 
Å2 of BHRF1, for a total of 1739 Å2; with 15 BAK residues and 25 BHRF1 residues contributing to the 
interface. The BHRF1:BIM BH3D interaction buries 1038 Å2 of the BIM BH3D and 882 Å2 of BHRF1, for a 
total of 1920 Å2; with 17 BIM residues and 27 BHRF1 residues contributing to the interface. Of these 
three complexes, the interaction with the BIM BH3D buries the largest surface area of each partner, 
which is consistent with the observation reported above that BHRF1 binds to the BIM BH3D with the 
tightest affinity compared to the BID and BAK BH3Ds.  
In order to improve our understanding of binding determinants for the BID, BAK, and BIM BH3Ds 
for BHRF1, we used PISA145 to analyze the BSA of conserved interface residues. Among the residues 
conserved between BID, BAK, and BIM; nine residues (corresponding to BID I86, A87, H89, L90, V93, 
G94, D95, M97, D98) are involved in the interface with BHRF1 (Figure 6.13A). These residues are all 
similarly oriented in each complex except for the BIM F69 aromatic ring, which is rotated relative to the 
BID M97 and BAK I85 side chains (Figure 6.13B). BID M97 and BAK I85 interact with BHRF1 I57, L102, 
and A103. The BIM F69 maintains contact with BHRF1 I57 and L102 but also contacts with BHRF1 L53, 
R60, and L98. The BHRF1:BIM BH3D complex buries 111 Å2 of BIM F69 and 181 Å2 of BHRF1 L53, I57, 
R60, L98, L102, and A103. The BHRF1:BID BH3D complex buries 98 Å2 of BID M97 and 96 Å2 of BHRF1 
L53, I57, R60, L98, L102, and A103. The BHRF1:BAK BH3D complex buries 55 Å2 of BAK I85 and 129 
Å2 of BHRF1 L53, I57, R60, L98, L102, and A103. In total, these BH3D and BHRF1 residues contribute 
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292 Å2 of the BHRF1:BIM complex BSA, compared to 194 Å2 of the BHRF1:BID complex BSA and 184Å2 
of the BHRF1:BAK complex BSA. Therefore, F69 may be important for the improved affinity for BHRF1 of 
BIM relative to BID and BAK. 
Additionally, among interface residues (Figure 6.13A), the BIM BH3D has an R in the position 
corresponding to BIM R63, which is moderately conserved among various pro-apoptotic BH3-only 
BCL2s175 but is an A in the BH3D of BID and BAK. BSA and interface analysis by PISA145 indicates that 
the BIM R63 contributes more to the BHRF1 interface than do the corresponding BID A91 and BAK A79. 
The BID A91 and BAK A79 contribute 37 Å2 and 47 Å2 BSA, respectively. The BIM R63 contributes 111 
Å2 BSA and forms two hydrogen bonds with the main chain of BHRF1 E89 via the BIM R63 side chain NΣ 
and NH2. The extra hydrogen bonds afforded by BIM R63 and greater buried surface area afforded by 
BIM F69 likely also contribute to the improved affinity of BIM for BHRF1 relative to BID and BAK. 
 
Figure 6.13. Comparison of pro-apoptotic BH3Ds that interact with BHRF1. 
A) Sequence alignment of the BH3D of BID, BIM, and BAK. Symbols beneath the alignment indicate 
residue conservation: with an asterisk (*) corresponding to invariant, colon (:) corresponding to highly 
conserved, and period (.) corresponding to moderately conserved residues. The arrows above the 
sequence denote the four hydrophobic residues of the BH3 consensus sequence. Red boxes indicate 
residues within the BH3 consensus sequence that form the interface with BHRF1. B) Structural 
superimposition of the BID (cyan), BIM (gray) (PDB entry 2V6Q), and BAK (orange) (PDB entry 2XPX) 
BH3Ds from the BHRF1 complex. Interface residues boxed in red in Figure 6.13A are shown in stick 
colored by atom type: oxygen, red; nitrogen, blue; carbon, cyan/gray/orange; sulfur, yellow). 
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6.3.12. Interface residues contribute differentially to BID BH3D interactions with BHRF1 and 
cellular anti-apoptotic BCL2s 
The BID BH3D has also been previously crystalized in the presence of human Bcl-XL (PDB entry 
4QVE; 2.05 Å resolution)201, human Mcl-1 (PDB entry 5C3F; 1.43 Å resolution)199, and mouse A1 (PDB 
entry 2VOI; 2.1 Å resolution)200. Our BHRF1:BID complex superimposes with the Bcl-XL:BID BH3D 
complex with a pairwise RMSD of 2.352 Å over 124 Cα atoms, the Mcl-1:BID BH3D complex with a 
pairwise RMSD of 3.555 Å over 136 Cα atoms, and the AI:BID BH3D complex with a pairwise RMSD of 
3.676 Å over 126 Cα atoms, indicating that the complexes are similar but have significant differences. 
However, the BID from our BHRF1:BID complex superimposes with the BID from the Bcl-XL:BID structure 
with a pairwise RMSD of 0.500 Å over 17 Cα atoms, with the BID from the Mcl-1:BID structure with a 
pairwise RMSD of 0.404 Å over 16 Cα atoms, and with the BID from the A1:BID structure with a pairwise 
RMSD of 0.434 Å over 16 Cα atoms, indicating that the BID BH3D structures are similar in all four 
complexes. 
In order to improve our understanding of binding determinants for the BID BH3D interactions with 
BCL2 proteins, we used PISA145 to analyze the BSA of interface residues within the BH3D. The BH3 
consensus sequence is ɸ1ΣΧΧɸ2ΧΧɸ3ΣDZɸ4Γ, where ɸ is a hydrophobic residue, Σ is a small residue, Z is 
usually an acidic residue, and Γ is usually a hydrophilic residue217. In BID, the BH3D corresponds to 
residues 86-98. BID BH3D residues involved in all interfaces include I86, A87, H89, L90, A91, V93, G94, 
D95, M97, and D98. BID S96 is involved in the interface in the Bcl-XL complex but is solvent exposed in 
the other three complexes. The Bcl-XL interface buries 26 Å2 of BID S96 and provides a hydrogen bond 
between the backbone carbonyl of BID S96 and the Bcl-XL R100 NH1. Since BID S96 contributes to the 
Bcl-XL interface, but not to the other interfaces, it is likely more important for binding specificity of the BID 
BH3D for Bcl-XL than for BHRF1, Mcl-1, or A1. 
Among the interface residues common to each complex, BSA analysis and structural 
superimposition of the BID BH3D from the four complexes demonstrate that the BID H89 and M97 side 
chains differ and have variable contributions to the BSA. The position of the C𝛄 of BID H89 differs by 2.3 
Å among the four complexes, causing the imidazole to occupy different positions when bound to BHRF1, 
Bcl-XL, Mcl-1, or A1 (Figure 6.14). BID H89 contributes 81 Å2 BSA to the Bcl-XL interaction, 74 Å2 BSA to 
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mouse A1 interaction, 49 Å2 BSA to BHRF1 interaction, and 41 Å2 BSA to Mcl-1 interaction. BID H89 
provides an additional salt bridge with A1 E47 but does not mediate a salt bridge with BHRF1, Bcl-XL, or 
Mcl-1. BID H89 also provides a hydrogen bond between the imidazole of BID H89 and the hydroxyl of 
Bcl-XL Y101 but does not mediate any hydrogen bonds with BHRF1 or Mcl-1. The increased BSA as well 
as the extra salt bridge and hydrogen bond mediated by BID H89 in the Bcl-XL and A1 indicate that BID 
H89 is likely more important for binding specificity of the BID BH3D for Bcl-XL and A1 than for BHRF1 and 
Mcl-1. The position of the C𝛄 of BID M97 differs by 2.7 Å among the four complexes, causing the side 
chain to occupy different positions when bound to BHRF1, Bcl-XL, Mcl-1, or A1 (Figure 6.14). BID M97 
contributes 128 Å2 BSA to the Bcl-XL interaction, 120 Å2 BSA to mouse A1 interaction, 98 Å2 BSA to 
BHRF1 interaction, and 92 Å2 BSA to Mcl-1 interaction. BID M97 provides a hydrogen bond between the 
backbone carbonyl of BID M97 and the hydroxyl of Bcl-XL Y195 bud does not mediate a hydrogen bond 
with BHRF1, Mcl-1, or A1. The increased BSA of BID M97 in the Bcl-XL and A1 complexes, as well as the 
extra hydrogen bond it provides in the Bcl-XL complex, indicate that BID M97 is likely more important for 
binding specificity of the BID BH3D for Bcl-XL and A1 than for BHRF1 and Mcl-1. 
 
Figure 6.14. Structural superimposition of the BID BH3D in complex with anti-apoptotic BCL2 homologs. 
The BH3Ds of BID from the BHRF1 complex (cyan), Bcl-XL complex (magenta) (PDB entry 4QVE), Mcl-1 
complex (lavender) (PDB entry 5C3F), and A1 complex (green) (PDB entry 2VOI). Interface residues from 
the BH3 consensus motif are shown in stick colored by atom type: oxygen, red; nitrogen, blue; carbon, 
cyan/magenta/lavender/green; sulfur, yellow). 
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BID D95 corresponds to the conserved D in the BH3 consensus sequence. In each complex, BID 
D95 forms a salt bridge with the anti-apoptotic BCL2 (via BHRF1 R100, Bcl-XL R139, Mcl-1 R263, and A1 
R88). The carboxyl of BID D95 is also involved in a hydrogen bond to the amide of Asns; Bcl-XL N136, 
Mcl-1 N260, or A1 N85. BID D95 contributes 46 Å2 BSA to the Bcl-XL, Mcl-1, and A1 interfaces and 30 Å2 
BSA to the BHRF1 interface. The increased BSA and extra hydrogen bonds of BID D95 in the Bcl-XL, 
Mcl-1, and A1 complexes suggest that BID D95 may be more important for binding specificity of the BID 
BH3D for the cellular BCL2s than for BHRF1. 
BID D98 forms a salt bridge with A1 K147, a hydrogen bond between the carboxyl of BID 98 and 
the backbone amine of A1 W86, a hydrogen bond between the carboxyl of BID D98 and the backbone 
amine of A1 G87, a hydrogen bond between the carboxyl of BID D98 and the backbone amine of Mcl-1 
G262, and a hydrogen bond between the carboxyl of BID D98 and the hydroxyl of BHRF1 S97. BID D98 
contributes 91 Å2 BSA to the A1 interface, 74 Å2 BSA to the Mcl-1 interface, 47 Å2 BSA to the Bcl-XL 
interface, and 38 Å2 BSA to the BHRF1 interface. Since BID D98 mediates a salt bridge and three 
hydrogen bonds with A1, mediates a hydrogen bond with Mcl-1, and contributes more BSA to A1 and 
Mcl-1 compared to BHRF1 and Bcl-XL, D98 is likely more important for binding specificity of the BID 
BH3D for A1 and Mcl-1 than for BHRF1 and Bcl-XL. 
Although BID E80 and R84 are located outside of the BH3 consensus sequence, these residues 
may also contribute differentially to binding specificity for cellular BCL2s and BHRF1. BID E80 forms two 
salt bridges with Mcl-1, one with Mcl-1 R248 and another with Mcl-1 H252, but does not mediate any salt 
bridges within the other complexes. Therefore, E80 is likely more important for binding specificity of the 
BID BH3D to Mcl-1 than to BHRF1, Bcl-XL, or A1. BID R84 forms a salt bridge with BHRF1 E89 but does 
not mediate any salt bridges or hydrogen bonds with Bcl-XL, Mcl-1, and A1. Therefore, BID R84 is likely 
more important for binding specificity of the BID BH3D to BHRF1 than to Bcl-XL, Mcl-1 and A1. 
6.3.13. Differences in BECN1 BH3D interface residues may destabilize the BHRF1 interaction 
In order to better understand why the isolated BECN1 BH3D does not bind BHRF1, we assessed 
sequence conservation of interface residues between the BH3Ds of BECN1, which binds M1144 and Bcl-
XL46, and BIM, BAK, and BID (Figure 6.15). Among the residues conserved between BECN1, BID, BAK, 
and BIM; eight residues (corresponding to BECN1 L112, S113, R115, L116, G120, D121, F123, D124) 
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are involved in the interface with BHRF1, M11, or Bcl-XL (Figure 6.15). BECN1 K117, which is equivalent 
to the BIM R63 identified above as contributing to the BHRF1 specificity and is moderately conserved 
among various pro-apoptotic BH3-only BCL2s175, also participates in the interface with M11 and Bcl-XL.  
The position equivalent to BID V93, which was a conserved hydrophobic residue in BID, BIM, and 
BAK is a polar residue in BECN1 (T119). BECN1 F123, which is equivalent to the BIM F69 identified 
above as contributing to the BHRF1 specificity, participates in the interface with M11 and Bcl-XL. 
Therefore, we performed structural superimposition of the M11:BECN1 BH3D44, Bcl-XL:BECN1 BH3D46, 
BHRF1:BAK and BHRF1:BIM complexes206 against our BHRF1:BID BH3D to analyze the different 
contributions of these residues to their respective interactions.  
 
Figure 6.15. Sequence alignment of the BH3D of BECN1, BIM, BID, and BAK. 
Symbols beneath the alignment indicate residue conservation: with an asterisk (*) corresponding to 
invariant, colon (:) corresponding to highly conserved, and period (.) corresponding to moderately 
conserved residues. The arrows above the sequence denote the four hydrophobic residues of the BH3 
consensus sequence. Red boxes indicate residues within the BH3 consensus sequence that form the 
interface with BHRF1. Green boxes indicate residues within the BH3 consensus sequence that form the 
interface with M1144 and Bcl-XL46. 
BECN1 contains K117 at a position equivalent to the BIM R63 (Figure 6.15). BECN1 K117 forms 
two hydrogen bonds via its NZ with the backbone carbonyl and side chain hydroxyl of S77 on M1144. 
BHRF1 contains a glutamate (E89) at the position equivalent to M11 S77. The side chain of BHRF1 E89 
is rotated away such that the BHRF1 E89 side chain carboxyls are positioned greater than 4 Å away from 
the NZ of BECN1 K117. Therefore, BECN1 K117 is unlikely able to mediate equivalents of either of the 
hydrogen bonds observed in the M11:BECN1 BH3D complex (with M11 S77) and the BHRF1: BIM BH3D 
complex (with BHRF1 E89 and BIM R63). BECN1 K117 forms salt bridges with Bcl-XL E129 and D13346. 
Bcl-XL E129 is positioned equivalent to BHRF1 E89, which is located at the C-terminus of α4. However, 
structural superimposition of the Bcl-XL:BECN1 BH3D, BHRF1:BIM, and BHRF1:BAK complexes onto our 
BHRF1:BID BH3D complex demonstrates that the BHRF1 E89 main chain is rotated relative to Bcl-XL 
E129 such that the Cα positions differ by 1 Å, pointing the BHRF1 E89 side chain away from the bound 
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BH3Ds such that the BHRF1 E89 side chain carboxyls are positioned greater than 5 Å away from the NZ 
of BECN1 K117. Therefore, BECN1 K117 is unlikely able to mediate a salt bridge with BHRF1. Bcl-XL 
D133 is located in a loop equivalent to the loop linking α4 and α5 of BHRF1. The only negatively charged 
residue in this loop of BHRF1 is D95, which is disordered in the BHRF1:BIM BH3D complex, and rather 
than interact with BHRF1 D95, the BIM R63 (equivalent to BECN1 K117) forms two hydrogen bonds with 
the main chain carbonyl of BHRF1 E89. Therefore, BECN1 K117 is unlikely able to form equivalent salt 
bridges with BHRF1 due to the suboptimal position of the BHRF1 E89 side chain and the flexibility of the 
loop containing BHRF1 D95. However, since BID and BAK have an alanine at the position equivalent to 
BECN1 K117 / BIM R63 yet still interact with BHRF1, the fact that the BECN1 BH3D is insufficient for an 
interaction with BHRF1 cannot be solely attributed to the inability of BECN1 K117 to mediate a double 
hydrogen bond or salt bridges with BHRF1. 
BECN1 T119, which was a conserved hydrophobic residue in BID, BIM, and BAK (Figure 6.15), 
occupies a position typically filled by a hydrophobic residue in BH3Ds. BH3D residues from pro-apoptotic 
BCL2 homologs corresponding to ɸ1-4 of the BH3 consensus sequence are significantly buried by Bcl-XL46, 
201, A1200, Mcl-1199, and M1144. Although BECN1 contains a polar residue (T119) at the ɸ3 position, 
equivalent residues of BID, BIM, and BAK bury similar amounts of surface area. Binding to BHRF1 buries 
78 Å2 of BID V93, 82 Å2 of BIM I65, and 71 Å2 of BAK I81, while binding to M11 buries 79 Å2 of BECN1 
T119, and binding of Bcl-XL buries 80 Å2 of BECN1 T119. A hydrophobic pocket, primarily formed by the 
aromatic rings of M11 F48 and Y52 or Bcl-XL F97 and Y101, accommodates the aliphatic part of the 
BECN1 T119 side chain in the M11 and Bcl-XL complexes. This pocket on BHRF1 is primarily formed by 
I57, N61, T64 C𝛄, and F65. Superimposition of the BECN1 from the M11 and Bcl-XL complexes onto the 
BHRF1:BID, BHRF1:BIM, and BHRF1:BAK complexes indicates that the BECN1 T119 C𝛄 would be 
positioned within ~2.8 Å of the BHRF1 N61 amide (BHRF1:BID complex), ~3.1 Å of the BHRF1 N61 
amide (BHRF1:BIM complex), or ~2.9 Å of the N61 amide (BHRF1:BAK complex). Therefore, this pocket 
of the BHRF1 hydrophobic surface groove should be able to accommodate BECN1 T119. Further, since 
BH3D residues equivalent to BECN1 T119 bury equivalent amounts of surface area in the BHRF1 
complexes, the presence of a polar residue in the ɸ3 position of the BECN1 BH3D is inadequate to explain 
why the BECN1 BH3D is insufficient to mediate the interaction with BHRF1. 
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The position equivalent to BECN1 F123 is conserved between all four BH3Ds analyzed (Figure 
6.15). However, since the equivalent BIM residue (F69) was identified above as a potential determinant 
for BIM specificity for BHRF1, we analyzed the structural superimposition of the BECN1 BH3D from the 
complex with M1144 and Bcl-XL46 against BIM from the BHRF1 complex206. The BIM F69 Cα is 0.6 Å from 
BECN1 F123 in the Bcl-XL complex and 1.1 Å from BECN1 F123 in the M11 complex, which alters the 
position of the aromatic ring, placing it within ~2 Å of BHRF1 I57 C𝛄 on the surface groove of BHRF1. 
Therefore, the pocket on the hydrophobic groove of BHRF1 is too shallow to accommodate these 
positions of the BECN1 F123 aromatic ring (Figure 6.16). Since BECN1 F123 has previously been 
identified as important for the BECN1 interaction with M11 and Bcl-XL140, this difference in the BHRF1 
hydrophobic groove likely destabilizes the BHRF1:BECN1 BH3D interaction. The destabilization caused 
by the orientation of BECN1 F123 combined with the absence of double hydrogen bond or salt bridges 
mediated by BECN1 K117 may be factors that contribute to the inability of the BECN1 BH3D to form a 
stable interaction with BHRF1. 
 
Figure 6.16. Comparison of BECN1 and BIM residues equivalent to BECN1 F123. 
Structural superimposition of the BECN1 from the Bcl-XL:BECN1 complex (magenta) (PDB entry 2P1L) 
and BECN1 from the M11:BECN1 complex (teal) (PDB entry 3DVU) against BIM (gray) from the 
BHRF1:BIM complex (PDB entry 2V6Q) with the BHRF1 surface colored by atom type: oxygen, red; 
nitrogen, blue, carbon, grey; sulfur, yellow. BH3D residues equivalent to BECN1 F123 are shown in stick. 
6.3.14. Designing a peptide to inhibit down-regulation of autophagy by BHRF1 
In an effort to discover a BHRF1-selective peptide, we also quantified the thermodynamics of 
binding to BHRF1ΔTM and Bcl-XLΔTM by the BID BH3D mutant peptides via ITC (Table 6.7, Figure 6.17, 
6.18). However, in all cases, the mutant BID BH3D peptides used here weakened binding 4 to 40-fold to 
BHRF1 and maintained or improved binding to Bcl-XL (Table 6.7) relative to the WT BID BH3D (0.3 µM 
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for BHRF1 and 1.1 µM for Bcl-XL) (Table 6.4). Unfortunately, therefore, the mutant BID BH3D peptides 
used here were not selective for BHRF1 but instead improved selectivity for Bcl-XL. 
Therefore, we decided to investigate whether a cell-permeable peptide derived from the WT BID 
BH3D would prevent BHRF1-mediated down-regulation of BECN1-dependent autophagy. Compared with 
untreated cells, TAT-BID peptide treatment markedly increases autophagy levels in starved cells that are 
transiently co-transfected with BHRF1 (p = 0.0130 for treated versus untreated cells co-transfected with 
BHRF1 and BECN1) (Figure 6.2B). This suggests that the TAT-BID peptide binds BHRF1 in mammalian 
cells and prevents BHRF1 from down-regulating BECN1-mediated autophagy, despite the low affinity of 
BHRF1 for the isolated BECN1 BH3D. 
Table 6.7. Thermodynamics of binding of BID BH3D mutants to BHRF1 and Bcl-XL. 
BID Peptide 
BHRF1ΔTM Bcl-XLΔTM 
Kd  
(µM) 
ΔH 
(kJ/mol) 
ΔS 
(J/K·mol) 
ΔG 
(kJ/mol) 
Kd  
(µM) 
ΔH 
(kJ/mol) 
ΔS 
(J/K·mol) 
ΔG 
(kJ/mol) 
BID G94A 1.2  
± 0.0 
43.9  
± 10.5 
268.5  
± 36.8 
-32.1 
± 0.0 
0.1  
± 0.0 
-17.1  
± 5.7 
73.0  
± 19.0 
-62.2 
± 13.3 
BID Mutant 1 1.2  
± 0.2 
-7.4  
± 0.9 
87.8  
± 1.6 
-32.3 
± 1.4 
0.1  
± 0.0 
-13.2  
± 1.1 
86.4  
± 4.4 
-37.7 
± 2.4 
BID Mutant 2 12.2   
± 2.0 
-1.8  
± 0.2 
88.0  
± 0.6 
-26.7 
± 0.0 
0.5  
± 0.1 
-7.0  
± 0.4 
96.6  
± 0.1 
-34.4 
± 0.4 
BID Mutant 3 1.6  
± 0.6 
8.9  
± 0.6 
143.1  
± 5.4 
-31.6 
± 0.9 
0.9  
± 0.4 
-31.4  
± 0.1 
5.7  
± 4.3 
-33.0 
± 1.3 
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Figure 6.17. ITC profiles of BID BH3D Mutants binding to BHRF1. 
A) BID G94A binding to BHRF1ΔTM, B) BID Mutant 1 binding to BHRF1ΔTM, C) BID Mutant 2 binding to 
BHRF1ΔTM, D) BID Mutant 3 binding to BHRF1ΔTM. 
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Figure 6.18. ITC profiles of BID BH3D Mutants binding to Bcl-XL. 
A) BID G94A binding to Bcl-XLΔTM, B) BID Mutant 1 binding to Bcl-XLΔTM, C) BID Mutant 2 binding to 
Bcl-XLΔTM, D) BID Mutant 3 binding to Bcl-XLΔTM. 
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6.4. Discussion and conclusions 
Based on the cellular assays and biophysical analyses reported here, we conclude that the EBV 
vBCL2, BHRF1, down-regulates autophagy by non-canonical binding to BECN1. Autophagy assays in 
MCF7 cells demonstrate that BHRF1 abrogates BECN1-mediated, starvation-induced autophagy, but has 
no effect on basal levels of autophagy. Unlike BECN1 BH3D interactions with Bcl-230, Bcl-XL46, and 
M1144; as well as BID174, BIM174, 206, BAK206, and PUMA174 BH3D interactions with BHRF1; wherein the 
BH3Ds are sufficient for interaction, the BECN1 BH3D is insufficient to mediate the BHRF1:BECN1 
interaction. Yeast two-hybrid assays, affinity pull-downs with purified protein, and binding affinity 
measurements by ITC all indicate that BECN1 residues 90-171 are required and sufficient for interaction 
with BHRF1. The region of BECN1 required for interaction with BHRF1 consists of 15 residues of the IDR 
preceding the BH3D, the BH3D, and the FHD. This suggests that BECN1 binds to BHRF1 via a non-
canonical mode of binding. 
Analysis of our 2.6 Å crystal structure of the BID BH3D bound to BHRF1 compared the BAK and 
BIM BH3Ds bound to BHRF1206 suggests that BIM F69 contributes to the improved binding affinity of BIM 
for BHRF1 compared to BID, which has M97 at the equivalent BH3D position, and BAK, which has I85 at 
the equivalent BH3D position. Although BECN1 has F123 at the BH3D position equivalent to BIM F69, 
comparison of the M11:BECN1 BH3D44, Bcl-XL:BECN1 BH3D46, and BHRF1:BIM complexes206 indicates 
that the orientation of BECN1 F123 combined with the inability of BECN1 K117 to mediate a double 
hydrogen bond or salt bridges with BHRF1 likely destabilize the interaction between the BECN1 BH3D 
and BHRF1. BECN1 K117 and F123 have previously been shown140 to contribute to the stability of 
BECN1 complexes with M11 and Bcl-XL, wherein a BECN1 K117A mutant weakens binding 10-fold to 
Bcl-XL, although it maintains similar binding M11, relative to WT BECN1. The BECN1 F123A mutant has 
a larger effect, as it weakens binding by 200-fold to Bcl-XL and by 5-fold to M11 relative to WT BECN1. 
The weaker interaction between BHRF1 and the BECN1 BH3D relative to other BH3Ds is consistent with 
our yeast two-hybrid assays, affinity pull-downs with purified protein, and binding affinity measurements 
by ITC indicating a non-canonical mode of binding between BHRF1 and BECN1 residues 90-171. 
BECN1 contains five Anchor regions likely to be energetically stabilized in ordered conformations 
upon binding30, 31. The minimal BHRF1-binding region (residues 90-171) contains one partial Anchor 
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region (residues 79-103) and three complete Anchor regions (residues 117-127, residues 137-145, and 
residues 162-169). The BECN1 BH3D Anchor region (residues 117-127) has previously been shown to 
nucleate concomitant disorder-to-helix transition and binding to Bcl-230. The FHD Anchor regions 
(residues 137-145 and residues 162-169)216 and the BECN1 IDR Anchor region (residues 79-103)41 have 
been previously shown, in the absence of binding partners through the use of TFE, to be likely to undergo 
binding-associated disorder-to-helix transitions. In a 4.4 Å crystal structure (PDB 5DFZ) of the full-length 
yeast VPS34:VPS15:VPS30:VPS38 complex (VPS30 is the yeast homolog of BECN1) it was shown that 
the VPS30/BECN1 FHD (labeled CC1 in this structure) folds into a helix which is stabilized by binding 
VPS38 (the yeast homolog of UVRAG) in a coiled-coil manner17. Therefore, in addition to the BECN1 
BH3D, the BHRF1:BECN1 interaction may involve additional binding-induced helical transitions within the 
IDR and FHD necessary to stabilize the non-canonical interaction. 
Comparison of our 2.6 Å crystal structure of the BID BH3D bound to BHRF1 to the BID BH3D 
bound to human Bcl-XL201, human Mcl-1199, and mouse A1200 indicates that each BID BH3D interface 
residue contributes differentially to the interaction with BHRF1 and each cellular anti-apoptotic BCL2. 
Based on analyses of the BSA of interface residues and electrostatic interactions that stabilize the 
complexes, BID R84 is likely more important for binding specificity of the BID BH3D for BHRF1 than for 
the cellular BCL2 proteins. We also conclude that BID E80, H89, D95, S96, M97, and D98 are likely more 
important for binding specificity of the BID BH3D for cellular BCL2 proteins than for BHRF1. We have 
previously shown140 that BECN1 D121, which is equivalent to BID D95, and BECN1 F123, which is 
equivalent to BID M97, are more important for the stability of BECN1 BH3D complexes with the cellular 
BCL2 Bcl-XL than with the vBCL2 M11. In that study, a BECN1 D121A mutant abrogated binding to Bcl-
XL, but maintained a similar binding affinity to M11, relative to WT BECN1. Likewise, a BECN1 F123A 
mutant weakened binding relative to WT BECN1 for Bcl-XL 40-fold more than for M11. 
Lastly, we show that a cell-permeable BID BH3D peptide inhibits down-regulation of autophagy 
by BHRF1. This is consistent with our binding association measurements demonstrating that BHRF1 
binds to the BID BH3D (~0.3 µM) approximately 400 times tighter than to BECN1 (~127 µM). Although 
the binding affinity for BECN1 appears to be sufficient for down-regulation of autophagy, it is substantially 
weaker than that for the BID BH3D. This suggests that the BID BH3D can displace BECN1 to inhibit 
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BHRF1-mediated down-regulation of autophagy. These results are significant because they suggest that 
if peptides that selectively bind to the BH3D-binding groove of BHRF1, but not to cellular BCL2s could be 
identified, as has been done by us for inhibition of M11 down-regulation of autophagy140, these BHRF1-
selective peptides could inform the rational design of therapeutics to prevent BHRF1 from down-
regulating autophagy. Indeed, a selective, BH3D-derived 117-residue protein that binds tightly to BHRF1 
has been designed and shown to induce apoptosis in EBV-infected cancer cells, slow tumor progression, 
and prolong survival in mice with human EBV-positive B cell lymphoma xenograft tumors219. However, a 
role for this inhibitor in autophagy regulation was not assessed.  
In summary, previous studies have established that BHRF1 down-regulates apoptosis, but here 
we show that, like other ɣHV BCL2 proteins, it also down-regulates autophagy. However, unlike other 
BCL2s, the BECN1 BH3D is insufficient for binding BHRF1. Instead, a longer flexible BECN1 region that 
includes, but is not limited to, the BECN1 BH3D is required and sufficient for the BHRF1 interaction. This 
study also reports the atomic details of the BHRF1:BID BH3D interaction, which adds to the information 
available for elucidating binding determinants that enforce BHRF1 specificity. Lastly, we demonstrate that 
despite this non-canonical binding, BHRF1 down-regulation of BECN1-mediated autophagy can be 
inhibited through the use of a cell-permeable peptide derived from the BID BH3D that tightly binds to 
BHRF1 in a canonical manner via its BH3D. Understanding the factors that enforce binding specificity 
may be used for the structure-based design of small molecules that selectively inhibit the BHRF1:BECN1 
interaction to prevent BHRF1-mediated down-regulation of autophagy. Such inhibitors would provide a 
useful tool to examine the role of EBV in regulating autophagy and may ultimately form the basis of novel 
therapeutics to treat EBV-associated cancers and infections. 
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CHAPTER 7. CONCLUSION AND FUTURE DIRECTIONS 
The work presented in this dissertation aims to identify and understand binding-induced disorder-
to-order and conformational transitions in proteins that regulate autophagy. First, we devised a method to 
identify IDRs likely to undergo helical transitions upon binding, even in the absence of known binding 
partners. We also investigated conformational flexibility within BECN1, which contains two structured 
domains sharing an overlapping region that appears to undergo conformational transitions. Lastly, we 
investigated the interaction between BECN1 and various viral proteins; including the HIV-encoded Nef 
and ɣHV vBCL2 homologs encoded by KSHV and EBV. These studies improve our structure-based 
understanding of the mechanism and biological function of these proteins in regulating autophagy. 
In this study, we developed a method to identify IDRs that are likely to undergo helical transitions 
upon binding by combining bioinformatics analyses followed by CD spectroscopy to monitor TFE-induced 
changes in the secondary structure content of IDRs. Our results indicate that this method may provide a 
novel, convenient experimental diagnostic to identify IDRs that become helical upon binding. This tool 
may help identify potential binding partners for the IDR from a wider list of potential interaction partners 
for the full-length protein by providing information about the IDR conformation and amino acids most likely 
to be involved in the interaction. This, in turn, would lead to a better mechanistic understanding of the 
function of proteins involved in IDR-mediated interactions, which may also be useful for developing 
therapeutics targeting these proteins. 
We also demonstrated that the overlapping helical region of BECN1, which we termed OH, 
shared by the CCD and BARAD appears to undergo conformational transitions. Without other binding 
partners, BECN1 self-associates via its CCD to form a homodimer. However, the last 18 CCD residues, 
composing the OH, have crystallized in two mutually exclusive states: a helix either as part of the CCD34 
or packed against the C-terminal BARAD36. We used CD spectroscopy, ITC, and SAXS to show that, in 
the homodimer, the OH transitions transiently between these two different packing states, with the 
predominant state comprising the OH packed against the BARAD. We confirmed this observation by 
comparing the impact of mutating four residues that mediate packing of the OH against both the CCD and 
BARAD on structure and stability of these domains. We also demonstrated that mutation of these OH-
interface residues abrogates starvation-induced up-regulation of autophagy through use of cellular 
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assays. Previous studies had established the BECN1 CCD and BARAD as structurally well-defined 
domains, but we showed that these domains include an OH that can transiently adopt two distinct, 
mutually exclusive packing states, emphasizing overall BECN1 conformational flexibility. Previous studies 
had also established that the OH forms part of the CCD in BECN1 interactions with heterologous binding 
partners, but we demonstrated that the OH preferentially packs against the BARAD in the BECN1 
homodimer. Our findings have important implications for the relative stability of autophagy-inactive and 
autophagy-active BECN1 complexes.  
As discussed in Chapter 3, packing of the OH against the BARAD in the BECN1 homodimer 
would likely require reorientation of the BARAD relative to that observed in the yeast 
PI3KC3:p150:BECN1:UVRAG structure of Complex II. Additional structural studies, through the use of X-
ray crystallization, CryoEM, or NMR, of the BECN1 homodimer are required to determine how this 
rearrangement of the BARAD would reposition the aromatic finger. Furthermore, the BECN1 homodimer 
and the BECN1-containing Complex II could be used to test binding to liposomes of different sizes, which 
may help determine if the repositioning of the aromatic finger in the BECN1 homodimer interferes with the 
ability of BECN1 to interact with membranes.  
The conformational flexibility of the OH may also be partially responsible for the difficulty in 
obtaining an atomic resolution crystal structure of the BECN1 CCD-BARAD since the transitions between 
packing in the CCD and against the BARAD likely hinders the attainment of high-resolution crystal 
structures. Since we have identified a preference by the OH for packing against the BARAD, it may be 
useful to remove the N-terminal CCD residues against which the OH packs in the anti-parallel CCD 
homodimer34 for further structural studies of the CCD-BARAD. This BECN1 fragment, consisting of 
residues 193-450, might minimize the flexibility of the CCD and BARAD and; therefore, improve 
crystallization and X-ray structure solution outcomes. A crystal structure of the homodimer state of 
BECN1 would provide the atomic details of the interaction of shortened CCD as well as the location of the 
re-oriented aromatic finger, which would improve our understanding of function of the likely autophagy-
inactive homodimer state of BECN1. 
Also discussed in Chapter 3, another important implication of the OH being preferentially packed 
against the BARAD in the homodimer is that this would release the N-terminal region of the partner helix 
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within the anti-parallel CCD homodimer, which contains an NES that binds CRM1 to enable nuclear 
export of BECN1158, 159. NES residues Leu184 and Leu187 are essential for BECN1 nuclear export, BECN1-
mediated autophagy, and tumor suppression158, 159. Therefore, these NES residues are likely critical for 
binding CRM1. However, in the CCD homodimer, NES residues Leu184 and Leu187 pack against OH 
interface residues18. Therefore, in order to bind CRM1, the BECN1 NES cannot be packed against the 
BECN1 OH. Our results showing that the OH preferentially packs against the BARAD in the homodimeric 
state suggest a mechanism of how the NES may be exposed for CRM1-binding to enable nuclear export. 
Further studies to delineate the structural basis for the CRM1:BECN1 NES interaction are required to 
determine if and how CRM1 stabilizes BECN1 conformations wherein the OH is packed against the 
BARAD. 
In the absence of other partners, the OH transitions between these states with a preference to 
packing against the BARAD, rather than the CCD as has been commonly assumed. The OH likely 
regulates BECN1 function in autophagy as interactions with different partners likely stabilize one packing 
state or the other to promote these different functions. It would be interesting to utilize HDX-MS 
experiments to generate a protein heat map showing the rate of deuterium exchange across the full-
length human BECN1 homodimer to provide structural dynamics information regarding the conformational 
flexibility in the OH and the regions against which the OH appears to transiently pack (i.e. the NES on the 
CCD N-terminus and the first β-sheet and third α-helix of the BARAD). Although this experiment has been 
done in yeast VPS3017, unlike vertebrates, lower eukaryotes lack a NES located at the N-terminus of the 
CCD. The yeast VPS30 NES comprises residues 12-21158, which is part of the IDR, rather than the CCD 
so the conformational switch of the OH between packing against the CCD versus the BARAD is likely not 
needed for nuclear export in yeast. Therefore, obtaining the structural dynamics information in the full-
length human BECN1 would improve our understanding of the importance of the conformational flexibility 
of the BECN1 OH. 
Additionally, we investigated the interaction between BECN1 and the HIV protein Nef via in vitro 
analyses with purified protein. We concluded that, despite previous cellular co-immunoprecipitation 
assays demonstrating that C-terminal residues of the Nef Core mediate an interaction with BECN1-
containing complexes68 and that BECN1 residues 267-284 of the BARAD are crucial for this interaction166, 
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the BECN1 BARAD in the context of the BECN1 homodimer is insufficient to mediate a direct interaction 
with Nef. As discussed in Chapter 4, it is possible that the preferential packing of the OH against the 
BARAD in the BECN1 homodimer occludes the Nef binding site. Furthermore, the role of Nef in 
autophagosome maturation inhibition suggests that Nef interacts with BECN1-containing heterodimers. 
Therefore, further binding assays and structural studies of the Nef interaction with the BECN1:UVRAG 
heterodimer or the full PI3KC3:p150:BECN1:UVRAG Complex II are needed to fully understand the 
mechanism of interaction. This would add to our current understanding of the mechanism by which Nef 
modulates autophagy in order to enhance HIV replication and pathogenesis. This information may be 
critical for designing inhibitors of Nef. The crucial role of Nef in disease progression to AIDS means that 
inhibition of Nef functions could represent a major breakthrough in HIV/AIDS treatment regimens. 
In this study, we also attempted to obtain structural information regarding the KSHV vBcl-2 
interaction with BH3Ds; however, we faced issues with the purification of the KSHV vBcl-2 due to protein 
precipitation. Although precipitation issues during protein purification prevented us from obtaining KSHV 
vBcl-2 at concentrations sufficient to permit biophysical and structural analyses to determine which 
residues contribute to binding specificity for the KSHV vBcl-2 by BH3Ds, we were able to test the binding 
affinity for a BECN1 BH3D G120E/D121A double mutant and mNOXA BH3D peptide, as well as assess 
the oligomeric state of the KSHV vBcl-2:mNOXA complex by SEC. Our experimental evidence showing 
that the BECN1 BH3D G120E/D121A double mutant does not bind the KSHV vBcl-2 binding suggests 
that KSHV vBcl-2 employs a distinct mechanism of binding to BH3Ds compared the ɣHV 68 vBCL2, M11. 
A unique binding mechanism is consistent with the observation that the binding affinity of KSHV vBcl-2 for 
other BH3Ds varies greatly compared to those of other anti-apoptotic BCL2 proteins44, 174. 
If a method for expression and purification of sufficient quantities of stable KSHV vBcl-2 could be 
developed, further structural studies of KSHV vBcl-2 interactions with the BECN1 and mNOXA BH3D 
would be required to elucidate the determinants of binding specificity for the KSHV vBcl-2 compared to 
other ɣHV BCL2 proteins. Although the moderate binding affinity (~13 µM) of the KSHV vBcl-2 for the 
BECN1 BH3D44 may be too weak to obtain diffraction quality crystals the KSHV vBcl-2:BECN1 BH3D 
complex, an NMR solution structure and chemical shifts analysis might enable identification of binding 
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determinants this interaction. This information will be critical for improving our understanding of how 
KSHV modulates autophagy. 
Our ITC and SEC co-elution results confirm the KSHV vBcl-2:mNOXA BH3D interaction. To date, 
there is no crystal structure deposited in the PDB of KSHV vBcl-2 bound to any BH3D. Determination of a 
high-resolution structure via X-ray crystallography should allow elucidation the atomic determinants of the 
KSHV vBcl-2:mNOXA BH3D interaction. Such information, especially if coupled with co-crystallization 
and structure determination of the Mcl-1:mNOXA and A1:mNOXA, would improve our understanding of 
the molecular basis for binding BH3Ds by the KSHV vBcl-2 and Bcl-2 homologs. Understanding these 
binding determinants may facilitate the rational design of a peptide that selectively inhibits KSHV vBcl-2, 
but not cellular Bcl-2, mediated inhibition of apoptosis or autophagy. However, development of a method 
for expression and purification of sufficient quantities of stable KSHV vBcl-2 would be required for these 
protein X-ray crystallography experiments. 
Lastly, we identified a role in autophagy regulation for BHRF1, a vBCL2 mimic encoded by EBV. 
BHRF1 binds the BH3D of pro-apoptotic Bcl-2 proteins, down-regulating apoptosis and promoting survival 
of infected cells174. We showed that, unlike the KSHV vBcl-226 and M1144, BHRF1 does not bind the 
isolated BECN1 BH3D. We used yeast two-hybrid assays to identify a minimal region of BECN1 
(consisting of 15 IDR residues preceding the BH3D, the BH3D, and the FHD) required to bind BHRF1. 
We confirmed this to be a direct, albeit weak, interaction via affinity pull-down assays and ITC, and 
determined that BHRF1 down-regulates autophagy in mammalian cells. We also show that the BID 
BH3D, a pro-apoptotic Bcl-2 protein, binds ~400-times tighter than the BECN1 BH3D to BHRF1. To 
further understand the structural basis of BHRF1 specificity, we solved the 2.6 Å crystal structure of the 
BID BH3D bound to BHRF1. Finally, we show that a cell-permeable peptide derived from the BID BH3D 
also inhibits BHRF1-mediated down-regulation of autophagy. 
Understanding the factors that enforce binding specificity may be used for the structure-based 
design of small molecules that selectively inhibit the BHRF1:BECN1 interaction to prevent BHRF1-
mediated down-regulation of autophagy. The information obtained from our structure of the BHRF1:BID 
BH3D complex, in combination with further future binding assays and cellular autophagy assays, may be 
utilized to design peptides that selectively inhibit BHRF1 from down-regulating autophagy. It would also 
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be interesting to test the previously described 117 residue protein that selectively inhibits BHRF1 from 
down-regulating apoptosis219 for an effect on autophagy regulation. Inhibitors of BHRF1-mediated down-
regulation of autophagy would provide a useful tool to examine the role of EBV in autophagy regulation 
and may even ultimately form the basis of novel therapeutics to treat EBV-associated cancers and 
infections. 
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